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Abstract 
Multipotent stromal cells/mesenchymal stem cells (MSCs) can differentiate into 
multiple lineages including osteogenic and adipogenic cells.  Wnt signalling has 
been implicated in controlling MSC fate, but the mechanism is unclear and 
apparently conflicting data exists. Here I show that a glycogen synthase kinase 3β 
inhibitor, AR28, is a potent activator of canonical Wnt signalling using β-catenin 
translocation studies and TCF-reporter assays.  AR28 induced axis duplication and 
secondary regions of chordin expression in Xenopus laevis embryos, when injected 
into the ventral marginal zone, indicative of canonical Wnt signalling. When human 
MSCs were grown under adipogenic conditions, AR28 caused a significant dose-
dependent reduction in FABP5/BODIPY double-positive cells with a corresponding 
rescue of proliferation.  In assays to determine the effects of AR28 on MSC 
osteogenesis using standard differentiation inducers (β-glycerophosphate, L-ascorbic 
acid and dexamethasone), AR28 caused a significant decrease in alkaline 
phosphatase (ALP) activity compared to vehicle controls, indicative of a reduced 
osteogenic response.  However, when using mild osteogenic stimulation, excluding 
dexamethasone, increases in both ALP and Alizarin Red mineral staining were 
identified following AR28 treatment, with corresponding increases in proliferation 
and cell number. This AR28-induced osteogenic response was blocked by 
mitomycin C, identifying cell proliferation as an important step in Wnt-induced 
osteogenesis under these conditions.  Pre-treatment of MSCs with AR28 for 7 days 
before osteogenic induction also increased ALP activity and mineralisation.  BMP2 
treatment of MSCs was capable of inducing both osteogenic and chondrogenic 
differentiation, to which AR28 caused a switch towards the osteogenic lineage, with 
synergistic increases in ALP.  AR28 simultaneously caused a decrease in the 
chondrogenic differentiation of MSCs treated with BMP2 through the down 
regulation of Sox9 transcription.  Together these results highlight the potential of 
GSK3β inhibitors as therapeutic modulators of canonical Wnt signalling, and there 
use to treat a multitude of bone related disorders. 
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Chapter 1: Introduction 
1.1 Stem cells 
Stem cells are a subset of cells defined by the ability of a single clonal cell to be 
capable of self renewal, maintaining the cells in an undifferentiated state, and 
differentiation into a number of mature cell types (Weissman et al, 2001).  The first 
evidence for the existence of stem cells was published in 1961, where, through the 
use of random chromosome markers, clonal colonies were identified and later shown 
to be composed of both differentiated cells and cells that could be used to 
reconstitute secondary hosts to produce all the blood cell lineages (Becker et al, 
1963; Till & McCulloch, 1961; Wu et al, 1968).   These cells were later isolated and 
termed haematopoietic stem cells (HSCs) (Spangrude et al, 1988).  Subsequently 
many types of stem cells from many tissues have been identified including skin 
(Blanpain et al, 2004), muscle (Wagers & Weissman, 2004), neural (Cattaneo & 
McKay, 1990), mesenchymal (Pittenger et al, 1999) and inner cell mass (Evans & 
Kaufman, 1981). 
Stem cells are broadly categorised into two main types, embryonic and adult stem 
cells, by the tissue from which they are isolated.  Embryonic stem (ES) cells are 
isolated from the inner cell mass of the developing embryo and can give rise to all 
the cell types of the developing organism, while adult stem cells are more germ 
layer- and tissue-specific giving rise to a smaller range of cell types.  Stem cells can 
be further categorised by the number of cell types they are able to form, a property 
known as potency.  The degree of potency can vary depending on the type of stem 
cell, and has been categorised into five families (Wagers & Weissman, 2004).  
Totipotent stem cells, which can differentiate into all the embryonic and extra-
embryonic cells types; pluripotent stem cells can produce all the cell types of the 
three germ layers; multipotent stem cells can form multiple closely related cell types 
from a single germ layer; oligopotent stem cells can only differentiate into a few 
very closely related cell types; unipotent stem cells are only capable of forming a 
single cell type, but maintain their ability to self renew.   
16 
 
1.1.1 Embryonic Stem cells 
ES cells are derived from the inner cell mass of a developing embryo before 
gastrulation, and therefore are capable of forming cells from all three germ layers.  
ES cells were first isolated from mouse embryos in 1981 (Evans & Kaufman, 1981; 
Martin, 1981), but it was some time until Thomson et al. generated the first human 
ES cell line in 1998 (Thomson et al, 1998).  While both mouse and human ES cells 
are derived from cells of the inner cell mass, they differ in some of their properties.  
For example, mouse ES cells require leukaemia inhibitory factor (LIF) to maintain 
their pluripotency and proliferative state (Niwa et al, 2009), yet LIF does not act to 
maintain pluripotency in human ES cells (Dahéron et al, 2004).  Human ES cells do 
however require a feeder layer of cells, traditionally derived from mouse embryonic 
fibroblasts (MEFs) (Thomson et al, 1998) to allow adhesion and provide a range of 
factors to maintain the pluripotency (Eiselleova et al, 2008).  However, recently 
other sources of feeder layers, particularly of human origin have been investigated 
(Eiselleova et al, 2008), as well as feeder free systems (Xu et al, 2001).  The 
pluripotency of mouse ES cells can be confirmed by the reconstitution of embryos 
and the generation of chimeric mice (Suda et al, 1987), while in humans, 
pluripotency can be demonstrated by the formation of teratomas after injection into 
severe combined immunodeficient (SCID) mice (Thomson et al, 1998) or other 
immunocompromised mouse models.  Despite these discrepancies in the requirement 
for LIF and feeder layers for the maintenance of pluripotency, the capacity of ES 
cells to be maintained in culture and proliferate indefinitely is thought to be due to a 
range of key transcription factors, including Oct4, Nanog and Sox2, but also 
epigenetic factors and miRNAs (Chen & Daley, 2008).  
The availability of a cell type capable of self renewal followed by the differentiation 
into any adult tissue offers clear uses in the treatment and repair of any damaged 
tissue in the adult body (Keller & Snodgrass, 1999), but the very nature of ES cells 
themselves makes their use in both research and therapeutics controversial.  Firstly, 
ES cells are derived from the inner cell mass of a developing embryo, therefore in 
order to generate an ES cell line a fertilised embryo must be destroyed.  While 
embryos are often obtained from excess/discarded in vitro fertilised embryos (Shand 
et al, 2012), there are examples of embryos purposefully fertilised for ES cell 
17 
 
extraction (Lanzendorf et al, 2001).  The creation of embryos specifically for ES 
isolation via nuclear transfer to generate patient-specific cells, reducing immune 
rejection, is also being considered (de Wert & Mummery, 2003).  Secondly, as ES 
cells are pluripotent, and characterised by their ability to form teratomas when 
implanted into animal models, there is also a clear safety issue in the use of ES cells 
in human patients.  This problem can be avoided by the differentiation of the self 
renewing ES cells in vitro into the chosen mature differentiated cell type, which 
would not be proliferative or tumourigenic.  However, full differentiation of ES cells 
into many cell types cannot be performed in vitro, and any remaining pluripotent 
cells would have the capacity to form teratomas in the patient. 
A recent discovery by the Yamanaka laboratory, which demonstrated the generation 
of mouse (Takahashi & Yamanaka, 2006) and human (Takahashi et al, 2007) ES-like 
cells from somatic cells, by the forced expression of the pluripotency genes Oct4, 
Sox2, Klf4, and c-Myc, termed induced pluripotent stem (iPS) cells, offer many 
advantages over ES cells in terms of ethics and the potential for autologous cell 
treatments.  However, they possess many difficulties of their own such as viral 
transformation techniques and epigenetic memories of the parental cells (Kim et al, 
2010). 
1.1.2 Adult Stem cells 
Adult stem cells are present as small populations of cells found in tissues of adults, 
and for a long time were thought to be restricted to tissues with high turnover/repair 
such as the gut, skin, testis and blood, but are now thought to be much more 
extensive, with the identification of populations of adult stem cells in the brain, 
ovaries, heart and bone marrow (Wagers & Weissman, 2004).  Adult stem cells are 
capable of self renewal and differentiation into multiple cell types, and are thought to 
reside within a niche in the adult tissues, maintaining the stem cells in a multipotent 
state, until the surrounding tissue is in need of repair or maintenance of homeostasis.  
Adult stem cells were originally presumed to have relatively restricted potency, to 
that of the tissue of origin, however there is emerging, sometimes controversial, 
evidence for the transdifferentiation into cells of other tissues (Raff, 2003), leading 
to increased therapeutic potential.   
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Although adult stem cells have the obvious disadvantage compared to ES cells of 
reduced potency, they offer several advantages over ES cells in their use in both 
basic science research and therapeutics.  Firstly, as adult stem cells are obtained from 
adult tissues, the ethical issues that surround the generation of ES cell lines are not 
relevant, and cells can be obtained for scientific research upon informed consent.  
Secondly, adult stem cells are much less tumourigenic than ES cells, with reduced 
potency reducing the risk when implanting into patients.  Thirdly, there is the 
possibility to use autologous cells during transplantation, or manipulate the 
endogenous stem cell population without the need for extraction and in vitro 
expansion or differentiation.  Indeed, these advantages over ES cells have allowed 
adult stem cell therapeutics to progress to the clinic with much more ease than ES 
cells.  Bone marrow transplants have been used for many years to treat leukaemia 
patients, and replenish all the cells of the blood via HSCs.  Similarly, autologous 
epidermal stem cells have been expanded in vitro and transplanted for the treatment 
of wounds or burns (Shi et al, 2006).  A third source of stem cells, mesenchymal 
stem cells or multipotent stromal cells (MSCs), are becoming an increasingly 
popular source of cells, with therapeutic potential for a multitude of reasons and are 
discussed in detail bellow. 
1.1.3 Mesenchymal Stem Cells 
The existence of a mesenchymal stem cell was first proposed by Friendenstein et al 
(1966), who reported a population of bone marrow stromal cells capable of 
generating bone following heterotopic transplantation.  These precursors were 
subsequently shown to be a subset of fibroblast like cells capable of forming 
colonies, termed colony-forming unit fibroblasts (CFU-Fs), when selected by 
adherence to plastic surfaces (Friedenstein et al, 1970).  Cells derived from a single 
CFU-F could be cultured in vitro and were able to proliferate, whist maintaining 
their ability to differentiate into osteoblasts, adipocytes and chondrocytes (Pittenger 
et al, 1999).  Together, these data are characteristics of the two hallmarks of 
stemness described above; the ability to self renew, and to differentiate into multiple 
lineages.  Consequently these cells came to be commonly known as mesenchymal 
stem cells.  
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1.1.3.1 MSC markers and isolation 
The study of MSCs in vivo and the isolation of MSC populations has been hindered 
by the lack of specific cell surface markers for immuno-phenotype identification.  
Cultured human MSCs do express a panel of cell surface markers, such as CD105, 
CD73 and CD90, and lack the haematopoietic markers CD45, CD34 and CD14 
(Dominici et al, 2006), however these can be donor-, isolation- and passage-
dependent and may not represent the true in vivo MSC population.  Various cell 
markers are now being used to isolate populations of MSCs from the heterogeneous 
plastic adherent cultures, such as Sca-1
+
/Thy-1
+
 (Locatelli et al, 2003) and CD271 
(Quirici et al, 2002), however no single marker has yet been universally adopted 
causing difficulty in the comparison of results from different labs. 
Consequently, the majority of work studying the properties of MSCs has been 
performed using cultured MSCs selected by adherence to culture plastic.  However, 
this generates problems of its own, with different species, isolation techniques, 
culture conditions and donor sites generating increased complexity in the system.  
Furthermore, some studies of MSC differentiation have been performed not with 
primary cells, but with cell lines such as C3H10T1/2 (Jackson et al, 2005; Kulkarni 
et al, 2006) and MC3T3-E1 for osteogenesis (Hakki et al, 2012), and MC3T3-L1 for 
adipogenesis (Bennett et al, 2002), preventing the direct extrapolation of the findings 
to human MSCs.  In addition to the difficulties faced due to the use of a range of cell 
lines and species, there is the added problem of MSC donor variation combined with 
heterogeneous MSC populations.  As MSCs are a primary cell line they are likely to 
differ in their properties between donors (Frank et al, 2002; Phinney et al, 1999; 
Siddappa et al, 2007), both in the proliferation rate and capacity to differentiate 
toward particular lineages.  Furthermore, as MSCs are solely selected by their 
adherence to plastic, the resulting cell population is often heterogeneous, containing 
multipotent stem cell, but also a population of less potent, early lineage committed 
cells (Minguell et al, 2001).  Together, these factors cause a difficulty in accurate 
reproduction between donors, in particular when combining absolute values, and as 
such comparisons between donors are often limited to trends.   
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As mentioned above, MSCs are classically derived from the bone marrow (Pittenger 
et al, 1999), however they have now been isolated from many adult stromal tissues 
(da Silva Meirelles et al, 2006; Kern et al, 2006; Sakaguchi et al, 2005), with the 
more common sources for in vitro differentiation analysis being bone marrow, 
skeletal muscle, adipose tissue, periosteum and synovium.  While cells isolated from 
all these tissue sources show similar epitope profiling irrespective of the source 
tissue, differences are observed in the colony forming capacity and differentiation 
capabilities of these cells (Sakaguchi et al, 2005).  Adipose-derived cells were shown 
to be less efficient at chondrogenic differentiation, whilst the periosteum extracted 
MSCs demonstrated poor adipogenic differentiation (Sakaguchi et al, 2005).  
Furthermore MSCs extracted from umbilical cord blood where not able to 
differentiate toward the adipogenic lineage at all (Kern et al, 2006).  Therefore the 
choice of MSC source is very important when considering experimental design and 
therapeutic uses. 
1.1.3.2 Therapeutic potential of MSCs 
Since their discovery, MSCs have generated a lot of interest in the biomedical field 
as a source for stem cell therapies, with their relatively simple ex vivo expansion, 
multilineage capacity and potential for autologous transplantation.  Indeed, clinical 
trials have been performed in patients with osteogenesis imperfecta, where 
allogeneic bone marrow-derived MSCs were given to patients after bone marrow 
transplantation.  MSC engraftment was shown and a marked increase in patient 
recovery was detected (Horwitz et al, 2002).  Another group implanted autologous 
bone marrow MSCs into articular cartilage defects of osteoarthritic patients 
(Wakitani et al, 2002).  Mouse models have also demonstrated the potential for 
MSCs in skeletal muscle repair, with engraftment and myogenic differentiation of 
human synovial membrane-derived MSCs leading to muscle repair in Duchenne 
muscular dystrophy mouse models (De Bari et al, 2003).  These studies, and others, 
coupled with cell scaffold engineering offer clear uses and delivery options for 
mesodermal tissue repair.  Tissue engineering techniques such as these involve the 
generation of a biocompatible scaffold on which cells are cultured before implanting 
into the patient, and in the case of MSCs this requires a thorough understanding of 
the differentiation process to ensure correct function of the implanted construct.  
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However, a lack of cell selection markers and the need to expand MSCs in culture 
creates problems of its own, most notably the rapid telomere shortening, a marker of 
ageing, and the resulting senescence of the MSCs (Baxter et al, 2004).  Any cells 
which are then used in therapeutic treatments after in vitro expansion will therefore 
have greatly impaired proliferation, differentiation and cell homing capability.  
Another area in which MSCs offer therapeutic potential is in regard to their 
immunosuppressive capacity.  While MSCs offer the obvious potential of tissue 
repair and replacement mentioned above, they also offer a broader therapeutic 
potential, through the regulation of the immune response.  Upon activation MSCs 
secrete soluble mediators, such as nitric oxide, prostaglandin, indoleamine 2,3-
dioxygenase, Interleukin-6, and human leukocyte antigen-G. These mediators can 
then regulate the proliferation and function of a variety of immune cells (Ghannam et 
al, 2010).  MSCs also demonstrate an ability to home to sites of inflammation, 
through the migration towards chemokines and cytokines (Sordi et al, 2005).  
Therefore there is a great deal of interest in the study of MSCs to treat inflammation 
through non-invasive systemic administration of MSCs (Ghannam et al, 2010). 
1.1.3.3 In vitro differentiation of MSCs 
MSCs have the ability to differentiate into multiple cell types including osteoblasts, 
adipocytes, chondrocytes, stomal cells and myocytes (Figure 1.1.1), and various 
methods have been developed to mimic these processes in vitro.  Osteoblasts 
develop through a series of phases, initiated by cellular proliferation, followed by 
extracellular matrix (ECM) maturation and matrix mineralisation.  These changes in 
cellular activity correlate with a pattern of maturation of the cells from committed 
osteoprogenitors to pre- and finally terminally differentiated osteoblasts.  This 
process of cell maturation can be induced in vitro by the addition of bone 
morphogenetic proteins (BMPs), often BMP-2 (Banerjee et al, 2001), or the addition 
of a differentiation cocktail of dexamethasone, ascorbate and β-glycerophosphate 
(Jaiswal et al, 1997).  While both these methods are capable of inducing the 
osteogenic differentiation of MSCs, it is likely that they act through different 
mechanisms to generate a comparable response.  This differentiation process 
ultimately leads to the formation of osteoblasts expressing osteoblast-specific genes 
such as a temporal increase in alkaline phosphatase (ALP) during osteogenic 
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commitment, followed by increases in osteopontin (OP), osteonectin (ON), bone 
sialoprotein (BSP) and osteocalcin (OC), accompanied by the deposition of a 
mineralised matrix upon osteoblast maturation.  
As with osteoblasts, adipocytes mature though a series of increasingly committed 
cell types, before becoming terminally differentiated adipocytes, expressing 
adipocyte-specific markers such as fatty acid binding protein (FABP) 4 and 5 
(Samulin et al, 2008), fatty acid synthase (FAS), lipoprotein lipase (LPL), and 
glucose transporter 4 (GLUT4) and forming lipid vesicles.  In vitro adipogenesis can 
be induced in MSCs by the addition of a differentiation cocktail of dexamethasone, 
isobutylmethylxanthine (IBMX), indomethacin and insulin.   
Methods to induce the process of chondrogenesis have also been developed in vitro.  
Chondrogenic differentiation in vivo requires an initial condensation of the MSCs, 
which is mimicked in vitro by culturing MSCs as micromass pellets.  Chondrogenic 
differentiation can then be induced by the presence of transforming growth factor-β 
(TGF-β3) resulting in the appearance of a chondrocyte-like phenotype characterised 
by an upregulation of cartilage-specific molecules such as collagen type II and X, 
aggrecan, versican, biglycan, and decorin (Pelttari et al, 2008).  Differentiating 
chondrocytes mature through a sequence of defined steps, initially the MSCs 
differentiate into a proliferative non-hypertrophic stage termed chondroblasts.  This 
stage is characterised by a change from collagen type-I to type-II, IX and XI 
expression and a highly ordered columnar organisation.  This stage is then followed 
by a hypertrophic stage, marked by the expression of collagen type-X, which is vital 
for vascular invasion, osteoblast differentiation, and bone formation during 
embryonic development.  
MSCs can also be induced to form other mesodermal cells, such as myocytes and 
stromal cells, as well as the more unusual cardiomyocytes (Li et al, 2006; Rangappa 
et al, 2003).  There is also some evidence to suggest that MSC have a greater 
potency, and can differentiate towards mesoderm, neuroectoderm and endoderm 
tissues (Jiang et al, 2002; Tropel et al, 2006).  However, this thesis will concentrate 
on the three main differentiation processes, osteogenesis, adipogenesis and 
chondrogenesis. 
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Figure 1.1.1. Schematic showing the potency of MSCs, and the progression of 
differentiation along the various lineages. 
MSCs are a multipotent cell capable of self renewal, and differentiation into 
multiple mesenchymal lineages, including osteoblasts, osteocytes, chondrocytes 
and adipocytes. MSCs differentiate through a series of committed progenitor 
cells, and differentiated stages before final maturation into fully committed 
terminally differentiated cells. Adapted from Caplan and Bruder (2001) 
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1.2 Transcriptional Control of MSC differentiation 
The differentiation of MSCs into the three predominant lineages of osteoblasts, 
adipocytes and chondrocytes is governed by a variety of transcription factors.  The 
important and best studied ones are reviewed in detail below. 
1.2.1 Osteogenesis 
1.2.1.1 Runx2 
Runx2 is considered the major transcription factor controlling osteoblast 
commitment and differentiation, and is a member of the Runt-domain gene family 
expressed in mesenchymal cells early in skeletal development and throughout 
osteoblast differentiation, with molecular and genetic studies indicating its necessity 
in osteoblast differentiation of mesenchymal cells (Ducy et al, 1997; Komori et al, 
1997; Xiao et al, 1998).  Runx2 was initially identified as an important transcription 
factor in osteogenesis by its binding to a cis-element on the osteoblast-specific OC 
gene, and its forced expression in osteoblast precursor cells, MC3T3-E1, caused the 
transcription of OC and Type I collagen alpha 1 chain (Col1A1).  Additionally, it 
was shown that over expression of Runx2 can induce osteogenesis in vitro and in 
vivo, demonstrated by increased osteoblastic markers, OP and OC, increased ALP 
expression and mineralisation in vitro, while in vivo studies showed accelerated 
healing in critical-sized skull defects (Zheng et al, 2004).  Runx2 null mice showed 
the converse to also be true, with a complete absence of ossification, due to the 
maturational arrest of osteoblasts (Komori et al, 1997).  Runx2 exerts is pro-
osteogenic effects through its consensus sequence, first named the osteoblast-specific 
element (OSE), which can be found in the promoter region of many osteoblast genes, 
such as Col1A1 (Rossert et al, 1996), OP (Hijiya et al, 1994), BSP (Marie, 2008) and 
OC (Ducy & Karsenty, 1995).  Binding to these regions allows for the regulation of 
gene expression, resulting in the establishment of an osteoblast phenotype (Marie, 
2008). 
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Figure 1.2.1. Schematic showing the expression levels of transcription factors 
during the osteogenic differentiation of MSCs.   
Osteogenic differentiation of MSCs progresses through a series of increasingly 
committed progenitors before finally becoming mature osteoblasts capable of 
mineralisation.  This process is accompanied by the expression of a range of 
transcription factors.  The onset of differentiation is driven by the expression of 
Runx2 and osterix prior to the increase in the expression of the homeobox 
proteins Dlx3/5/6 and Msx2, which together regulate the maturation of the 
osteoblasts.  Adapted from Frith and Genever (2008) 
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More recent work has also implicated Runx2 in the trans-differentiation of 
preadipocytes into osteoblasts.  Takahashi (2011), demonstrated that over expression 
of Runx2 in the preadipocyte cell line, 3T3-E1, decreased the adipocyte markers 
Peroxisome proliferator-activated receptor (PPAR) γ2 and CAAT/enhancer binding 
protein (C/EBP) α and resulted in increased osteogenic markers such as ALP, OC 
and BSP (Takahashi, 2011).  This trans-differentiation was further enhanced by the 
addition of dexamethasone or the over expression of the mitogen-activated protein 
kinase phosphatase-1 (MKP-1).  Dexamethasone, a synthetic glucocorticoid, acts to 
enhance the activity of Runx2 by reducing the amount of Runx2 phosphoserine 
levels via MKP-1 (Phillips et al, 2006).  While others have demonstrated the 
phosphorylation of Runx2 on tyrosine, theonine and serine residues increases during 
dexamethasone induced osteogenesis (Shui et al, 2003). 
1.2.1.2 Osterix 
Osterix (Osx) has also been shown to be an important transcription factor involved in 
osteoblast commitment.  Osx-deficient mice were shown to have an absence of 
osteoblasts and defective bone formation (Nakashima et al, 2002), however, Osx 
appears to act downstream of Runx2 (Figure 1.2.1) as Osx is not expressed in Runx2 
null mice, but Runx2 expression remains in Osx null mice (Nakashima et al, 2002).  
The studies into the effects of over expression of Osx are a little less clear, with 
multiple groups demonstrating that Osx over expression is sufficient to induce 
osteogenesis (Tu et al, 2006; Wu et al, 2007), whereas Kurata et al (2007) recorded 
that Osx over expression was capable of initiating osteogenesis, shown by early 
marker expression, but failed to generate terminally differentiated osteoblasts 
(Kurata et al, 2007). This is further confirmed by experiments where human MSCs 
were subjected to over expression and knockdown of Osx, generating little effect 
alone, but in combination with BMP6 resulted in increased and reduced osteogenesis 
respectively (Zhu et al, 2012).  This group were also able to show that Osx over 
expression lead to an increase in osteoblast-specific ECM proteins, suggesting a role 
for Osx in the initiation of matrix deposition. 
Osx has also been implicated in the commitment decisions of osteo-chondro 
progenitor cells (Tominaga et al, 2009).  Mouse bone marrow MSCs, ST-2 and 
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C3H10T1/2 cells were induced to differentiate by BMP6 treatment, which resulted in 
the differentiation to both osteoblasts and chondrocytes in a cell type dependent 
manner.  MSCs, and to a smaller extent ST-2 cells formed osteoblasts when treated 
with BMP6, whilst C3H10T1/2 cells did not.  However, C3H10T1/2 cells 
differentiated strongly toward chondrogenesis.  ST-2 cells again differentiated 
slightly towards chondrogenesis, while MSCs failed to form chondrocytes.  The 
level of Osx in these different cell types was studied and shown to be highest in 
MSCs, and lowest in the C3H10T1/2 cells (Tominaga et al, 2009).  Furthermore, 
over expression of Osx in the C3H10T1/2 cells switched the differentiation from 
chondrogenic to osteogenic in response to BMP6, suggesting Osx acts during the 
lineage commitment decision of osteo-chondro progenitor cells, pushing the cells 
towards an osteogenic lineage.   
It is thought that Osx may act, at least in part through the formation of a complex 
with the nuclear factor of activated T cells (NFAT), resulting in activation of Col1A1 
promoter activity (Koga et al, 2005).  A proposal backed up by the constitutive 
activation of NFAT leading to increased bone formation and bone mass (Winslow et 
al, 2006). 
1.2.1.3 Homeobox proteins 
Dlx and Msx are homeodomain transcription factors homologous to the Drosophila 
Distal-less and muscle specific homeobox genes.  The expression patterns of Dlx5 
and 6 are very similar, and are present throughout almost all of the skeletal elements 
(Chen et al, 1996).  Over expression and knock out studies of these genes show a 
partial redundancy, and have implicated them in osteoblast differentiation.  Over 
expression of Dlx5 accelerated osteoblast differentiation in vitro (Tadic et al, 2002), 
while Dlx5 knockout mice had craniofacial and sensory skeletal defects (Depew et 
al, 1999).  Double knockouts of Dlx5 and 6 presented more severe defects (Robledo 
et al, 2002), implying partial redundancy or compensation between the two 
transcription factors.  A third member of the Dlx family, Dlx3, has also been 
implicated in osteogenic differentiation.  Dlx3 expression in the mouse embryo was 
associated with new bone formation and regulation of osteoblast differentiation.  
Furthermore, Dlx3 was expressed in ex vivo osteoblasts, which when over expressed 
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or reduced by RNAi knock down resulted in increased and decreased osteogenesis 
respectively (Hassan et al, 2004).   
In contrast to the expression of Dlx transcription factors in regions of osteoblast 
differentiation and bone formation, Msx2 is expressed in the proliferating osteogenic 
precursors (Hassan et al, 2004).  Fitting with this expression pattern, over expression 
of Msx2 prevented osteogenic differentiation and mineralisation of primary cultured 
chick calvarial osteoblasts, while over expression of the antisense mRNA resulted in 
decreased proliferation and enhanced osteogenesis (Dodig et al, 1999).  Therefore 
homeobox proteins can act to both enhance osteogenesis, but also maintain the 
precursors in a proliferative undifferentiated state. 
1.2.2 Adipogenesis 
1.2.2.1 PPARγ 
As with Runx2 in osteogenesis, there is a key transcription factor involved in the 
adipogenic differentiation of MSCs, peroxisome proliferator activated receptor-γ 
(PPARγ) (Figure 1.2.2).  PPARγ is a nuclear hormone receptor, thought to be the 
master regulator of adipogenesis.  Alternative splicing generates 2 isoforms of 
PPARγ, PPARγ1 is ubiquitously expressed whilst PPARγ2 is restricted to adipose 
tissues and is a more potent stimulator of adipogenesis (Mueller et al, 2002).  PPARγ 
was discovered as key player in adipogenesis through its interaction with the 5'-
flanking region of the FABP4 gene, a gene capable of inducing adipocyte-specific 
gene expression.  It was subsequently shown to be expressed very early in the 
differentiation of adipocytes, with forced over expression of PPARγ inducing 
adipogenesis in cultured fibroblasts (Tontonoz et al, 1994).  Interestingly, the 
capacity of PPARγ to induce adipogenesis is not limited to fibroblastic cells; 
myoblastic cell lines transdifferentiated to adipocytes upon ectopic expression of 
PPARγ and C/EBPα, and PPARγ activation (Hu et al, 1995).  Complementary 
experiments have also been performed.  PPARγ deletion in fibroblasts resulted in 
reduced adipogenesis (<2% efficiency) despite the addition of another stimulator of 
adipogenesis, C/EBPα (Discussed in 1.2.2.2) (Rosen et al, 2002), suggesting C/EBPα 
acts through PPARγ to stimulate adipogenesis.  These results and others suggest 
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Figure 1.2.2. Schematic showing the expression levels of transcription factors 
during the adipogenic differentiation of MSCs.   
Adipogenic differentiation of MSCs progresses through a series of gradually 
committed progenitors prior to terminal differentiation.  Hormonal signals induce 
the expression of C/EBPβ/δ in early commitment and mitotic clonal expansion 
(MCE) before CHOP10 is reduced, allowing C/EBPβ to stimulate C/EBPα and 
PPARγ, which increase each other’s expression through a positive feedback 
mechanism, causing the upregulation of adipogenic genes, and adipocyte 
maturation.  Adapted from Frith and Genever (2008) 
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PPARγ is both sufficient and indispensable for adipogenic differentiation.  While 
PPARγ is widely considered the master regulator of adipogenesis, it has also been 
implicated in the reciprocal regulation of adipogenesis and osteogenesis.  Akune et 
al (2004) showed that embryonic stem cells from homozygous PPARγ-deficient 
mice would spontaneously differentiate into osteoblasts, while PPARγ 
haploinsufficiency resulted in enhanced bone formation with increased osteogenesis 
from bone marrow progenitors both in vivo and ex vivo.  
1.2.2.2 C/EBPs 
CAAT/enhancer binding proteins (C/EBPs) are members of the basic-leucine zipper 
class of transcription factors, which function as homo- or heterodimers with other 
C/EBP family members.  Three C/EBP family members have been shown to play a 
role in adipogenesis, C/EBPα, β and δ.  C/EBPα has the most prominent role, 
dramatically demonstrated by the over expression of C/EBPα in fibroblastic cells, 
which resulted in the induction of adipogenesis in up to 50% of the cells (Freytag et 
al, 1994); conversely antisense mRNA knockdown resulted in reduced adipose 
phenotype in differentiated MC3T3-L1 cells (Lin & Lane, 1992).  In vivo mouse 
models were able to confirm these in vitro findings, with the restriction of C/EBPα 
expression to the liver in mice, which subsequently presented reduced adipose tissue 
formation (Linhart et al, 2001).  The study of endogenous C/EBP levels during 
adipogenic differentiation of cultured cells showed that C/EBPα is expressed late in 
the differentiation process immediately prior to the activation of the many adipocyte 
specific genes (Figure 1.2.2).  The other two isoforms, C/EBPβ and δ are only 
transiently expressed, accumulating during the early stages of differentiation (Figure 
1.2.2), before diminishing prior to terminal differentiation (Yeh et al, 1995).  This 
early transient increase in C/EBPβ and δ allows them to act by relaying the hormonal 
signals such as dexamethasone and methylisobutylxanthine, leading to the activation 
of C/EBPα (Yeh et al, 1995).  This signal transduction is likely to function through 
the activation of PPARγ, via C/EBP binding sites in the PPAR promoter.  This 
PPARγ expression is then thought to activate C/EBPα, which then enters a positive 
feedback loop, increasing the expression of PPARγ.  This process is apparent 
through the generation of PPARγ and C/EBPα null cell lines (Rosen et al, 1999; Wu 
et al, 1999), where PPARγ null cells fail to express C/EBPα despite normal early 
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differentiation (Rosen et al, 1999).  Additionally, C/EBPα null fibroblasts have 
reduced levels of PPARγ expression, which can be rescued by retroviral transfection 
and expression of C/EBPα (Wu et al, 1999).  It is thought that this positive feedback 
loop maintains the expression of these two important transcription factors through to 
terminal differentiation of the adipocytes. 
1.2.2.3 SREBP1 
Another transcription factor of note for its pro-adipogenic effects is Sterol regulatory 
binding element protein-1 (SREBP1)/Adipocyte differentiation and determination 
factor-1 (Add1).  Dominant negative expression of SREBP1 in MC3T3-L1 cells 
sharply repressed adipogenic differentiation, while over expression of SREBP1 in 
the fibroblastic line, NIH-3T3, increased adipogenesis in a synergistic manner with 
PPARγ over expression, suggesting its involvement in this pathway (Kim & 
Spiegelman, 1996).  SREBP1 exerts it pro- adipogenic effects through the interaction 
with E-box domains in the PPARγ promoter regions, allowing further regulation of 
PPARγ gene expression (Fajas et al, 1999). 
1.2.2.4 Negative regulation of adipogenesis 
As with osteogenesis, there are inhibitors of adipogenesis allowing for tight 
regulation of the differentiation process.  C/EBP homologous proteins (CHOPs) 
negatively regulate adipogenesis through interactions with C/EBPs.  An example of 
this effect is elegantly demonstrated by the Lane laboratory (Tang & Lane, 2000; 
Tang et al, 2003a; Tang et al, 2003b).  During adipogenesis, growth-arrested pre-
adipocytes re-enter the cell cycle and undergo mitotic clonal expansion (MCE) prior 
to the expression of C/EBPα and PPARγ which act as antimitotics.  As discussed 
above, C/EBPβ/δ relay the hormonal signals through the upregulation of C/EBPα 
and PPARγ, and are expressed early in the differentiation program, prior to MCE.  
However, in order to allow MCE to occur, C/EBPβ must not activate C/EBPα and 
PPARγ until cell division has occurred.  This was shown to be achieved through the 
binding of CHOP10 to C/EBPβ prior to MCE, preventing it from binding the 
C/EBPα and PPARγ promoter regions.  When the dividing cells entered S phase, 
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CHOP10 was down regulated leading to alleviation of C/EBPβ inhibition, and 
adipogenic progression (Tang & Lane, 2000) (Figure 1.4.2).   
The activity of SREBP1 is also negatively regulated during adipogenesis, by the 
binding of Inhibitor of DNA binding (Id) proteins which prevent SREBP1 from 
binding to the E-box DNA regulatory sequences (Moldes et al, 1999).  Another 
transcription factor important in the negative regulation of adipogenesis is the GATA 
binding transcription factor family.  GATA2 and 3 have been shown to be expressed 
in pre-adipocytes, and their down regulation leads to enhanced adipogenesis.  Forced 
expression of GATA2 and 3 prevents the switch from pre-adipocytes to mature 
adipocytes, in part through binding directly to PPARγ (Tong et al, 2000), but also 
through the formation of protein complexes with C/EBPα or β (Tong et al, 2005). 
1.2.3 Chondrogenesis  
1.2.3.1 Sox family of transcription factors 
As with both adipogenesis and osteogenesis, there is an apparent master regulator of 
chondrogenesis, Sox9.  Sox9 is a member of a family of transcription factors that 
contain a High mobility group (HMG) -type DNA binding domain, and is expressed 
throughout chondrogenic differentiation until the cells become hypertrophic, where it 
is rapidly shut off (Zhao et al, 1997) (Figure 1.2.3).  The requirement for Sox9 is 
clearly demonstrated in the work by Akiyama et al (2002), where deletion of Sox9 
expression in the mesenchymal cells of limb buds led to the complete absence of 
chondrogenic mesenchymal condensations in the developing limbs, while deletion of 
the Sox9 gene in mesenchymal condensations led to the arrest of chondrogenesis at 
this stage (Akiyama et al, 2002), demonstrating roles in both mesenchymal 
condensation and chondrogenic progression. 
Furthermore, Sox9 was identified as part of a triad of Sox genes, with L-Sox5 and 
Sox6, which are sufficient for the induction of chondrogenesis in embryonic stem 
cells (Ikeda et al, 2004).  L-Sox5 and Sox6 differ from Sox9 in that they do not 
possess a transactivation domain and therefore do not affect gene expression directly, 
but are thought to alter gene expression through the recruitment of other 
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transcriptional activators (Frith & Genever, 2008).  L-Sox5 and Sox6 are 
co-expressed with Sox9 during chondrogenesis (Figure 1.2.3) and therefore share 
expression patterns with the chondrogenic marker type 2 collagen alpha 1 (Col2A1), 
prompting further studies into the role of these transcription factors in 
chondrogenesis.  L-Sox5- and Sox6-deficient mice present chondrogenic defects, 
with the dual knockout generating a more severe phenotype, suggesting some 
redundancy.  However, in contrast to Sox9-deficient mice, Sox5/6-deficient mice do 
develop chondrogenic mesenchymal condensations (Smits et al, 2001), implicating 
their role later in the differentiation process.  It is thought that these three Sox 
transcription factors work in collaboration to activate chondrocyte-specific markers, 
with enhanced Col2A1 reporter expression when all three Sox genes are coexpressed 
in non-chondrogenic cells (Lefebvre et al, 2001).  Similarly, the three Sox proteins 
have been shown to cooperatively activate the chondrocyte marker, type XI collagen 
alpha 2 (Bridgewater et al, 1998).  As discussed above, Sox transcription factors are 
required for the progression of chondrogenesis, but over expression of the Sox triad 
also causes chondrogenesis arrest at the pre-hypertrophic cell stage preventing 
terminal differentiation (Ikeda et al, 2004).  It is thought that this terminal 
differentiation inhibition is at least in part due to the action of two genes, S110A1 
and S100B, members of the S100 protein family which carry the Ca
2+
-binding EF-
hand motif.  These proteins are expressed during the late proliferative and pre-
hypertrophic stages of chondrogenesis, and when over expressed in chondrogenesis 
inhibited the terminal differentiation step.  Furthermore, S100B protein expression is 
responsive to the Sox triad through enhancer elements in the 5’ flanking region 
(Saito et al, 2007).  
1.2.3.2 Runx2 
As described above, Runx2 is a master regulator of osteogenesis, but it also has 
important roles in regulating chondrogenesis.  The initial evidence for this was 
presented in the Runx2 null mice used to identify its function in osteogenesis.  It was 
noted that these mice also had cartilage defects as well as the more obvious bone 
defects (Kim et al, 1999).  Runx2 null mice had a lack of hypertrophic chondrocytes, 
implying an important role for Runx2 in this step.  The expression levels of Runx2 
are at their highest in chondrocytes during the hypertrophic stage 
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Figure 1.2.3. Schematic showing the expression levels of transcription factors 
during the chondrogenic differentiation of MSCs.   
Chondrogenic differentiation of MSCs progresses through a series of increasingly 
committed pre-hypertrophic progenitors, before undergoing hypertrophy and 
becoming terminally differentiated hypertrophic chondrocytes.  Sox9 is expressed 
upon the onset of chondrogenesis, which activates L-Sox5 and Sox6 which act 
together to promote the pre-hypertrophic stages of chondrogenic differentiation.  
The Sox triad is then switched off and Runx2 is up regulated and induces 
hypertrophy and the maturation of the chondrocytes.  Adapted from Frith and 
Genever (2008) 
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(Kim et al, 1999) (Figure 1.2.3), and over expression of Runx2 during hypertrophy 
caused enhanced maturation and increased endochondral ossification (Enomoto-
Iwamoto et al, 2001). 
1.3 Cell signalling 
Cell signalling pathways are important in many aspects of embryonic development 
and adult tissue homeostasis, including that of MSC self renewal and differentiation.  
Three pathways that have been extensively linked to MSC differentiation are that of 
Wnt, TGFβ-superfamily and Hedgehog signalling, and are described in more detail 
below. 
1.3.1 Wnt signalling 
Wnt molecules are a family of cysteine-rich secreted glyco-lipoproteins, 
approximately 40kDa in size, that regulate many processes including development, 
cell proliferation and cell fate (Clevers & Nusse, 2012).  Wnt signalling acts through 
two known pathways, the canonical pathway involving β-catenin, and the β-catenin 
independent pathways termed the non-canonical pathways. The canonical Wnt 
pathway is the better studied and will be discussed in more detail here.  Canonical 
Wnt ligands mediate their effects by binding to their receptors frizzled (Fzd) and co-
receptors, low-density lipoprotein receptor related protein (LRP) 5 and 6. This leads 
to the inhibition of a protein destruction complex, resulting in the stabilisation and 
nuclear translocation of β-catenin, inducing gene transcription via the T Cell 
Transcription factor/Lymphoid enhancer-binding factor (LEF/TCF) family of 
transcription factors. In the absence of Wnt signalling, the destruction complex is not 
inhibited and can therefore perform its function to phosphorylate β-catenin, leading 
to degradation by the proteosome (Figure 1.3.1).  
Human and most other mammalian genomes contain 19 Wnt genes, which fall into 
12 conserved subfamilies.  Furthermore Wnt genes can be found in all multicellular 
organisms, including sponges, but not single cellular organisms, highlighting the 
crucial role of Wnt in evolution and cellular patterning (Clevers & Nusse, 2012).  
The first successful purification of a functional Wnt ligand was achieved by Willert 
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et al. (2003), who were able to purify Wnt3a capable of stabilising β-catenin, a 
downstream target of canonical Wnt signalling.  Wnt3a was shown to be 
palmitoylated on a conserved cysteine, and the removal of the palmitate caused the 
protein to become water soluble, and lose the ability to stabilise β-catenin.  The 
importance of this palmitoleic acid lipid modification has subsequently been 
reinforced by structural studies of the Xenopus Wnt8 protein in complex with a Fzd 
receptor (Janda et al, 2012).  The proteins where shown to interact in two places, one 
of which included the palmitoleic acid lipid.   
The Wnt ligands bind a heterodimeric complex, composed of a Fzd receptor 
component, and a LRP5/6 co-receptor.  The ten mammalian frizzled receptors, are 
seven transmembrane receptors with large cysteine-rich extracellular domains, 
important for Wnt ligand binding (Janda et al, 2012).  The interaction between Wnt 
ligands and the frizzled receptors is promiscuous, with the ability of a single Wnt 
ligand to bind multiple Fzd receptors and vice versa (Bhanot et al, 1996; Wodarz & 
Nusse, 1998).  As stated above,  a co-receptor of either LRP5 or 6 is required for 
signal transduction (Wehrli et al, 2000), which act as a complex to transduce the 
signal.  A crucial step in canonical Wnt signalling transduction is the recruitment of 
Axin to the cytoplasmic tail of the LRP5/6 co-receptor (Mao et al, 2001), which is a 
process regulated by the phosphorylation of the LRP5/6 cytoplasmic tail by GSK3β 
and casein kinase 1 (CK1) (Zeng et al, 2005).  
While LRP5/6 transduces the signal, through the binding of Axin, Fzd function is 
required for LRP5/6 phosphorylation, furthermore, the forced association of Fzd and 
LRP6 is sufficient to trigger the phosphorylation of LRP6 (Zeng et al, 2008).  One 
model for the involvement of the Frizzled receptors draws from the requirement of 
Dishevelled (Dvl)/Fzd interaction for the recruitment of Axin to LRP5/6 and its 
subsequent phosphorylation (Bilic et al, 2007; Zeng et al, 2008).  This is thought to 
act through the binding of Dvl to the Axin component of the destruction complex, 
causing its recruitment to the Fzd/LRP receptor complex by Dvl binding to Fzd.  
This allows for the phosphorylation of LRP5/6 by GSK3β, inducing Axin/ LRP5/6 
interaction (Zeng et al, 2008). 
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The mechanism by which Axin recruitment to the LRP5/6 co receptor leads to signal 
transduction can be explained by first understanding the mechanism for maintaining 
low levels of β-catenin in the cell.  In resting cells, β-catenin is efficiently captured 
by a destruction complex, composed of Axin, Adenomatous polyposis coli (APC), 
Dvl, CK1 and GSK3β. This destruction complex causes the phosphorylation of β-
catenin, first by CK1 at Ser45, priming β-catenin for phosphorylation by GSK3β at 
Thr41, Ser37, and Ser33 (Liu et al, 2002).  This phosphorylation primes β-catenin 
for recognition by the F-box-containing protein β-TrCP ubiquitin E3 ligase, leading 
to the ubiquitination of β-catenin and its degradation by the proteosome (Aberle et 
al, 1997; Kitagawa et al, 1999), removing β-catenin from the complex thereby 
recycling the destruction complex for further β-catenin phosphorylation (Li et al, 
2012).  However, upon Wnt ligand binding to the Fzd receptor and co-receptor 
LRP5/6, Dvl and Axin are recruited to the receptor complex, as described above, 
leading to the disruption of β-catenin phosphorylation and degradation by the 
destruction complex allowing for β-catenin accumulation in the cytoplasm of the 
cell.  The precise mechanism underlying this process is not clear, but a recent 
publication (Li et al, 2012) suggests that the recruitment of the destruction complex 
to the receptor complex prevents the ubiquitination of β-catenin, and therefore the 
removal of β-catenin from the destruction complex by the proteosome.  This leads to 
the saturation of the destruction complex, allowing for the accumulation of β-catenin 
in the cytoplasm, where it can go on to translocate into the nucleus and alter gene 
expression. 
Ultimately, canonical Wnt signalling exerts its effect through transcriptional control 
by β-catenin and its interaction with the TCF/LEF1 family of transcription factors 
(Behrens et al, 1996; Molenaar et al, 1996).  TCF/LEF1 proteins are HMG (high 
mobility group) DNA-binding factors, which bind to a DNA sequence termed the 
Wnt responsive element (WRE), AGATCAAAGG (van de Wetering et al, 1997). In 
the inactive state, without β-catenin binding, TCF/LEF1 transcription factors interact 
with Groucho transcriptional repressors preventing gene expression (Cavallo et al, 
1998).  Upon Wnt activation and β-catenin translocation to the nucleus, Groucho is 
displaced by β-catenin, which then interacts in a complex with DNA, generating 
DNA bending and causing alterations in local chromatin structure (Behrens et al, 
1996).  The complex also recruits various transcriptional coactivators and histone 
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Figure 1.3.1. Schematic of Canonical Wnt signalling   
In the absence of Wnt signalling, a destruction complex containing Axin, APC, 
GSK3β, CK1, βTrCP phophorylates β-catenin, leading to degradation by 
ubiquitination and the proteosome.  Canonical Wnt signalling mediates its effect 
by binding to the receptors frizzled (Fzd) and co-receptors, LRP 5/6. This causes 
recruitment of the destruction complex to the membrane through Axin and Dvl 
interactions with the LRP5/6 co-receptor and Fzd receptor respectively.  This 
leads to the dissociation of βTrCP and the proteosome from the destruction 
complex, and prevents the degradation of β-catenin, resulting in the stabilisation 
and nuclear translocation of β-catenin, inducing gene transcription via the 
LEF/TCF family of transcription factors.  
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modifiers to induce gene transcription (Clevers & Nusse, 2012).  The process by 
which β-catenin enters the nucleus to interact with TCF/LEF1 transcription factors 
and instigate transcription is poorly understood, although recent work suggests a role 
for microtubule rearrangement and active transport of β-catenin upon Wnt activation 
(Sugioka et al, 2011)  
In addition to the complexity of regulation dictated by the large array of Wnt ligands 
and receptors, there is also a range of negative regulators of the canonical Wnt 
pathway.  Two protein families important in Wnt regulation are secreted Frizzled-
related proteins (sFRPs) and Wnt inhibitory proteins (WIFs).  Both of these are 
capable of binding to Wnt ligands, preventing the binding of Wnt proteins to their 
Fzd receptors.  sFRPs can also bind the Fzd receptors themselves, blocking Wnt 
ligand binding (Bovolenta et al, 2008).  A further two families, the Dickkopf (DKK) 
and WISE/SOST families, act by disrupting the formation of the Fzd/LRP receptor 
complex by binding to the LRP5/6 co-receptor (Semenov & He, 2006; Semënov et 
al, 2005).  A final example of negative Wnt regulation is that of the Shisa protein 
family.  Shisa acts within the endoplasmic reticulum, by interacting with immature 
forms of Fzd, preventing the post translational maturation and trafficking of the 
receptor (Yamamoto et al, 2005). 
1.3.2 TGFβ-Superfamily Signalling Pathways 
The TGFβ-superfamily is a large family of growth factors, containing at least 30 
members in mammals.  However, these can be categorised into two main groups; the 
transforming growth factor (TGF)β-like group that includes TGFβs, Activins, Nodals 
and some Growth and Differentiation Factors (GDFs), and the Bone Morphogenetic 
Proteins (BMP)-like group comprised of BMPs, most GDFs and Anti-Müllerian 
Hormone (AMH).   
TGFβ-superfamily ligands are translated as large precursor proteins, consisting of a 
large amino terminal prodomain, important in protein folding, and a highly 
conserved carboxy-terminal region, containing the active ligand.  These precursors 
dimerise due to disulphide linkages via conserved cysteine residues before being 
cleaved by proprotein convertases, to leave the TGF-β ligands non-covalently 
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Figure 1.3.2. Schematic of TGFβ superfamily signalling   
TGFβ/BMPs signal through a receptor heterodimer complex on the cell surface.  
The interaction with the ligand brings the type I (RI) and type II (RII) receptors 
together, allowing for the phosphorylation, and activation of RI, by the 
constitutively active RII.  RI then phosphorylate and activate their respective R-
SMADs, which in turn bind to the Co-SMAD (SMAD 4).  This R-SMAD/Co-
SMAD complex then enters the nucleus where it interacts with transcription 
factors to induce gene expression 
41 
 
associated with their prodomains, which are then secreted from the cell.  The 
prodomain is thought to localise TGF-β ligands toward their target cells via 
interactions with extracellular matrix proteins (Harrison et al, 2011).  Generally, 
ligands form homomeric complexes, although the existence of heteromeric 
complexes has been noted.  These dimeric complexes then transmit their signal via a 
heteromeric receptor complex, comprising of type I and II transmembrane 
serine/threonine kinase receptors (Figure 1.3.2).  In mammals, five Type I and seven 
Type II receptors exist, characterised by a cytoplasmic kinase domain that has strong 
serine/threonine kinase activity and weaker tyrosine kinase activity (Moustakas & 
Heldin, 2009).  The effect of ligand binding, creating this heterotetrameric complex, 
is to bring the constitutively active Type II receptor into contact with the dormant 
Type I receptor, allowing for the phosphorylation of the Type I receptor, activating 
the kinase activity, and propagating the signal (Wrana et al, 1994).  Despite the 
seven Type I receptors, they can be categorised into two families, those which 
propagate TGFβ-like ligand signalling onto TGFβ-like specific SMADS (SMADs 
2/3), or those which propagate BMP-like ligand signalling onto BMP-like specific 
SMADS (SMADs 1/5/8).  The phosphorylated Type I receptors phosphorylate the 
receptor SMADs (R-SMADs), which in turn leads to the interaction of the R-
SMADs with SMAD4 (Co-SMAD).  This R-SMAD/Co-SMAD complex then 
translocates to the nucleus of the cell, where they bind to chromatin and interact with 
other transcription factors and alter gene expression (Moustakas & Heldin, 2009).  In 
the basal state, SMAD proteins continuously shuttle between the nucleus and the 
cytoplasm by interactions with nucleoporins, however when complexed as R-
SMAD/Co-SMAD the transfer into the nucleus requires nuclear import and export 
factors (Hill, 2009).  A third member of the SMAD family, the inhibitory SMADS 
(I-SMADS), also plays an important role in TGFβ-superfamily signalling.  I-SMAD 
expression is activated by TGFβ-superfamily signalling, and they act as negative 
regulators of the signalling pathway through the binding to the Type I receptor, 
preventing binding to Type II receptors.  I-SMADs also recruit phosphatases and 
Smurf ubiquitin ligases to down regulate receptor levels by ubiquitination and 
degradation (Kavsak et al, 2000).   
SMAD complexes bind to the DNA at SMAD binding element (SBE) regions, which 
consist of direct or inverted repeats of its core sequence 5′-AGAC-3′ (Shi et al, 
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1998).  In basal conditions, these SBE regions are bound by the transcriptional 
repressors SKI and SNON, which are rapidly degraded upon TGFβ-superfamily 
signalling (Levy et al, 2007).  These short SBE regions only allow weak binding to 
the DNA and often require the interaction with other DNA-binding factors.  The first 
factor that was shown to interact with SMADs to target DNA binding was Foxh1, 
which binds to the TGFβ R-SMADs 2/3, leading to the proposal that R-SMADs 
determine gene specificity through interaction with DNA binding partners, while the 
Co-SMAD acts to promote translational activity.  Upon DNA binding, the SMADs 
recruit coregulators to promote transcription, including basic chromatin remodelling 
complexes and histone modifying acetyltransferases. 
1.3.3 Hedgehog Signalling Pathway 
Another well studied signalling pathway shown to be involved in bone development 
is the hedgehog (Hh) pathway (Hu et al, 2005; Long et al, 2004; St-Jacques et al, 
1999) (Figure 1.3.3).  Hedgehog signalling was first identified in Drosophila , where 
a single Hh protein regulates many diverse aspects of embryonic and adult 
patterning.  Subsequent work has identified a highly conserved pathway in 
mammals, which shows a greater degree of complexity.  This is most obvious in that 
there are three Hh proteins; Sonic hedgehog (Shh), Desert hedgehog (Dhh), and 
Indian hedgehog (Ihh).  Some functional redundancy can be seen between these 
types, however they possess distinct expression profiles with little overlap (Bitgood 
& McMahon, 1995). 
Hh proteins are transcribed as precursor molecules, which require a series of 
cleavage and translational modification events before secretion from the cell  
(Varjosalo & Taipale, 2007).  All Hh proteins signal through the same receptors and 
signalling pathway, which is triggered by the binding of Hh to its receptor, Patched 
(Ptc).  In the absence of any Hh interaction, Ptc acts to inhibit the activity of a 7-
transmembrane protein, Smoothened (Smo).  One explanation for this inhibition was 
proposed by Taipale et al, (2002), where in the absence of Hh, Ptc translocates a 
small molecule, which can regulate Smo activity, across the membrane bilayer.  The 
small molecule substrate could then be acting either as a Smo agonist before or as an 
antagonist after translocation by Ptc.  Upon Hh binding to Ptc, Smo repression is 
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Figure 1.3.3. Schematic of Hedgehog signalling   
In the absence of any Hedgehog ligand the Hedgehog signalling complex 
phosphorylates the Gli family of transcription factors, leading to degradation or 
proteolytic cleavage to transcriptional repressors (GliR). In the presence of 
Hedgehog ligand, signalling is mediated through the binding of Hedgehog to their 
receptor Patched (Ptc). This causes the inhibition of a second transmembrane 
protein, Smoothened (Smo), to be relieved. Smo is then able to inhibit the 
Hedgehog signalling complex preventing the phophorylation of the Gli proteins, 
priming them for transcriptional activation (GliA). 
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alleviated leading to signal transduction and the conversion of the Ci/Gli family of 
transcription factors to an activating state.  It is at this stage that an additional level 
of complexity is generated in mammals.  Drosophila possess a single Ci 
transcription factor, while there are three Gli transcription factors in mammals; Gli1, 
2, which generally act as transcriptional activators, and Gli3, which acts as a 
repressor (Gupta et al, 2010).   
Smo exerts its effect on signal transduction by inhibiting the hedgehog signalling 
complex, primarily consisting of GSK3β, protein kinase A (PKA) and CK1.  Under 
inactive conditions, when Smo activity is inhibited by Ptc, this complex acts to 
phosphorylate the Gli transcription factors, priming the Gli proteins for degradation 
or proteolytic cleavage.  This has the overall effect of increasing the transcriptional 
repressor forms of the Gli proteins, preventing target gene transcription.  Conversely, 
the release of inhibition of Smo, by Hh binding to Ptc, results in inhibition of the 
Hedgehog signalling complex, and therefore prevents phosphorylation of the Gli 
proteins.   The predominant Gli state is therefore converted to activatory, leading to 
the transcription of target genes. 
1.4 Cell signalling during MSC differentiation 
Cell signalling is important for both the embryonic development and maintenance of 
adult tissues and organs, including that of MSC differentiation and bone 
homeostasis.  The involvement of three important signalling pathways in MSC 
differentiation are described below, and their role in the commitment towards 
osteoblasts, adipocytes and chondrocytes is reviewed.  
1.4.1 Osteogenesis 
1.4.1.1 Canonical Wnt signalling 
Wnt signalling was first implicated in bone regulation by studies of osteoporosis 
pseudoglioma syndrome patients (characterised by low bone mineral density) who 
possessed loss of function mutations in the co-receptor LRP5, and therefore reduced 
canonical Wnt signalling (Gong et al, 2001).  Subsequent studies in patients with 
high bone mass showed the converse to also be true.  Mutations in the N-terminus of 
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LRP5 reduce its binding affinity with the Wnt signalling inhibitor Dkk1, thereby 
preventing Wnt inhibition, leading to this high bone mass phenotype (Boyden et al, 
2002).  Mouse models have reinforced these discoveries, in which LRP5 over 
expression (Babij et al, 2003) and reduced inhibition of Wnt signalling by sFRP1 
knock down (Bodine et al, 2004) resulted in increased bone mass and density.   
In light of these bone anabolic responses to altered Wnt signalling and the clear 
correlation between osteo-inducers and increased Wnt signalling, many in vivo and 
in vitro studies have been carried out using a range of activators and inhibitors of the 
Wnt signalling pathway, with the aim of identifying the molecular basis behind the 
increased bone mass phenotype.  One process by which Wnt signalling may act to 
increase bone formation that has received a lot of attention is the stimulation of 
osteoblast development.  Inhibition of GSK3β enzyme activity using LiCl or small 
molecules, caused increased β-catenin nuclear translocation, and stimulated the 
mouse mesenchymal precursor cell line, C3H10T1/2, to express osteoblast specific 
genes (Jackson et al, 2005; Kulkarni et al, 2006).  Similar studies were also carried 
out using Wnt10b to stimulate the canonical Wnt pathway (Bennett et al, 2005) in 
bipotential ST2 cells, resulting in increased expression of osteoblast-specific genes 
and mineralisation.  Similarly, over expression of Dkk1 reduces osteoblast 
differentiation (Krishnan et al, 2006).  Further to this, in vivo work has shown that 
administration of LiCl, a GSK3β inhibitor, to C57BL/6 mice for 4 weeks 
dramatically increased bone formation rate (Clement-Lacroix et al, 2005).  One route 
by which Wnt is thought to promote osteogenesis is through the direct stimulation of 
Runx2 expression (Gaur et al, 2005).  Gaur et al. (2005) identified a TCF binding 
site in the promoter of Runx2 and demonstrated an increase in Runx2 expression in 
response to co-expression of TCF and canonical Wnt proteins. 
However, while there is a good deal of evidence in mouse in vivo and in vitro for the 
role of Wnt in inducing osteogenic differentiation, the research in human MSCs is 
much less conclusive and straightforward.  This difference is clearly demonstrated 
by the work carried out by Boland et al (2004), which demonstrated that Wnt3a 
conditioned media, leading to canonical Wnt signalling, caused inhibition of 
osteogenic differentiation demonstrated by reduced ALP mRNA and activity and 
decreased mineralisation (Boland et al, 2004).  Induced Wnt signalling did however 
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Figure 1.4.1. Schematic showing the interplay between transcription factors 
and cell signalling during osteogenic differentiation 
Both BMP and canonical Wnt signalling play important roles in osteogenic 
differentiation of MSCs.  BMPs induce the expression of Runx2, via Dlx5, 
leading to the upregulation of osteogenic genes.  Runx2, also acts to direct 
SMAD1/5 transcription factor complexes to specific chromatin loci, where 
osteogenic genes are grouped.  The role of canonical Wnt signalling is less clear.  
Canonical Wnt signalling appears to increase the initial stages of osteogenesis, 
generating ALP positive pre-osteoblasts, potentially through the up regulation of 
Runx2.  However, canonical Wnt signalling prevents the final maturation into 
mineralising osteoblasts. 
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appear to increase the proliferation rate of human MSCs, whilst at the same time 
reducing apoptosis.  Similar results have been shown in human MSCs by inducing 
Wnt signalling at different stages of the canonical pathway, including LRP5 and 
TCF1 (Baksh et al, 2007a), which caused reductions in the osteogenic marker, ALP, 
and increased cell numbers.  Interestingly these studies also identify the non- 
canonical Wnt signalling pathway, induced by Wnt5a, as an activator of osteogenesis 
in human MSCs, capable of inhibiting the effect of Wnt3a activity. 
One explanation for the discrepancies in the literature is the differentiation state of 
the cells receiving the Wnt stimulation, and several publications attempt to address 
this in more detail.  Eijken et al (2008) used a human foetal osteoblastic cell line, 
with which they generated a non-differentiating and differentiating population, 
through the addition of the synthetic glucocorticoid, dexamethasone.  By generating 
these two populations of undifferentiating and differentiating cells, Eijken et al. 
(2008) demonstrated that non-differentiating cells have higher endogenous canonical 
Wnt signalling, and that increased signalling by LiCl had differential effects on these 
two populations.  Non-differentiating cells generated increased ALP in response to 
LiCl, indicative of enhanced early osteogenesis, while the differentiating cells had 
reduced ALP activity upon LiCl treatment, and reduced mineralisation.  Using an 
alternative approach, utilising the range of cell types that can be obtained from 
mouse models, Quarto et al. (2010) used a selection of multipotent, pre-osteoblast 
and osteoblast cells to study the effect of Wnt manipulation on cells at different 
stages of osteogenesis.  As shown by Eijken et al. (2008), the undifferentiated cells 
had higher basal levels of canonical Wnt signalling, demonstrated by downstream 
target expression and nuclear β-catenin levels.  This approach also allowed for the 
study of the effect of increased canonical Wnt signalling by Wnt3a on the 
differentiation of cells at different stages of osteoblast progression.  Multipotent cells 
derived from the adipose tissue or embryonic calvaria failed to differentiate towards 
osteoblasts in the presence of Wnt3a, however osteoblast cells responded positively 
to Wnt3a, with increased ALP and mineralisation in combination with differentiation 
conditions.  In addition to these studies, a series of publications studying the effect of 
LEF1 on osteogenic differentiation demonstrated an inhibitory effect of increased 
canonical Wnt signalling on osteoblast maturation (Kahler et al, 2006; Kahler & 
Westendorf, 2003).  Conversely, Krause et al. (2010) used a mild osteogenic 
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stimulus to promote the early stages of osteogenesis, and demonstrated an increase in 
early osteogenic markers such as ALP and Osteoprotegerin in response to GSK3 
inhibition with 6-bromoindirubin-3′-oxime (BIO), suggesting an enhancement of the 
early stages of osteogenesis by canonical Wnt signalling.  Collectively it seems that 
canonical Wnt stimulates differentiation of cells committed to the osteogenic 
lineage, but can inhibit the differentiation of multipotent cells, and prevent the 
terminal differentiation of mature osteoblasts (Figure 1.4.1).  
Furthermore, increased canonical Wnt signalling has regularly been linked to 
increased bone mass in response to osteo-inductive substances such as Fibroblast 
growth factor (FGF) 2 (Fei et al, 2011), estrogen-related receptor α (Auld et al, 
2012), strontium (Yang et al, 2011), bisindoylmaleimide I (Zhou et al, 2012), 
sclerostin (Jawad et al, 2013) and miR-142p (Hu et al, 2013), again suggesting an 
important role for canonical Wnt signalling in the increased differentiation and 
maturation of osteoblasts.  However, despite the clear involvement of canonical Wnt 
in these situations, the manner in which they function remains unclear. 
1.4.1.2 TGFβ-superfamiliy signalling 
In addition to canonical Wnt signalling, BMPs have also been shown to play an 
important role in the osteogenic differentiation of MSCs.  BMPs were first identified 
as proteins that were capable of inducing endochondral bone formation and 
increasing osteoblast differentiation in vitro (Sampath et al, 1992).  However it is 
now known that BMPs play vital roles in a wide variety of embryonic processes, 
including gastrulation, neural development and endothelial cell function (Gitelman et 
al, 1995; Valcourt & Moustakas, 2005).  This review of the literature will however 
concentrate on the roles of BMPs on the differentiation of MSCs.  As stated above, 
the application of recombinant BMPs to in vitro pre-osteoblast cultures results in 
increased osteoblastogenesis, demonstrated by increased ALP, OC expression and 
matrix mineralisation (Sampath et al, 1992), while the blocking of BMP signalling 
both arrests osteogenesis and prevents the programmed cell death of mature 
osteoblasts.  BMPs are thought to induce osteoblast differentiation through the 
activation of Runx2 (Lee et al, 2000).  Work in multiple mouse cell lines has 
demonstrated that this increase in Runx2 activity in response to BMPs is indirect and 
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acts through Dlx5 (Lee et al, 2003a).  Runx2 is also thought to interact with SMAD1 
and 5.  These SMAD-Runx2 complexes are directed by the Runx2 targeting signals 
to sub-nuclear foci where gene targets for both transcription factors are present. This 
suggests that SMAD transcriptional activation is at least in part dependent on the 
targeting factors of Runx2 (Zaidi et al, 2002) (Figure 1.4.1).  It is interesting to note 
that BMP2 stimulation of Dlx5 increased the expression of Osx independently of 
Runx2, implicating Dlx2 as an important regulator of early and late BMP-induced 
osteogenesis (Lee et al, 2003b).  
Another member of the TGFβ-superfamily, TGFβ also plays a role in the regulation 
of osteogenic differentiation.  Unlike BMP-specific SMADs, TGFβ SMADs do not 
induce osteogenesis, but in fact act to repress the pro-osteogenic effects of BMPs. 
This inhibition is mediated through SMAD3, which interacts with Runx2 repressing 
its transcriptional activity (Alliston et al, 2001).   
1.4.1.3 Hedgehog signalling 
Hh signalling, and more specifically Ihh signalling, has been linked to osteogenesis, 
and is indispensable for osteoblast development during endochondral ossification.  
This was strikingly shown in Ihh
-/-
 mice, which demonstrated a complete failure of 
osteoblast development in endochondral bones (St-Jacques et al, 1999).  Further to 
this, genetic manipulation of Smo, resulting in removal of Smo from the 
perichondral cells using a Cre-LoxP system, resulted in the failure of osteoblast 
differentiation (Long et al, 2004).   In addition to these in vivo experiments, the role 
of Hh signalling in mesenchymal commitment has been studied in vitro.  The 
induction of the hedgehog pathway, by addition of recombinant Hh protein, in 
C3H10T1/2 cells, induced osteogenesis, with ALP activity detectable after just two 
days of treatment (Hu et al, 2005).   
Furthermore there is evidence for interactions between the Hh and Wnt pathways in 
relation to osteogenesis.  Ihh
-/-
 mice showed a disrupted Wnt signalling phenotype at 
E14.5 and E16.5, with an absence of nuclear β-catenin staining in the perichondral 
cells, as compared to the positive staining of the wild type mice (Hu et al, 2005).  To 
investigate the functional relationship between Hh and Wnt signalling as inferred by 
50 
 
the Ihh
-/-
 mice, the same group used an in vitro C3H10T1/2 differentiation model, in 
which Ihh over expression led to ALP expression in the Ihh-expressing cells.  This 
osteogenic differentiation was however reduced by ~50% when the cells were co-
transfected with either DKK or double negative Tcf4 constructs.  In addition to this, 
Wnt5a, Wnt7b and Wnt 9a mRNA levels were significantly induced over controls in 
response to 24 and 48 hours of Hh treatment.  This body of work suggests that Hh 
signalling acts upstream of Wnt signalling and that Wnt signalling is required, at 
least in part, for the osteogenic inducing potential of Hh. 
1.4.2 Adipogenesis 
1.4.2.1 Canonical Wnt signalling 
In addition to the large number of studies looking into the role of canonical Wnt 
signalling in osteogenesis, it is also well studied with relation to adipogenic 
differentiation.  Many studies have been performed which implicate canonical Wnt 
signalling as an inhibitor of adipogenesis (Prestwich & Macdougald, 2007), and 
some of the key findings are discussed here.  Upon canonical Wnt stimulation 
adipogenesis of MC3T3-L1 cells is completely inhibited, but does not affect the 
expression of the early adipocyte transcription factors, C/EBPβ and δ.  It does 
however block the expression of C/EBPα and PPARγ and the downstream gene, 
FABP4 (Bennett et al, 2002).  The inhibition of PPARγ is thought to be via the 
activation of chicken ovalbumin upstream promoter transcription factor II  
(COUP-TFII), leading to the recruitment of the silencing mediator of retinoid and 
thyroid  hormone receptors (SMRT) co-repressor complex (Figure 1.4.2).  This binds 
to the PPARγ gene, maintaining the chromatin in a hypoacetylated state repressing 
its expression (Okamura et al, 2009).  Conversely, the expression of Wnt inhibitors, 
reducing endogenous Wnt, causes the spontaneous adipogenic differentiation of pre-
adipocytes (Bennett et al, 2002).   
This work, along with related findings, identifies canonical Wnt as an important 
switch in the lineage decisions of MSCs, with canonical Wnt maintaining the cells in 
a multipotent state until its coordinated removal results in adipogenesis.   Recently, 
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Figure 1.4.2. Schematic showing the interplay between transcription factors 
and cell signalling during the adipogenic differentiation   
Hormonal signals such as glucocorticoids and insulin lead to the upregulation of 
C/EBPβ+δ, which in turn up regulate C/EBPα expression.  C/EBPα and PPARγ 
enter a positive feedback loop, increasing each other’s expression.  PPARγ is then 
able to induce expression of adipocyte genes and induce adipocyte maturation.  
Canonical Wnt signalling inhibits adipocyte maturation via COUP-TFII and 
SMRT, inhibiting PPARγ transcription.  Both C/EBPα and PPARγ inhibit the 
mitotic clonal expansion stage, and therefore their expression must be delayed.  
This is achieved through the expression of CHOP10 in pre-adipocytes, which 
interacts with C/EBPβ, preventing its up regulation of C/EBPα. 
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work has been carried out studying the relationship between adipogenesis and 
osteogenesis in response to canonical Wnt signalling (Liu et al, 2009).  Liu et al 
(2009) were able to show that human MSCs under dual osteogenic and adipogenic 
conditions, preferentially formed osteoblasts in response to Wnt3a administration.  
This response was shown to be due to differential inhibition of the two 
differentiation processes, where adipogenesis is totally inhibited at low Wnt 
stimulation, and osteogenesis is only partially inhibited.  This suggests that under 
dual lineage differentiation conditions, differences in sensitivity to Wnt inhibition 
may alter the equilibrium and shift the commitment from adipocytes toward 
osteoblasts.   
1.4.3 Chondrogenesis 
1.4.3.1 Canonical Wnt signalling 
Canonical Wnt signalling is also influential in the differentiation of MSCs into 
chondrocytes.  This was demonstrated by Day et al (2005) who generated mice with 
ectopic induction of canonical Wnt signalling in the developing limb bud.  These 
mice showed enhanced ossification and reduced chondrocyte formation.  
Furthermore, inactivation of β-catenin, therefore preventing canonical Wnt created 
the opposite phenotype, with ectopic chondrocyte differentiation, and reduced 
osteogenesis (Day et al, 2005).  These findings correlate with those in human MSC 
culture, where inhibition of canonical Wnt signalling by sFRPs and DKK over 
expression causes enhanced chondrogenesis, with up regulation of Col2A1, Sox9 
and glycosaminoglycan expression, and a decrease in Col1A1.  However, Wnt 
inhibition does not induce the expression of type X collagen alpha 1 (Col10A1) (Im 
et al), suggesting Wnt inhibition can induce early chondrocyte differentiation, but 
not final maturation and hypertrophy.  In vitro investigations studying the activation 
of canonical Wnt in chick upper sternal chondrocytes, by the over expression of 
Wnt8c, 9a or β-catenin, demonstrated that canonical Wnts where in fact required for, 
and could increase chondrocyte hypertrophy.  Canonical Wnt activation led to 
decreased Sox9 and Col2A1 expression, whilst increasing the hypertrophic markers 
Col10A1 and Runx2.  Canonical Wnt exerts these effects, at least in part, through the 
LEF/TCF activation of Runx2 and in turn induces the expression of Col10A1 (Dong 
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et al, 2006).  In summary, down regulation of canonical Wnts can increase the early 
stages of chondrogenesis, increasing Sox9 and Col2A1, but its up regulation is 
required for the final maturation, and hypertrophy, through Runx2 and Col10A1 
upregulation, and reduction of Sox9. 
1.4.3.2 TGFβ-superfamiliy signalling 
BMPs not only induce osteoblast differentiation, but also have pro-chondrogenic 
characteristics, and have been shown to increase the expression of type II and X 
collagen in growth plate cultures (De Luca et al, 2001).  BMPs exert their effect on 
chondrogenesis through the chondrogenic master regulator Sox9.  Beads soaked in 
BMP4 implanted into mouse mandibular explants induced ectopic cartilage 
formation in the proximal position of the explants.  These same areas also had 
upregulation of the Sox9 transcription factor, implicating its role in BMP induced 
chondrogenesis.  Interestingly, BMP4-soaked beads did not induce chondrogenesis 
in the rostral position, despite similar up regulation of Sox9.  However, upregulation 
of the homeodomain transcription factor Msx2 was also seen in the areas 
surrounding the beads, and to a much greater degree in rostral region of the explants.  
Furthermore, ectopic expression of Msx2 prevented the BMP4-induced 
chondrogenesis, and reduced endogenous chondrogenesis (Semba et al, 2000).  This 
body of work demonstrates that BMP induction of chondrogenesis via Sox9, is also 
dependent on the expression of Msx2, generating a threshold for chondrogenesis, 
thereby providing a means for positional regulation of chondrogenesis in vivo.  
In contrast to the inhibitory effect of TGFβ signalling on osteogenesis, it is required 
for the in vitro chondrogenic differentiation of multipotent mesenchymal cells, 
acting through the p38, ERK-1, and JNK MAP Kinases (Lutz & Knaus, 2002). 
1.4.3.3 Hedgehog signalling 
Chondrogenesis is also reliant on the complex cross-talk between the BMP and Shh 
signalling pathways.  Shh signalling initiates the expression of the homeobox 
protein, Nkx3.2, while BMP signals act to maintain its expression (Murtaugh et al, 
2001), allowing the transcription repressor activity of Nkx3.2 to block the activity of 
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Figure 1.4.3. Schematic showing interactions between transcription factors 
and signalling pathways during chondrogenic differentiation   
Shh and BMPs act together to generate a positive feedback loop with Sox9 and 
Nkx3.2, stimulating the differentiation of MSCs into prehypertrophic 
chondrocytes, while Wnt signalling inhibits the initiation of chondrogenic 
differentiation. Wnt signalling is, however, required for the switch between pre-
hypertrophic and hypertrophic chondrocytes, through increased Runx2 activity, 
leading to reduced Sox9 expression and increased Col10A1. Ihh expression in 
pre-hypertrophic chondrocytes stimulates the switch to hypertrophic 
chondrocytes, and also causes PTHrP expression in the surrounding 
perichondrium, which in turn inhibits hypertrophy in the leading edge of the 
developing limb, generating a positional negative feedback loop 
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inhibitors of BMP-induced chondrogenesis.  Interestingly, Nkx3.2 also acts to 
repress Runx2 activity, which otherwise prevents the onset of differentiation 
(Lengner et al, 2005).  Furthermore, Nkx3.2 can induce the expression of Sox9 
(Zeng et al, 2002), which in turn can increase expression of Nkx3.2, generating a 
positive feedback loop maintaining the expression of pro-chondrogenic factors 
(Figure 1.4.3).  In summary, BMP acts to induce Runx2, stimulating osteogenic 
differentiation, yet acting alongside Shh signalling during chondrogenesis, generates 
and maintains high levels of Nkx3.2 leading to the down regulation of Runx2 and 
increased Sox9, allowing the onset of chondrogenesis.  
Ihh is also implicated in the switch between pre- and hypertrophic differentiation, 
where it is thought to act with parathyroid hormone-related protein (PTHrP) to 
generate a negative feedback loop regulating the onset of hypertrophy.  Ihh 
signalling by the developing chondrocytes targets the surrounding perichondrium, 
where it leads to PTHrP expression.  PTHrP then signals to the pre-hypertrophic 
chondrocytes preventing the initiation of hypertrophic differentiation (Vortkamp et 
al, 1996) (Figure 1.4.3).  It is postulated that the level of Ihh/PTHrP signalling can 
regulate the distance between the joint region and the onset of hypertrophy. 
1.5 GSK3β inhibitors 
GSK3β inhibitors have commonly been used as Wnt mimetics, through the 
disruption of the destruction complex, leading to β-catenin stabilisation, allowing its 
nuclear translocation and gene activation.  The use of GSK3β inhibitors to stimulate 
the canonical Wnt pathway offers two clear advantages over the use of Wnt ligands; 
1) they act downstream of the ligand-receptor complex formation, alleviating the 
complexities originating from the large array of both ligands and receptors 
(discussed in 1.3.1), preventing differences in the response to a particular stimulus 
by cells expressing subtly different receptors.  2) Small molecule inhibitors are much 
easier and cheaper to produce than functionally active Wnt proteins, increasing their 
potential as therapeutic canonical Wnt modulators. 
In fact GSK3β inhibition has been extensively studied for its capacity to correct a 
variety of bone disorders in mouse models.  Lithium, a naturally occurring GSK3β 
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inhibitor has been shown to increase the bone mass of mice after oral administration 
for 4 weeks, and restore that of LRP5 deficient animals (Clement-Lacroix et al, 
2005).  In a similar manner, Wnt signalling was shown to be required for fracture 
repair in mouse models, and lithium treatment after fracture lead to enhanced repair 
(Chen et al, 2007a).  These findings support the observations from human patients, 
in which lithium treatment reduced the risk of fracture (Vestergaard et al, 2005), and 
patients treated with lithium carbonate for neurological disorders had significant 
increases in bone mass (Zamani et al, 2009).  Lithium is however a relatively non-
specific and weak inhibitor of GSK3β (Davies et al, 2000), leading to the generation 
of pharmacological inhibitors of GSK3β, with increased specificity and potency, 
such as 6-bromoindirubin-3′-oxime (BIO), LY603281, and AR28.  LY603281 was 
shown to increase the bone density and strength in mice after 60 days administration 
(Kulkarni et al, 2006), and restored both the bone volume and marrow adiposity due 
to oestrogen deficiency in ovariectomised rats (Kulkarni et al, 2007).  Similarly, 
AR28 administration both by subcutaneous injection and orally lead to increased 
bone mass and trabecular bone thickness in mice, and is discussed in more detail 
below (Gambardella et al, 2011; Marsell et al, 2012; Sisask et al, 2013). 
1.5.1 AR28 
AR28 (or AZD2858) is designed around a pyrazine structure, with the addition of 
multiple functional groups (Figure 1.5.1 A) and has been shown to be a potent 
inhibitor of GSK3, with an IC50 of 5 nM for GSK3β, and relatively high specificity 
over a panel of other kinases (Gambardella et al, 2011).  Using X-ray 
crystallography, it was shown that AR28 interacts with the ATP binding site of the 
GSK3β protein (Figure 1.5.1 B), preventing ATP binding and therefore enzyme 
activity (Berg et al, 2012).  Furthermore, inhibition of GSK3β by AR28 has been 
shown to increase nuclear β-catenin in C3H10T1/2 cells after 24 hours treatment, 
which is indicative of activation of the canonical Wnt signalling pathway 
(Gambardella et al, 2011). 
Due to the links between canonical Wnt signalling and bone anabolism, AR28 has 
been studied in several mouse models.  Initial work demonstrated that subcutaneous 
injection into BALB/c mice lead to increased bone density after 14 days of 
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Figure 1.5.1. AR28 chemical structure and protein interaction 
A) Chemical structure of AR28. B) X-ray crystal structure of AR28 in the ATP 
binding site of GSK3β, showing hydrogen bond formation between compound 
and amino acids of GSK3β (Taken from Berg et al, (2012)). 
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treatment, and that this was likely through the increased proliferation of 
mesenchymal progenitors which were then driven to the osteogenic lineage 
(Gambardella et al, 2011).  Subsequent studies demonstrated the capacity for oral 
administration of AR28, with detectable levels of AR28 in the circulating blood of 
Sprague Dawley rats (Marsell et al, 2012).   As with subcutaneous injection, orally-
administered AR28 caused increased bone mass, preferentially at sites of trabecular 
bone.  Compression and diaphysea strength were also increased by AR28 
administration.  This increase in bone mass was accompanied by increases in serum 
marker levels for bone formation and resorption, suggesting an increase in bone 
formation and remodelling is responsible for the increases in bone mass, and not a 
reduction in resorption (Marsell et al, 2012).  Finally, oral administration of AR28 
one day after the generation of femoral fractures in rat models lead to enhanced 
fracture repair within 3 weeks of treatment, with increased mineral density and 
content in the calluses (Sisask et al, 2013).  Interestingly, AR28 treated fractures 
healed without the formation of cartilage islets, suggesting a strong osteogenic 
induction, but inhibition of cartilage formation by GSK3β inhibition. 
1.6 Project Aims 
Despite the ever growing number of publication linking the effect of proteins to 
increased osteogenesis through the upregulation of canonical Wnt (Hu et al, 2013; 
Jawad et al, 2013; O'Shea et al, 2012; Zhou et al, 2012), the mechanism by which 
canonical Wnt signalling leads to these increases remains unclear.  Therefore the 
aims of this project are to investigate these discrepancies in the literature, through the 
activation of canonical Wnt signalling downstream of receptor binding, by GSK3β 
inhibition, and identify its role in human MSC differentiation.  Initial work aims to 
further characterise the ability of AR28, a GSK3β inhibitor, to activate the canonical 
Wnt signalling pathway in vitro, through study of β-catenin stabilisation and 
TCF/LEF1 transcription factor activation, but also in in vivo conditions using 
Xenopus axis duplication studies.  Following AR28 characterisation, it will be used 
to uncover the unresolved questions regarding the differentiation of MSCs, focussing 
on osteogenesis in particular.  Differentiation will be studied using a range of 
osteogenic cues, to study the effect of activated canonical Wnt signalling on different 
stages of differentiation.  Finally, the effect of canonical Wnt activation under bi-
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potential conditions will be identified, as during in vivo differentiation multiple cues 
are likely to be acting upon mesenchymal precursors simultaneously.  A highly 
regulated signalling pathway such as canonical Wnt signalling is therefore a likely 
candidate for regulation of the response to these various signals, controlling lineage 
commitment decisions. 
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Chapter 2: Materials and Methods 
2.1 Materials 
All chemicals were purchased from Sigma Aldrich (St. Louis, MO, USA) unless 
otherwise stated.  All cell culture flasks and plates were purchased from Corning 
Life Sciences (Corning, NY, USA).  Cell culture media, foetal bovine serum (FBS), 
phosphate buffered saline (PBS), TrypLE Express and Trypsin-EDTA were 
purchased from Invitrogen (Carlsbad, CA, USA).  All Dulbecco's Modified Eagle 
Medium (DMEM) used contained L-glutamine and high glucose (Cat# S41966-052).  
The TOPFlash plasmid was a kind gift from R Moon (University of Washington, 
Seatle, WA USA). The 4Col2E plasmid was a kind gift from Shuji Muramatsu 
(Asahi Kasei Pharma Corp.).  The Gli-BS and m3’Gli-BS plasmids were kind gifts 
from Hiroshi Sasaki (CDB, Riken , Kobe, JP)  The pRK5-Sox9 plasmid was made 
by Aixin Cheng in the Genever Lab (Cheng & Genever, 2010).  Recombinant BMP2 
was purchased from NIBSC (South Mimms, UK).  Recombinant mouse Wnt3a was 
purchased from R&D systems (Minneapolis, MN, USA). 
2.2 General Methods 
2.2.1 Cell Culture methods 
2.2.1.1 Cell line culture conditions 
The mouse multipotent stromal cell line, C3H10T1/2, and Human Embryonic 
Kidney cell line, HEK293, were cultured in DMEM with 10% FBS and 100U/ml 
Penicillin/100µg/ml Streptomycin (1% P/S).  Cells were passaged upon reaching 
90% confluency at 1:4 using trypsin/EDTA.  All cells were incubated at 37°C in 5% 
CO2 /95% air humidified atmosphere. 
2.2.1.2 Extraction of MSCs from Femoral heads 
Extraction was performed as described in Etheridge et al. (2004)  Briefly, trabecular 
bone was mechanically removed from the femoral head and transferred to a tube 
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containing 10 ml DMEM containing P/S.  The trabecular bone was then minced, and 
the bone fragments allowed to settle before the media was transferred to another 
tube.  Fresh media was added to the bone fragments and the bone minced again 
before the media was transferred to another tube.  The process was repeated two 
more times before medium was added to the bone fragments and vortexed for 1 
minute before the media was transferred to a separate tube.  The collected medium 
was then centrifuged for 5 minutes at 450g and the supernatant removed.  The pellet 
was resuspended in 16 ml of medium and passed through at 70 µm cell strainer (BD 
Falcon, Oxford, UK).  The cell solution was then layered over 12 ml of Ficoll-Paque 
Plus (GE Healthcare, Waukesha, WI, USA) and centrifuged at 250g for 30 minutes 
with low braking.  The white mononuclear layer was then collected from the 
interface and added to 10 ml wash buffer (5 mM EDTA, 0.2% Bovine Serum 
Albumin (BSA) in PBS).  The cells were centrifuged at 450g for 5 minutes and the 
supernatant removed before resuspension in MSC expansion media (DMEM, 15% 
FBS, 1% P/S) and seeded onto cell culture plastic T75 flasks.  The cells were 
allowed to settle for 3-4 days before the medium was replaced.  The cells were then 
expanded as below. 
2.2.1.3 Extraction of MSCs from knee samples 
Bone samples from knee surgery were dissected into small pieces and placed cut 
face down onto cell culture treated plastic petri dishes, and covered in MSC 
expansion media.  Cells were allowed to migrate out of the bone tissue and attach to 
the flasks for 1 week before bone fragments were removed and the media replaced.  
Cells were then expanded as below. 
2.2.1.4 MSC and hADSC expansion 
Bone marrow MSCs extracted as described above were cultured in MSC expansion 
media (DMEM, 15% FBS, 1% P/S).  Cells were passaged upon reaching 90% 
confluency at 1:3 using trypsin/EDTA.  Human adipose derived stem cells (ADSCs) 
were cultured in MesenPRO RS (Invitrogen, Carlsbad, CA, USA).   Cells were 
passaged upon reaching 90% confluency using TrypLE Express and counted and 
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seeded at 4x10
3
 cell/cm
2
. All cells were incubated at 37°C in 5% CO2 /95% air 
humidified atmosphere. 
2.2.1.5 Mycoplasma testing 
All cell cultures were regularly tested for mycoplasma contamination.  Cells were 
washed twice in PBS and fixed with 100% methanol for 5 minutes.  Samples were 
washed twice more in PBS before the addition of DAPI at 1µg/ml.  Samples were 
incubated for 5 minutes in the dark before the DAPI was removed and the samples 
washed in PBS, and finally stored in PBS.  Samples were viewed using fluorescence 
microscopy to identify the presence or absence of mycoplasma, identifiable as small 
pin pricks of DAPI positive staining in the cell cytoplasm.   
2.2.1.6 Cell Assay Culture Conditions 
For all cell assays, basal media was composed of DMEM, 10% FBS and 1% P/S.  
For differentiation assays, MSCs and hADSCs were seeded at 2x10
4
 cells/cm
2
 unless 
otherwise stated and allowed to attach overnight.  For osteogenic differentiation, the 
medium was then replaced with osteogenic medium (Basal medium plus 50μg/ml L-
Ascorbic acid-2-phosphate, 5mM β-glycerophosphate and 10nM Dexamethasone, 
unless stated otherwise).  BMP2 treatments were performed at 100ng/ml in Basal 
medium.  For adipogenic differentiation, the medium was replaced with adipogenic 
medium (Basal medium plus 1μM Dexamethasone, 500μM 3-isobutyl-1-
methylxanthine (IBMX), 1μg/ml Insulin and 100μM indomethacin).  For micromass 
chondrogenic differentiation, 2x10
5 
MSCs in basal media were centrifuged at 450g 
for 5 minutes in a universal tube for each pellet.  The pellets were then allowed to 
contract into a micromass pellet for 48 hours before the media was replaced (Day 0) 
with chondrogenic media (Basal media plus 50 µg/ml L-ascorbic acid-2-phosphate, 
100 nM dexamethasone, 40 µg/ml L-proline, 1% ITS
+
1, 10 ng/ml TGFβ3).  Medium 
was changed every 3-4 days.   
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2.2.2 Microbiology Methods 
2.2.2.1 Bacterial Transformation 
DNA plasmids were transformed into competent E. coli strain Hi-coli-5A 
(Advantagen Ltd, Dundee, UK).  1 µl of purified plasmid was added to 50 µl of 
competent E. coli and incubators on ice for 30 minutes.  Heat shock was performed 
at 42ºC for 30 seconds, and returned to ice for 2 minutes.  250 µl of SOC medium 
(Sigma-Aldrich, St. Louis, MO, USA) was added to the E. coli and incubated at 37ºC 
at 200 rpm for 1 hour.  100 µl was then plated onto an LB-agar plate containing an 
appropriate antibiotic and incubated at 37°C overnight.  Colonies were picked and 
cultured overnight at 37ºC at 200 rpm in LB media (10 g tryptone, 10 g NaCl, 5 g 
yeast extract per litre).  Glycerol stocks were generated by combining 750 µl E. coli 
culture and 250 µl sterile 50% glycerol, and stored at -80ºC. 
2.2.2.2 Plasmid Purification 
Plasmid DNA was purified from transformed E. coli cultures.  5 ml LB media was 
inoculated with scrapings from glycerol stocks, and cultured at 37ºC at 200 rpm for 8 
hours.  200 ml cultures were then inoculated with 1 ml of the small inoculated 
culture and grown overnight at 37ºC at 200 rpm.  Plasmid purification was 
performed using midi-prep kits (Macherey-Nagel) and NucleoBond Finalizers 
(Macheret-Nagel, Dueren, DE).  Plasmids were eluted in nuclease free H2O, and the 
concentration determined using a NanoDrop 1000 Spectrophotometer (Thermo 
Scientific, Waltham, MA, USA).  
2.2.3 Transfection of mammalian cell cultures 
2.2.3.1 Lipofectamine transfection of C3H10T1/2 Cells 
Cells were seeded (without antibiotics) and allowed to attach overnight.  The cells 
were then transfected, using Lipofectamine and Plus Reagent (Invitrogen, Carlsbad, 
CA, USA).  Optimised DNA and lipofectamine volumes are given in specific chapter 
methods sections.  DNA was combined with Plus reagent and DMEM and incubated 
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for 15 minutes at room temperature.  Lipofectamine diluted in DMEM was added to 
the DNA solution and incubated a further 15 minutes at room temperature.  DNA 
solutions were diluted in DMEM as described in specific chapter methods sections 
and added to the cells, followed by incubation at 37ºC for 3 hours.  The same volume 
of DMEM + 20% FBS was then added to each well, and incubated overnight.  Media 
was then changed to assay conditions, and cultured for the desired time the next day.   
2.2.3.2 Lipofectamine LTX transfection of HEK293 Cells 
Cells were seeded (without antibiotics) in 24 well plates and allowed to attach 
overnight.  The cells were then transfected, using Lipofectamine LTX and Plus 
Reagent (Invitrogen, Carlsbad, CA, USA).  Optimised DNA and lipofectamine LTX 
volumes are given in specific chapter methods sections.  DNA and Plus reagent were 
combined in 100 µl Optimem before the addition of Lipofectamine LTX solution.  
The DNA/Lipofectamine LTX mix was then incubated at room temperature for 10 
minutes.  The DNA/Lipofectamine LTX mix was added to the wells containing 
500 µl complete culture medium.  Samples were incubated at 37ºC overnight.  Media 
was then changed to assay conditions, and cultured for the desired time. 
2.2.4 Dual Glo Luciferase assay 
After a determined time period, reporter activity was analysed using the Dual Glo 
Luciferase assay system (Promega, Fitchburg, WI, USA), first measuring Firefly 
luciferase, generated by the reporter plasmids, followed by Renilla luciferase using a 
TopCount NXT luminometer (Packard).  Briefly, the culture medium was removed, 
the cells were washed twice with PBS and the media replaced with 50 µl DMEM 
(No Phenol Red) per well.  50 µl luciferase reagent was added to each well and 
incubated in the dark for 10 minutes.  The Firefly luciferase was then measured 
using the 96 well plate luminometer.  50 µl Stop and Glo solution was added to each 
well, and samples incubated in the dark for 10 minutes.  The Renilla luciferase was 
measured using the 96 well plate luminometer.  For analysis, Firefly luciferase was 
normalised to Renilla to reduce the effect of differences in transfection efficiencies 
between wells. 
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2.2.5 Protein Based Methods 
2.2.5.1 Protein sample preparation 
Total cell lysates were produced by lysis in RIPA buffer (Invitrogen, Calsbad, CA, 
USA) supplemented with protease inhibitor cocktail 3 (Calbiochem, Nottingham, 
UK) and 1mM Na3VO4.  Nuclear and cytoplasmic fractions were prepared using NE-
PER Nuclear and Cytoplasmic Extraction Kit (Thermo Scientific, Waltham, MA, 
USA).  Briefly, cells were harvested with trypsin-EDTA, and centrifuged to pellet 
the cells.  The cells were then washed by suspending in PBS before centrifugation, 
and the supernatant removed producing a pellet volume of ~5 µl.  50 µl of ice cold 
CER I buffer was added to the cell pellet, before being vortexed for 15 seconds.  
Samples were incubated on ice for 10 minutes, followed by addition of 2.5 µl of 
buffer CER II.  Samples were mixed and incubated on ice for 1 minute.  Samples 
were then pelletted by centrifugation at 16,000 g for 5 minutes and the supernatant 
(cytoplasmic fraction) transferred to another tube.  The insoluble pellet was then 
suspended in 25 µl ice cold buffer NER by vortexing, and incubated on ice for 40 
minutes with vortexing every 10 minutes.  The samples were then centrifuged at 
16,000 g for 10 minutes and the supernatant transferred to new a tube (nuclear 
fraction).  Samples were stored at -80ºC. 
2.2.5.2 BCA Protein Assay 
Protein concentrations were calculated using a BCA protein assay (Thermo 
Scientific, Waltham, MA, USA).  10μl of each standard (BSA supplied with kit) or 
unknown sample replicate was pipetted into a microplate well.  200μl of the 
Working Reagent (50:1, Reagent A:B)  was added to each well and incubated at 
37°C for 30 minutes.  The plate was cooled to room temperature, and the absorbance 
measured at 570nm on a plate reader. A standard curve was generated from the 
standard samples, allowing the unknown samples concentrations to be calculated. 
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2.2.5.3 SDS-PAGE 
Protein samples were separated by size using SDS-polyacrylamide gel electrophoresis 
(SDS-PAGE) using a Bio-Rad mini gel electrophoresis kit.  Resolving gel composition 
of 375 mM Tris pH 8.8, 10% acrylamide, 0.1 % SDS, 0.05% APS, 0.01% TEMED.  
Stacking gel composition of 125 mM Tris, pH 6.8, 4% acrylamide, 0.1% SDS, 0.05% 
APS, 0.01% TEMED.  Protein samples were diluted in 4x Laemmli buffer, boiled for 5-
10 minutes before loading onto the gel.  Gels were run at 180V until the dye front 
reached the bottom of the gel.  Running buffer was composed of 25 mM Tris, 192 mM 
glycine, 0.1% SDS.   
2.2.5.4 Transfer to PVDF membrane and immune blotting 
SDS-PAGE gels were transferred to PVDF membranes (GE Healthcare, Little 
Chalfont, UK) using a Bio-Rad wet tank transfer kit. Transfer buffer composition; 
25mM Tris, 192mM Glycine, 20% methanol.  Transfer was performed at 200mA for 
2 hours.  After transfer the membrane was blocked in 4% milk Tris buffered Saline 
Tween20 (TBS-T); 20mM Tris, 137mM NaCl, 0.1% Tween-20.  Primary antibodies 
were used as described in specific chapter methods sections.  After primary antibody 
probing, the membranes were washed in TBS-T before incubation with horseradish 
peroxidise-conjugated (HRP) secondary antibodies identified in specific chapter 
methods sections for 2 hours at room temperature.  Immunoreactive bands were 
visualised by enhanced chemiluminescence (ECL) reagent (GE Healthcare, Little 
Chalfont, UK) and chemi-imager.  Bands were quantified using ImageJ Software. 
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Chapter 3: Characterisation of AR28 
3.1 Introduction 
There are many ways to study the effects of enhanced canonical Wnt signalling in 
vitro.  Three of the most common methods used are; the administration of 
recombinant Wnt ligands or Wnt-conditioned media to the cell culture, over-
expression or knockdown of pathway components, and stabilisation of β-catenin 
though GSK3β inhibition.  However, there are pros and cons for each method.  
Whilst using recombinant Wnt ligands should in principle supply the most 
biologically relevant levels of canonical Wnt activation, there are multiple problems 
associated with their use.  Firstly, the availability of bioactive recombinant Wnt 
ligands is limited.  While this is continuously improving with the generation of new 
ligands, there is the added complexity of ligand-specific effects, an area which is still 
relatively poorly understood.  As mentioned previously, Wnt ligands can signal 
through multiple pathways, the canonical pathway, of interest here, and the non-
canonical pathways.  This offers the first level of complexity as several ligands are 
thought to be active through both pathways, while others are not clear (Mikels & 
Nusse, 2006).  A second level of complexity is due to the current poor understanding 
of the differing effects of known canonical Wnt ligands in different situations, and 
the frizzled receptor and LRP co-receptor combinations to which they bind.  With 19 
Wnt ligands, and 10 Frizzled receptors (Mikels & Nusse, 2006), in combination with 
one of two co-receptors, one cannot even be certain that the cell of interest in any 
particular situation will be able to respond to the chosen ligand.  This instantly 
makes it very difficult to draw conclusions about the ability of a particular ligand to 
generate a canonical Wnt response, and therefore the response of the cells to the Wnt 
stimulus.  
In an attempt to circumvent these problems of ligand availability and specificity, 
manipulation of the pathway by altering the expression of key signalling molecules 
has been an attractive alternative.  This can be done through the over-expression of 
positive regulators of the pathway; such as Wnt ligands (Wright et al, 1999), and 
β-catenin (Gould et al, 2007; Kim et al, 2006), or the down regulation of negative 
regulators; such as GSK3β (Cho et al, 2009), or DKK1 (Fleming et al, 2008).  While 
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this does offer strong stimulation of the canonical Wnt pathway as a whole, it allows 
for little regulation of the degree or duration of the activation.   
The final method described here is the use of small molecule GSK3 inhibitors, to 
prevent the phosphorylation of β-catenin and its subsequent degradation.  This 
allows for a more controlled stimulation of the canonical Wnt pathways, and 
inhibitors can be added at a range of concentrations for different time periods.  
Furthermore they are much more translatable for therapeutic uses.  LiCl (de Boer et 
al, 2004; Etheridge et al, 2004; Spencer et al, 2006) and 6-bromoindirubin-3′-oxime 
(BIO) (Krause et al, 2010; Wang et al, 2009) are two commonly used inhibitors of 
GSK3 and are regularly used to mimic canonical Wnt signalling in vitro.  However, 
they are not ideal, with off target effects and toxicity (Davies et al, 2000; Liu et al, 
2011; Meijer et al, 2003).  In addition to the non-specific effects of the inhibitors on 
GSK3β, GSK3β itself is not specific to the canonical Wnt signalling pathway, with 
involvement in hedgehog signalling (Jia et al, 2002) and regulation of the NFAT 
transcription factor (Kaytor & Orr, 2002). 
There are multiple ways to study Wnt activation in vitro, most commonly the 
identification of nuclear β-catenin within the cell (Gambardella et al, 2011; Krause et 
al, 2010; Spencer et al, 2006), or increased stable dephosphorylated β-catenin levels 
(Boland et al, 2004; Krause et al, 2010; Kulkarni et al, 2006).  More specific analysis 
of canonical Wnt activation examines the degree of TCF/LEF1 transcription factor 
activity (Boland et al, 2004; Etheridge et al, 2004; Kulkarni et al, 2006).  The family 
of TCF/LEF1 transcription factors is the ultimate response to increased canonical 
Wnt signalling, generating the Wnt-dependent changes in gene expression.  
Therefore, the degree of activity of this transcription factor family gives an 
indication of the functional canonical Wnt response generation by whichever 
stimulation.   
As mentioned previously, canonical Wnt stimulation is an appealing therapeutic 
target, and any method of stimulation must therefore also be able to generate a 
functional canonical Wnt response in vivo.  One body of research which has 
provided a valuable method for studying the ability of compounds to stimulate 
canonical Wnt signalling in vivo is the Xenopus model of embryonic development.  
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Spemann et al first identified the importance of the Spemann organiser in 
developmental organisation in 1924 and showed that grafting a second organiser 
region onto the ventral side of the embryo caused the duplication of the embryonal 
axis (Spemann H., 1924).  The signalling mechanisms that underlie the initial 
positioning of the organiser region are now known (Figure 3.1.1) and together, they 
form the principles of the in vivo canonical Wnt activation assay (Kuhl & Pandur, 
2008).  Briefly, during the blastula stage of embryonic development, there is an 
accumulation of β-catenin in the dorsal side of the embryo that occurs in response to 
canonical Wnt signalling.  This, in combination with VegT and Vg1 signals from the 
vegetal region, leads to the positioning of the Nieuwkoop centre.  The Nieuwkoop 
centre releases Xenopus Nodal related factors which induce the formation of the 
Spemann organiser (De Robertis & Kuroda, 2004; Takahashi et al, 2000).   
The canonical Wnt activation assay is carried out by the injection of the proposed 
canonical Wnt stimulus into the ventral side of the embryo.  If successful in 
stimulating the canonical Wnt pathway, this leads to the generation a second area of 
increased β-catenin.  Which, in turn, leads to the duplication of the various organiser 
regions, and results in the duplication of the embryonal axis (Figure 3.1.1), providing 
a clear readout for canonical Wnt stimulation.   The accumulation of nuclear β-
catenin also causes the formation of the blastula Chordin and Noggin expression 
(BCNE) centre, in the dorsal animal cap and marginal zone above the Nieuwkoop 
centre, resulting in the expression of BMP inhibitors, such as chordin and noggin 
(Wessely et al, 2001), which can be used as markers for induced β-catenin.      
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Figure 3.1.1. Schematic of Xenopus embryonic patterning and duplication by 
Canonical Wnt 
Injection of canonical Wnt agonists in the ventral side of the embryos leads to the 
duplication of the β-catenin accumulation, leading to the formation of second 
Nieuwkoop centre, and therefore Spemann organiser, which ultimately leads to 
the duplication of the embryonal axis. 
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3.2 Aims 
The general aims of the work presented in this chapter are to characterise the ability 
of the GSK3β inhibitor, AR28, to stimulate the canonical Wnt signalling pathway in 
mesenchymal progenitor cell cultures and the in vivo Xenopus model, and to 
determine its potency in relation to other commonly used canonical Wnt activators. 
More specifically the aims are to: 
 Characterise the MSCs extracted from both femoral heads and knees using a 
panel of markers by flow cytometry. 
 Identify the effect of AR28 on β-catenin stabilisation and nuclear 
translocation. 
 Identify the capacity of AR28 to stimulate TCF/LEF1 transcription factor 
activity and compare this to other known canonical Wnt stimulators. 
 Determine the ability of AR28 to induce canonical Wnt signalling in vivo 
using Xenopus embryonal development as an assay for increased canonical 
Wnt signalling. 
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3.3 Methods 
3.3.1 Analysis of MSC markers 
MSC markers were analysed using a panel of antibodies to cell surface proteins by 
flow cytometry.  MSCs were washed twice in PBS and removed from the cell culture 
flasks using wash buffer (5 mM EDTA, 0.2% BSA in PBS).  Cells were centrifuged 
and resuspended in 1 ml of wash buffer before separating into 10 separate tubes in 
volumes of 100 µl.  Primary antibodies were added to the cells at the concentrations 
shown in Table 3.3.1. and incubated on ice for 45 minutes.  1 ml of wash buffer was 
added to each sample before centrifugation at 400g for 5 minutes at 4ºC and the 
supernatant removed.  Samples labelled with fluorescently-conjugated antibodies  
Table 3.3.1.  MSC marker antibodies 
Target Conjugate Host Dilution Supplier Catalogue No. 
CD45 FITC Mouse 1:100 Caltag Labs MRC04501 
CD166 PE Mouse 1:50 
BD 
Pharmingen 
559263 
CD44 FITC Mouse 1:10 
BD 
Pharmingen 
555478 
CD34 FITC Mouse 1:50 
Miltenyi 
biotech 
130-081-001 
CD90 
(5E10) 
Purified 
IgG 
Mouse 1:100 ebioscience 14-0909-81 
CD105 
(SN7) 
Purified 
IgG 
Mouse 1:100 ebioscience 14-1057-81 
CD29 
Purified 
IgG 
Mouse 1:100 
BD 
Pharmingen 
36741A 
CD73 
Purified 
IgG 
Mouse 1:100 
BD 
Pharmingen 
550256 
Anti-mouse 
IgG 
Alexafluor 
647 
Donkey 1:200 Invitrogen A-31571 
 
were resuspended in 500 µl of wash buffer and stored on ice.  Samples for secondary 
antibody probing were resuspended in 100 µl wash buffer and the AlexaFlour 647 
Donkey anti-mouse antibody applied at 1:200 dilution, before incubation on ice for 
45 minutes.  Samples were then washed again with 1 ml wash buffer and centrifuged 
to remove the supernatant.  Samples were resuspended in 500 µl wash buffer and 
stored on ice.  Marker expression was analysed using CyAn
TM
 ADP Analyzer 
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(Beckman Coulter, Fullerton, CA, USA) at the appropriate excitation and emission 
wavelengths and analysed using Summit software. 
3.3.2 β-catenin Immunocytochemistry 
Cells were fixed with 4% paraformaldehyde for 15 min, before blocking in PBS + 
1.1% BSA + 0.1% triton X-100 for 2 hours at RT.  Incubation with anti-active β-
catenin (BD Transduction laboratories) at 1.25 µg/ml, or IgG control in blocking 
buffer was performed overnight at 4°C.  The cells were washed in PBS before 
addition of the secondary antibody, Donkey anti-mouse IgG Alexafluor 647 
(Invitrogen, Calsbad, CA, USA) at 1:500.  Samples were incubated for 2 hours at 
4°C in the dark.  The secondary antibody was removed and the samples washed 3 
times in PBS before mounting.  Samples on coverslips were mounted on slides using 
VECTASHIELD mounting medium with DAPI (Vector laboratories, Burlingame, 
CA, USA).  The cells in chamber slides were treated with DAPI at 1 µg/ml. before 
storing in PBS. 
3.3.3 Western Blot analysis of Sox9 and β-catenin  
Nuclear and cytoplasmic fractions or total protein lysate samples were obtained and 
separated by SDS-PAGE and transferred to PVDF membranes as described in  
Table 3.3.2. Optimised antibody concentrations for Western Blot analysis 
Target Conjugate Host Conc. Supplier Cat. No. 
β-catenin 
Purified 
IgG 
Mouse 0.25 µg/ml 
BD Transduction 
Laboratories 
610154 
Active-β-
catenin (8E7) 
Purified 
IgG 
Mouse 1 µg/ml Millipore 05-665 
Lamin B 
(M20) 
Purified 
IgG 
Goat 0.25 µg/ml 
Santa Cruz 
Biotech 
SC-6217 
GAPDH 
Purified 
IgG 
Mouse 0.5 µg/ml Genetex 28245 
Anti-mouse 
IgG 
HRP Goat 0.1 µg/ml 
Santa Cruz 
Biotech 
SC-2005 
Anti-rabbit 
IgG 
HRP Swine 0.17 µg/ml DAKO P0399 
Anti-goat 
IgG 
HRP Rabbit 0.25 µg/ml DAKO P0449 
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2.2.5.3 and 2.2.5.4. Antibody probing was performed using the antibodies 
concentrations given in Table 3.3.2.  Densitometry of the protein bands was 
performed using Image J. 
3.3.4 TOPFlash / Gli-BS Reporter assays 
C3H10T1/2 cells were seeded in white opaque 96 well plates at 1x10
4
 cells/well 
(without antibiotics), and allowed to adhere overnight.  Cells were then transfected 
with the TOPFlash or Gli-BS reporter plasmid in combination with the pCMV-
Renilla plasmid using Lipofectamine as described in 2.2.3.1.  Optimised conditions 
are given in Table 3.3.3.  After 24 hours, the cells were treated with AR28, BIO, 
LiCl, recombinant mWnt3a or vehicle controls.  After the specified time, the reporter 
activity was assayed using the Dual Glo Luciferase assay system (2.2.4). 
Table 3.3.3. Optimised transfection conditions for C3H10T1/2 in 96 well plates 
See 2.2.3.1 for protocol. 
DNA/Reagent Amount/well 
TOPFlash/Gli-BS 30 ng 
pCMV-Renilla 3 ng 
Plus Reagent  0.3 µl 
Lipofectamine Reagent 0.3 µl 
DMEM 4 µl 
DMEM for final dilution 32 µl 
 
3.3.5 Xenopus laevis protocols  
3.3.5.1 X. laevis culture 
Xenopus laevis (X. laevis) females were primed by subcutaneous injection with 50 
units of human chorionic hormone (HCG) a week before the experiment.  X. laevis 
females were induced by injecting 250 units of HCG and incubated overnight (for 15 
hours) at 18°C.  Eggs were fertilised using a sperm suspension generated from male 
X. laevis testes, homogenised in water.  Embryos were cultured in NAM/10 (Normal 
Amphibian Medium) in 55mm Petri dishes coated with 1% agarose at 21°C and de-
jellied after 45 minutes of culture in 2.5% L-cysteine hydrochloride monohydrate, 
pH 7.8, followed by culture in NAM/10. 
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3.3.5.2 Bathing of X. laevis embryos in BIO and AR28 
Embryos were cultured until the four cell stage, at which point they were transferred 
to NAM/10 containing either BIO at 10 and 50 µM, AR28 at 10, 50, and 100 µM, or 
1% DMSO control.  Embryos were incubated at 18ºC until the embryos reached the 
8 cell stage, before washing in NAM/10, followed by culture in NAM/10 until the 
embryos reached Nieuwkoop and Faber stage (NF) stage 40 (Nieuwkoop & Faber, 
1994).  Embryos were then fixed in 4% formaldehyde in PBS. 
3.3.5.3 X. laevis injection 
Embryos were cultured until the four cell stage when AR28 or DMSO control was 
microinjected into the ventral marginal zone of a single blastomere.  Embryos were 
cultured until NF stage 40 and fixed in 4% formaldehyde in PBS.  
3.3.5.4 Sectioning and Histological staining of X. laevis Embryos 
Fixed Embryos were stained using borax carmine (10% in 35% ethanol) overnight.  
Embryos were destained in acid ethanol and then cleared using a series of histoclear 
(National Diagnostics, Charlotte, NC, USA) washes before being embedded in 
paraffin wax and sectioned. Sections were counterstained with picro-blue-black 
(97.5% saturated picric acid, 0.25% naphthalene blue black).  
3.3.5.5 Chordin In-situ Hybridisation 
Digoxigenin (Roche, Welwyn Garden City, Hertfordshire, UK) labelled chordin 
(IMAGE:5161617) probe was generated as previously described (Freeman et al, 
2008).  Injected embryos were cultured until Nieuwkoop and Faber stage 10.5, fixed 
in MEMFA (0.1 M MOPS, 2 mM ethylenediaminetetraacetic acid [EDTA], 1 mM 
MgSO4, 3.7% formaldehyde) for 1 hour at room temperature and stored in methanol 
at -20˚C.  Whole mount in-situ hybridisation was carried out using a modified 
version of the Harland protocol (Tindall et al, 2005). 
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3.4 Results 
3.4.1 MSC Characterisation 
In order to demonstrate that the cells extracted from both femoral head bone marrow 
and bones from knee surgery expressed cell surface proteins typical of MSCs, 
randomly selected cultures were subject to a panel of markers by flow cytometry.  
All samples tested were positive for MSC markers (CD44, CD166, CD29, CD73, 
CD90, CD105) and negative for the haematopoietic markers (CD34, CD45).  
Example flow cytometry results from a femoral head (Figure 3.4.1) and knee (Figure 
3.4.2) extracts are presented here.  Both donors gave positive shifts by flow 
cytometry analysis for MSC markers with the exception of CD166 on the femoral 
head sample, which showed no change.  Both samples showed no expression of 
either haematopoietic markers. 
3.4.2 AR28 causes nuclear translocation of β-catenin in vitro 
During the canonical Wnt signalling cascade, β-catenin is stabilised within the 
cytoplasm by the inactivation of the destruction complex.  This stabilisation of 
β-catenin results in an increase in the nuclear translocation of β-catenin.   Therefore 
to analyse the in vitro capability of AR28 to induce a canonical Wnt response, the 
stabilisation of β-catenin was studied by immunocytochemistry.  Mouse multipotent 
mesenchymal cell line, C3H10T1/2, cells were seeded on coverslips and allowed to 
attach before treatment with AR28 and vehicle controls for 24 hours.   Samples were 
then immunostained against β-catenin and counterstained with DAPI.  IgG controls 
showed small amounts of non-specific staining, with slight increased staining 
towards the centre of the cell.  Despite this non-specific staining in the IgG controls, 
probing with the antibody for β-catenin in unstimulated and DMSO control cells 
showed a clear absence of β-catenin in the nucleus of the cells, with strong staining 
in the cytoplasm of the cells.  This cytoplasmic staining is likely identifying β-
catenin in its other cellular function as a matrix protein.  However, when treated with 
2.5µM AR28 for 24 hours, clear nuclear staining for β-catenin was detected (Figure 
1.2.1).  
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Figure 3.4.1. Flow cytometry analysis of femoral head extract. 
MSCs from a femoral head culture (FH388) were antibody probed for MSC 
(CD44, CD166, CD29, CD73, CD90 and CD105) and haematopoietic (CD34 and 
CD45) markers in solution and analysed by flow cytometry.  The results are 
presented as histograms of marker expression (Blue) relative to control (Red) 
fluorescence.  Positive shifts in fluorescence, demonstrating antibody staining and 
protein expression, were observed for the MSC markers, while no change was 
detected for the haematopoietic markers. 
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Figure 3.4.2. Flow cytometry analysis of knee extract. 
MSCs from a knee culture (K16) were antibody probed for MSC (CD44, CD166, 
CD29, CD73, CD90 and CD105) and haematopoietic (CD34 and CD45) markers 
in solution and analysed by flow cytometry.  The results are presented as 
histograms of marker expression (Blue) relative to control (Red) fluorescence.  
Positive shifts in fluorescence, demonstrating antibody staining and protein 
expression, were observed for the MSC markers, while no change was detected 
for the haematopoietic markers. 
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Figure 3.4.3. Nuclear localisation of β-catenin in C3H10T1/2 cells.   
C3H10T1/2 cells were cultured for 24 hours in basal media (control images) plus 
treatment with 2.5 µM AR28 or vehicle control (DMSO).  Samples were fixed 
and immuno-cytochemically stained against β-catenin (red) and DAPI (white) 
before imaging using confocal microscopy.  IgG and secondary antibody 
(AlexaFluor 647) controls were also performed and showed no clear localisation.  
Both the no treatment and DMSO vehicle control showed cytoplasmic β-catenin 
staining, with an absence in the nucleus of the cells (blue arrows), while cells 
treated with 2.5 µM AR28 had clear, strong β-catenin staining both in the 
cytoplasm and nucleus of the cells (White arrows).  Arrows indicate β-catenin 
nuclear staining. 
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Similarly, to check the ability of AR28 to cause nuclear translocation of β-catenin in 
human MSCs, MSCs were plated in chamber slides and allowed to attach before 
treatment with AR28 and vehicle controls for 24 hours.  As with the C3H10T1/2 
cells, untreated and vehicle control cells showed no nuclear β-catenin staining.  
However when treated with 2.5µM AR28, nuclear β-catenin staining was detected 
(Figure 3.4.4).  Furthermore, when 10µM AR28 was used, enhanced nuclear staining 
was detected, suggesting a dose dependent response to AR28 in the activation of 
canonical Wnt signalling.  Again small amounts of non-specific staining were 
detected in the IgG and Secondary antibody only controls, but were faint, with no 
patterning. 
3.4.3 AR28 causes dose dependent stabilisation of β-catenin 
3.4.3.1 AR28 increases nuclear and cytoplasmic β-catenin  
While β-catenin immunostaining allows for the identification of β-catenin 
stabilisation, it is difficult to quantify the extent of stabilisation, and therefore 
canonical Wnt activation.  In order to gain a more quantifiable readout of β-catenin 
stabilisation, β-catenin protein levels were analysed by SDS-PAGE and Western 
blot.  MSCs were seeded at 1x10
4
 cells/cm
2
 and allowed to attach overnight before 
treatment with AR28 and vehicle controls for 24 hours.  Nuclear and cytoplasmic 
protein fractions were then extracted using the NE-PER nuclear and cytoplasmic 
extraction kit.  Samples were run on an SDS-PAGE gel and transferred to a 
nitrocellulose membrane for anti-β-catenin antibody probing.  Densitometric analysis 
identified a dose-dependent increase of both cytoplasmic and nuclear β-catenin when 
normalised to endogenous loading controls (GAPDH – cytoplasmic, Lamin B – 
Figure 3.4.4. Nuclear localisation of β-catenin in human MSCs  
MSCs were cultured for 24 hours in basal media (control images) plus 
treatment with 2.5 µM AR28 or vehicle control (DMSO).  Samples were fixed 
and immuno-cytochemically stained against β-catenin (red) and DAPI (white) 
before imaging using confocal microscopy.  IgG and secondary antibody 
(AlexaFluor 647) controls were performed and showed no clear localisation.  
Both the no treatment and DMSO vehicle control showed cytoplasmic β-
catenin staining, with an absence in the nucleus of the cells, while cells treated 
with 2.5 µM AR28 had clear, strong β-catenin staining both in the cytoplasm 
and nucleus of the cells.  Arrows indicate β-catenin nuclear staining. 
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Figure 3.4.5. Western blot analysis of total β-catenin in nuclear and 
cytoplasmic fractions of AR28 treated MSCs 
A) Nuclear and B) cytoplasmic protein fractions were obtained from MSCs 
cultured for 24hours with AR28 at the concentrations given, vehicle control 
(DMSO) or a no treatment control, followed by Western blot analysis for β-
catenin. Subsequent probing for Lamin B or GAPDH was performed for nuclear 
and cytoplasmic fraction loading controls respectively.  Densitometric analysis of 
the bands was performed using ImageJ, and plotted relative to the no treatment 
control. 
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Figure 3.4.6. Western blot analysis of Active-β-catenin in AR28 treated 
MSCs 
Total cell extracts were obtained from 3 MSCs donors cultured with AR28 at the 
concentration given, vehicle control (DMSO) or a no treatment control for 
24hours, and analysed by western blot.  Membranes were probed against Active-
β-catenin and GAPDH for the loading control.  An example blot is shown here.  
Densitometric analysis of the bands was performed using ImageJ, relative to the 
no treatment control, and the three donor samples grouped, with the mean (± 
standard deviation) relative normalised intensity displayed as a bar chart. 
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nuclear) (Figure 3.4.5).  However, while this showed clear increases in stabilised 
β-catenin, the Lamin B antibody identified multiple different sized proteins (Figure 
3.4.5A), making normalisation difficult.  Furthermore, the nuclear/cytoplasmic 
fractionation relies on the complete removal of the soluble cytoplasmic fraction, 
allowing for cytoplasmic protein contamination within the nuclear fraction.   
3.4.3.2 AR28 increases the level of stable β-catenin  
In order to counter this problem total protein samples were generated from similar 
experiments, lysed with RIPA buffer.  These samples were generated from 3 separate 
donors and run on SDS-PAGE gels and transferred to nitrocellulose membranes 
before probing with an anti-active-β-catenin (anti-ABC) antibody.  The anti-ABC 
antibody detects β-catenin dephosphorylated on Ser37 or Thr41.  This form is 
therefore not targeted for degradation by the proteosome and represents the active 
form of β-catenin capable of interacting with transcription factors and inducing gene 
expression.  Hence, these samples did not require fractionation or nuclear loading 
controls.  As with the total β-catenin, the active-β-catenin showed a dose-dependent 
increase, in response to increasing AR28 concentrations, which appeared to have 
peaked by 2.5 µM, with higher concentrations having little further effect in 
enhancing the β-catenin stabilisation (Figure 3.4.6). 
3.4.4 TCF/LEF1 reporter assay 
While the experiments described above show the ability of AR28 to generate an 
increase in stabilised β-catenin, in order to analyse the transcriptional responses 
generated by AR28 a TOPFlash luciferase reporter was used, which utilises four 
copies of the TCF/LEF1 response element to report Wnt signalling activity.  
TOPFlash analysis was carried out in C3H10T1/2 cells, as MSCs frequently suffer 
from low transfection efficiencies.  C3H10T1/2 cells were seeded at 1x10
4
 cells per 
well of a 96 well plate, followed by transfection with both the TOPFlash reporter 
(M50) and a constitutively expressing Renilla (pCMV-Renilla) plasmid.  TCF 
activity was then measured as Firefly luciferase normalised to Renilla luciferase.   
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3.4.4.1 AR28 can stimulate TCF/LEF1 reporter activity 
Initial studies compared AR28 treatment with two other commonly used activators 
of canonical Wnt signalling, LiCl and recombinant Wnt3a, over a 24 hour treatment 
period.  LiCl is commonly used at 20 mM, while recombinant Wnt3a is shown to 
cause a range of effects over concentrations of 5-100 ng/ml (Liu et al, 2009).  Using 
the TOPFlash assays, AR28 caused a dose-dependent increase in luciferase activity 
with increases ranging from 10-fold to 500-fold with 0.1 µM and 2.5 µM AR28 
respectively. These increases were comparable to the effects caused by Wnt3A (5-
100 ng/ml). LiCl, an alternative GSK3β inhibitor, was less effective at eliciting a 
Wnt response, only causing a 10-fold increase in reporter activity compared to NaCl 
controls when used at 20 mM (Figure 3.4.7 A).  A similar assay, using a mutated 
form of the TOPFlash reporter plasmid, containing mutated TCF/LEF1 binding sites, 
showed no change in response to either AR28 at the same concentrations of LiCl 
treatments (Figure 3.4.7 B), confirming the validity of the increases in TCF/LEF1 
activity. 
3.4.4.2 AR28 stimulated TCF/LEF1 reporter activity is time and dose dependent 
The TOPFlash reporter was also able to identify changes in transcriptional activation 
in response to differing concentrations and treatment duration of AR28, and compare 
this to another commonly used GSK3β inhibitor, BIO (Figure 3.4.8).  AR28 
administration generated a strong TCF reporter response in a time- and 
concentration-dependent manner, with increasing luciferase expression with 
concentration and time.  1 µM AR28 was able to generate clear increases in reporter 
activity within 4 hours of treatment, which continued to increase overtime.  
Similarly, higher AR28 concentrations generated large increases from 4 hours 
onwards, increasing in intensity with time, and not reaching a plateau by 40 hours 
(Figure 3.4.8 A).  However, BIO at similarly high concentrations generated early 
increases in reporter expression, but peaked by 36 hours at around 100-fold 
increased expression (Figure 3.4.8 B) compared to over 1000-fold increases by 
AR28 at 40 hours.  
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Figure 3.4.7. TOPFlash analysis ofAR28 compared to other Canonical Wnt 
stimulators 
A) C3H10T1/2 cells were co-transfected with the TOPFlash (LEF1/TCF firefly 
reporter) plasmid and pCMV-Renilla before being treated with a range of 
canonical Wnt stimuli.  Firefly and Renilla luciferase were assayed after 24 hours.  
Reporter activity (Firefly luciferase) was normalised to Renilla luciferase and the 
mean of 6 independent technical replicates calculated for each treatment.  The 
relative increases, compared to respective vehicle controls, were then calculated.  
The graph presents mean ± standard deviation of normalised data from three 
independent biological samples, each consisting of six independently transfected 
and treated technical replicates.  B)  C3H10T1/2 cells were co-transfected with 
the FOPFlash plasmid and pCMV-Renilla before being treated with a range of 
canonical Wnt stimuli.  Firefly and Renilla luciferase were assayed after 24 hours.  
Firefly luciferase was normalised to Renilla luciferase.  The relative increases, 
compared to respective vehicle controls, were calculated.  The graph presents 
mean ± standard deviation of six independently transfected and treated technical 
replicates. 
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Figure 3.4.8. TOPFlash analysis of GSK3 inhibition over a 40 hour time-
course 
C3H10T1/2 cells were co-transfected with the TOPFlash (LEF1/TCF firefly 
reporter) plasmid and pCMV-Renilla before being treated with A) a range of 
AR28 concentrations or B) 10 µM BIO.  Firefly and Renilla luciferase were 
assayed after 4, 16, 36 and 40 hours of treatment.  Reporter activity (Firefly 
luciferase) was normalised to Renilla luciferase and the mean of 6 independent 
technical replicates calculated for each treatment.  The relative increases, 
compared to respective vehicle controls, were then calculated.  Values given as 
the mean fold change ± standard deviation of six independently transfected and 
treated technical replicates. n=6, * p<0.05, ** p<0.005, *** p<0.001.  Statistical 
significance is relative to vehicle control at relevant time point, by Mann-Whitney 
U and Kruskal-Wallis tests. 
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Figure 3.4.9. TOPFlash analysis of AR28 pulse treatment 
C3H10T1/2 cells were co-transfected with the TOPFlash (LEF1/TCF firefly 
reporter) plasmid and pCMV-Renilla before being pulse treated with 10 µM 
AR28 for 4 hours before its removal.  Firefly and Renilla luciferase were assayed 
at 4, 10, 16 and 22 hours after treatment initiation.  Reporter activity (Firefly 
luciferase) was normalised to Renilla luciferase and the mean of 6 independent 
technical replicates calculated for each treatment.  The relative increases, 
compared to respective vehicle controls, were then calculated.  Values given as 
the mean fold change ± standard deviation of six independently transfected and 
treated technical replicates. n=6, * p<0.05, ** p<0.005, *** p<0.001.  Statistical 
significance is relative to vehicle control at relevant time point, by Mann-Whitney 
U and Kruskal-Wallis tests. 
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3.4.4.3 AR28 induced TCF/LEF1 reporter stimulation is reversible 
This system was also able to study the effect of pulse treating with AR28.  TOPFlash 
transfected C3H10T1/2 cells were pulse treated with 10 µM AR28 for 4 hours before 
removal of the compound.  The reporter expression peaked shortly after removal of 
AR28, but then began to decline again over time (Figure 3.4.9).  However, reporter 
levels did not reach basal levels within the 22 hour time period of the experiment. 
3.4.5 AR28 does not stimulate the Hedgehog pathway 
As discussed in section 1.3.3 GSK3β is also involved in transduction of the 
Hedgehog signalling pathway, therefore to identify any effect of AR28 on this 
pathway C3H10T1/2 cells were transfected with a hedgehog reporter plasmid (Gli-
BS) (Sasaki et al, 1997) and treated with AR28, purmorphamine or a combination of 
both for 24 hours.  The cells were co-transfected with pCMV-Renilla as a 
transfection control.  Purmorphamine is a Hedgehog agonist, which acts by 
stimulating the Smo transmembrane protein, leading to signal transduction upstream 
of Gli transcription factor phosphorylation.  Purmorphamine at a concentration of 
1 µM generated a significant (p<0.005) 2.5 fold increase in Gli reporter activity, 
while AR28 appeared to create small decreases in Gli reporter activity at 2.5 µM 
(p<0.05).  However, when added in combination AR28 did not affect the increase in 
reporter activity generated by purmorphamine (Figure 3.4.10 A).  Cells transfected 
with a mutated version of the Gli reporter plasmid (m3’Gli-BS) did not present any 
change in reporter expression in response to either AR28 or purmophamine (Figure 
3.4.10 B). 
3.4.6 AR28 induces embryonal axis duplication in Xenopus laevis 
In order to analyse the ability of AR28 to selectively activate a functional Wnt 
response, an in vivo Xenopus model system was used.  It is known that during 
Xenopus embryonic development there is a β-catenin gradient toward the dorsal side 
of the embryo, and that this is important for the positioning of the BCNE centre and 
Nieuwkoop centre, which in turn dictates the location of the Spemann organiser (De 
Robertis & Kuroda, 2004).  It is also well documented that the injection of Canonical 
Wnt ligand RNA into the ventral side of the embryo before organiser 
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Figure 3.4.10. Hedgehog reporter analysis of AR28 treatment 
C3H10T1/2 cells were co-transfected with the A) Gli-BS or B) 3’ Gli-BS 
plasmids and pCMV-Renilla before being treated with purmorphamine (Pur.) 
and/or AR28 at the concentrations shown.  Firefly and Renilla luciferase were 
assayed after 24 hours.  Reporter activity (Firefly luciferase) was normalised to 
Renilla luciferase and the relative increases, compared to no treatment, were 
calculated.  The graph presents mean ± standard deviation of six independently 
transfected and treated technical replicates 
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 region formation results in the formation of a second Spemann organiser region 
(Sokol et al, 1991).  
3.4.6.1 BIO, but not AR28 causes dorsalisation when added to bathing medium 
A more straightforward assay however is to bathe the embryos in a Wnt stimulus 
during this early stage of β-catenin patterning, causing an increase in β-catenin 
throughout the embryo, in turn leading to the dorsalisation of the embryo (Meijer et 
al, 2003).  X. laevis embryos at 4 cell stage were bathed in either BIO or AR28 until 
they reached the 8 cell stage.  The embryos were then allowed to progress to NF 40.  
As in published data (Meijer et al, 2003) 50 µM BIO was able to induce complete 
dorsalisation in 90% of the embryos (Figure 3.4.11.), while 10 µM BIO was only 
capable of partially dorsalising 6%.  In contrast, AR28 was unable to induce 
dorsalisation of the embryos at concentrations of 10 and 50 µM.  When used at 
100 µM, one of 30 embryos was identified as partially dorsalised (Figure 3.4.11.) 
3.4.6.2 AR28 causes axis duplication upon injection 
It was proposed that AR28 was unable to diffuse across the vitalline membrane; 
therefore, X. laevis embryos were injected with 4.2 nl of AR28 at concentrations of 
100-400 μM into the ventral marginal zone at the four cell stage of development, and 
allowed to progress to NF 40.  AR28 generated a dose-dependent axis duplication of 
the X. laevis embryos, which was first visible at NF 20, with embryos showing the 
characteristic Y-shaped neural tube formation.  At the later stage of NF 40, the 
embryos had developed Y-shaped dorsal axes and second heads (Figure 3.4.12), with 
58% of the injected embryos showing some level of axis duplication with 200 and 
400 μM AR28, compared to 0% in the DMSO and uninjected controls.  Furthermore, 
the severity of the axis duplication increased with increasing AR28 concentrations, 
identified by a higher occurrence of duplicated eyes, with 37% of embryos with extra 
eyes when injected with 400 µM, compared to only 5% in the 200 µM samples 
(Table 3.4.1). 
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Figure 3.4.11. BIO, but not AR28, induces dorsalisation in X. laevis embryos 
when added to bathing medium 
Example images of NF stage 40 embryos, bathed in BIO or AR28 at 
concentrations given.  Embryos were treated between the 4 and 8 cell stage for 40 
minutes at 18ºC.  BIO was able to completely dorsalise 90% of treated embryos 
when used at 50 µM, and partially dorsalise 6% at 10 µM.  AR28 was unable to 
dorsalise embryos with 10-100 µM treatments, with the exception of one of 30 
treated embryos at 100 µM which appeared partially dorsalised. 
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Figure 3.4.12. AR28 induces axis duplication when injected into the ventral 
marginal zone of four cell X. laevis embryos 
4.2 nl 400 µM AR28 or 1% DMSO (vehicle control) was injected into the ventral 
marginal zone of four cell X. laevis embryos, which were allowed to progress to 
NF stage 40.  The developed X. laevis tadpoles demonstrated clear second axis 
formation in a proportion of the embryos (example images of embryos with axis 
duplication), with the percentage of duplicated embryos given in Table 3.4.1.  
Control embryos (Uninjected, and vehicle injected) showed normal single axis 
development. 
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To confirm the formation of second neural tube structures in the duplicated axes, 
embryos with second axis from the 400 µM treatment and control samples were wax 
embedded, sectioned and histologically stained.  The embryos with second axes 
clearly showed secondary neural tube formation (Figure 3.4.13, arrows), again with 
varying degrees of severity.  In addition to secondary neural tube formation some 
samples also had other secondary structures such as eyes (Figure 3.4.13, red arrow) 
and other internal organs.  
3.4.6.3 Injection of AR28 induces secondary regions of Chordin expression 
Axis duplication of Xenopus embryos is a well documented result of increased 
canonical Wnt signalling (Sokol et al, 1991), however similar effects can also be 
generated by manipulating other signalling pathways such as BMPs that act after 
organiser region formation (Suzuki et al, 1994).  Chordin is a marker for the 
Spemann organiser (Sasai et al, 1994), offering a more specific readout of canonical 
Wnt activation.  Therefore, embryos were prepared and injected with 400 µM AR28 
and controls as above and allowed to develop to NF 10.5, followed by fixation and 
in-situ hybridisation against chordin.  Injection of 400 μM AR28 resulted in clear 
second regions of chordin expression in the ventral side of the embryo in 95% of the 
injected samples, with no secondary regions detected in control embryos (Figure 
3.4.14).  The size of the secondary chordin expressing region was not uniform across 
the embryos, suggesting different degrees of axis duplication.   
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Table 3.4.1. X. laevis axis duplication by AR28 
4.2 nl 400 µM AR28 or 1% DMSO (vehicle control) was injected into the ventral 
marginal zone of four cell X. laevis embryos, which were allowed to progress to NF 
stage 40.  Embryos were then counted and assigned a degree of axis duplication. 
 
 Normal 
Phenotype 
Second 
Axis 
Second 
cement 
glands 
Second 
eyes 
Total No. 
Embryos 
Wnt 
Phenotype 
No injection 16 (100%) 0 0 0 19 0 
1% DMSO 27 (100%) 0 0 0 19 0 
100 µM AR28 16 (67%) 7 (29%) 0 1 (4%) 24 8 (34%) 
200 µM AR28 8 (42%) 6 (32%) 4 (5%) 1 (5%) 27 11 (58%) 
400 µM AR28 8 (42%) 2 (10%) 2 (10%) 7 (37%) 16 11 (58%) 
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Figure 3.4.13. Histologically stained sections of X. laevis embryos injected 
with AR28. 
X. laevis embryos which showed clear axis duplication after 4.6 nl of 400 µM 
AR28 injection, and DMSO injected control embryos were wax embedded, 
sectioned and histologically stained.  DMSO injected control embryos showed 
normal development with a single neural tube and body axis.  AR28 injected 
Embryos showed clear second neural tube formation (Black arrows) in all the 
sectioned embryos, and second body axis and eye (red arrow) structures in some 
embryos.   
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Figure 3.4.14. Chordin in-situ hybridisation of AR28 injected X. laevis 
embryos 
4.2 nl 400 µM AR28 or 1% DMSO (vehicle control) was injected into the ventral 
marginal zone of four cell X. laevis embryos, which were allowed to progress to 
blastula stage.  Samples were fixed and probed for chordin by in situ 
hybridisation.  Control and vehicle injected (DMSO) embryos showed single 
regions of chordin expression in the ventral side of the embryos, while 98% of 
AR28 injected embryos showed a second region of chordin expression in the 
dorsal side of the embryo, with varying degrees of intensity.  Arrows identify 
second regions of chordin. 
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3.5 Discussion 
The MSCs extracted and tested from both femoral heads and knees were positive for 
the MSC markers selected, except for CD166 in the femoral head sample presented 
here.  The panel of markers was selected from the many commonly used MSC 
markers (Salem & Thiemermann, 2010), however there are often differences 
between donors, species and culture methods.  Furthermore, the International Society 
for Cellular Therapy defined MSCs as CD105, CD73 and CD90 positive, with other 
MSC markers less strictly required (Dominici et al, 2006; Horwitz et al, 2005).  The 
International Society for Cellular Therapy also identify the importance of being 
negative for the Haematopoietic markers CD34 and CD45, with which all samples 
here complied.   
AR28 was first published on by Gambardella et al. (2011).  In this study, AR28 was 
shown to be selective to GSK3 over a panel of other kinases, with an IC50 of 5 nM.  
The ability of AR28 to stimulate the canonical Wnt signalling pathway had only 
been briefly examined in this work.  Gambardella et al. (2011) studied canonical 
Wnt activation by calculating nuclear:cytoplasmic β-catenin from 
immunocytochemical images of AR28-treated C3H10T1/2 cells.  The work 
presented in this chapter also demonstrated increased nuclear staining in C3H10T1/2 
cells in response to AR28.  In addition to the staining in C3H10T1/2 cells, nuclear 
staining was also detected in AR28 treated human MSCs, however concentrations of 
2.5 µM or higher were needed to generate clear increases in nuclear β-catenin 
staining within 24 hours.  Further quantification of this increase in β-catenin stability 
was performed by western blot analysis of both cytoplasmic and nuclear β-catenin, 
which demonstrated a clear increase in both cytoplasmic and nuclear β-catenin levels 
upon AR28 treatment.  However, nuclear loading controls were poor and it was 
difficult to ensure complete nuclear/cytoplasmic fractionation, making it hard to 
confirm the presence of active stabilised β-catenin available for cell signalling.  The 
use of an anti-ABC antibody allowed for the study of total cell lysates, alleviating 
the difficulties with fractionation, whilst at the same time allowing for the 
identification of the level of the active form of β-catenin involved in canonical Wnt 
signal transduction.  This more sensitive approach also allowed for increases in 
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active β-catenin, and therefore canonical Wnt signalling, to be detected upon lower 
AR28 treatments of 1 µM.   
In addition to these increases in stable β-catenin induced by AR28, which 
complimented the work by Gambardella et al. (2011), the work presented here also 
provides more functional information by the use of TCF/LEF1 reporter assays.  
These reporter assays demonstrated significant increases in the canonical Wnt 
transcription factor activity in a clear dose dependent manner.  Furthermore BIO was 
not able to generate comparable increases in TCF reporter activity to AR28 over a 40 
hour period, with approximately 10 fold lower reporter expression.  The increase in 
reporter expression also appeared to plateau at around a 100-fold increase in reporter 
activity compared to controls by 40 hours, corresponding with a reduction in Renilla 
expression, indicative of reduced cell numbers.  AR28 is therefore more potent than 
BIO at stimulating a canonical Wnt response in vitro.  Furthermore BIO caused 
reductions in Renilla luciferase expression levels over the 40 hour incubation period 
that were not seen in controls or AR28 treated samples, suggesting a detrimental 
toxic effect on cell number and reporter expression.  In support of this, BIO has been 
shown to inhibit the JAK/STAT pathway, leading to apoptosis (Liu et al, 2011).  The 
comparison of AR28’s ability to stimulate the canonical Wnt signalling pathway 
relative to ligand activated signal transduction was also possible.  Recombinant 
Wnt3a was chosen as a comparator as it has been shown to stimulate osteogenesis in 
C3H10T1/2 cells (Winkler et al, 2005) and is therefore related to these studies by 
cell type and differentiation.  This direct comparison between AR28 and 
recombinant Wnt3a demonstrated that AR28 is capable of generating increases in 
TCF transcriptional activity in a biologically relevant, ligand activated, range and 
one which allows comparison to other work (Liu et al, 2009).   
Reporter assays were also used to demonstrate the specificity of AR28 treatment for 
the activation of canonical Wnt signalling over Hedgehog signalling.  Another 
function of GSK3β, in addition to canonical Wnt signal transduction, is during the 
phosphorylation of the Gli family of transcription factors involved in Hh signal 
transduction.   Phosphorylation leads to the cleavage or degradation of the 
transcription factors, altering them to an inhibitory form (See 1.3.3).  Inhibition of 
this phosphorylation process would therefore increase the activatory forms of the Gli 
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transcription factors and induce gene expression.  Conversely AR28 treatment 
caused small decreases in Hedgehog reporter activity when added alone.  However, 
these changes where small, and a similar reduction was not detected upon co-
stimulation of the Hh pathway by purmorphamine.  This would suggest that while 
GSK3β is involved in Hh signal transduction it is not completely necessary, with Gli 
phosphorylation and processing/degradation still occurring, possibly through GSK3β 
activity remaining at sufficient levels after these treatment concentrations or its 
partial requirement for Gli processing.  Therefore any effects caused by AR28 
treatment at these concentrations or lower are unlikely to be due to alterations in Hh 
signalling, but instead due to the large effect upon the canonical Wnt signalling 
pathway. 
As discussed above, canonical Wnt signalling is an attractive therapeutic target for 
many diseases and of particular interest to this thesis, in osteoporosis treatments as 
increased Wnt can increase bone mass in mice.  Indeed, Gambardella et al. (2011) 
demonstrated that AR28 is also capable of increasing the bone mass of mice when 
injected subcutaneously for up to 14 days.  Therefore to demonstrate the ability of 
AR28 to functionally stimulate canonical Wnt signalling in vivo an alternative model 
system was used, in which canonical Wnt signalling affects the embryonic patterning 
of Xenopus embryos.  As mentioned above, when Xenopus embryos were cultured 
with AR28 in the growth solution, there was no effect on embryo development, 
whereas BIO was able to completely dorsalise 90% of the embryos.  The ability of 
BIO to dorsalise Xenopus embryos confirms previous work by Meijer et al. (2003) in 
which both LiCl and BIO were capable of diffusing into the Xenopus embryo and 
inducing an increase in β-catenin throughout the embryo.  AR28 was unable to cause 
the dorsalisation of X. laevis embryos by this technique, despite demonstrating 
greater potency in vitro.  One explanation for this is that AR28 is less able to diffuse 
throughout the embryo.  This proposition is strengthened by the ability of AR28 to 
induce embryonal axis duplication by injection into the ventral marginal zone of a 
four cell X. laevis embryo.  In order for axis duplication to occur, and not 
dorsalisation, β-catenin stabilisation must only occur in a small area in the ventral 
side of the embryo, and not throughout the embryo as achieved by the bathing 
experiments.  Therefore, if AR28 was able to rapidly diffuse throughout the embryo 
after injection, AR28 would become dilute throughout the embryo, where, if still 
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potent enough it would cause dorsalisation of the embryos, and not axis duplication.  
The need for such high AR28 concentrations for the induction of axis duplication 
may suggest that there is some degree of diffusion, therefore requiring high starting 
concentrations.  Alternatively AR28 may be sequestered or degraded in the in vivo 
environment, whereas it is not during the in vitro assays. 
Several other GSK3 inhibitors have been developed with similarly high potency and 
specificity for GSK3, however they have only briefly been shown to induce the 
canonical Wnt signalling pathway.  One small molecule inhibitor of GSK3 is 
LY603281, which has an IC50 of 1.3 nM (Engler et al, 2004).  This IC50 is lower than 
that calculated for AR28, and has also been shown to increase total β-catenin in 
C3H10T1/2 cells with concentrations as low as 0.01 µM (Kulkarni et al, 2006).  
However, TOPFlash analysis of the ability of LY603281 to increase TCF reporter 
expression were only able to create up to 7-fold increases in reporter activity over 24 
hours, which peaked at concentrations of 0.1 µM.  Above this concentration, reporter 
activity reduced again, to around 3-fold increases with both 1 and 10 µM treatments 
(Kulkarni et al, 2006).  This increase in TOPFlash reporter activity is similar to that 
calculated for LiCl in this work, and that of the lower AR28 concentrations.  
However, the increase in reporter activity generated by AR28 did not plateau or peak 
by 10 µM, the highest concentration tested, and could generate over a 100-fold 
increase in luciferase expression after 24 hours treatment.  
The CHIR-family of GSK3 inhibitors are another interesting comparator, with 
CHIR-99021 (IC50 6.7 nM) and CHIR-98014 (IC50 0.58 nM) being very potent and 
specific inhibitors of GSK3 (Ring et al, 2003).  Furthermore CHIR-99021 has been 
studied for its ability to activate the canonical Wnt pathway in vitro.  CHIR-99021 
was able to cause a 2-fold increase in cytoplasmic β-catenin after 4 hours treatment 
at 3 µM in 3T3-L1 cells (Bennett et al, 2002).  This is likely comparable to the ~8 
fold increase in active β-catenin seen after 24 hours of treatment, although a direct 
comparison is not possible due to the difference in experimental design.  To my 
knowledge however, the more potent CHIR-98014 has not been investigated for its 
ability to stimulate the canonical Wnt pathway.  However, the ability of LY603281 
or the CHIR family of inhibitors to stimulate the canonical pathway in vivo has not 
been studied. 
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In conclusion, AR28 is a potent stimulator of canonical Wnt signalling, through the 
inhibition of GSK3β, allowing for the stabilisation of β-catenin, its translocation into 
the nucleus of cells, and ultimately increase TCF/LEF1 transcription factor activity 
and gene expression.  AR28 is much more potent than both LiCl and BIO, 
demonstrated in this work, but also LY603281, when comparing fold changes in 
TCF reporter expression to published work (Kulkarni et al, 2006).  AR28 is therefore 
a valuable tool for studying the canonical Wnt signalling pathway in vitro, capable of 
generating large increases in signalling with little effect on cell viability.  AR28 is 
less able to diffuse throughout tissues in vivo than BIO and LiCl, but once present 
within the cells is able to generate specific canonical Wnt responses.  While this low 
capacity to diffuse throughout tissues may provide difficulties for administration, it 
does allow for a more targeted approach to canonical Wnt stimulation in vivo. 
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Chapter 4: AR28 and lineage commitment 
of MSCs 
4.1 Introduction 
Enhanced canonical Wnt signalling has been demonstrated to increase bone mass 
(Gambardella et al, 2011; Kulkarni et al, 2006) and bone remodelling (Krause et al, 
2010) in mice in multiple studies, yet the mechanism underlying this bone anabolic 
effect remains unclear.  One explanation is the effect of canonical Wnt signalling on 
the MSC pool in the bone marrow and how these cells then differentiate into 
osteoblasts, adipocytes and chondrocytes.   
The study of canonical Wnt signalling in in vitro mesenchymal differentiation has 
been performed using a variety of techniques/experimental approaches.  Firstly, the 
canonical Wnt pathway can be stimulated using a range of Wnt ligands and agonists, 
as discussed in chapter 3.  Secondly, a wide array of murine cell lines has been used 
in preference to primary human MSCs.  While several are either bi-potent, ST2 
(Bennett et al, 2005), or multipotent, C3H10T1/2 (Date et al, 2004) and C2C12 (Lee 
et al, 2000), preosteoblast and preadipocyte (MC3T3-E1 (Date et al, 2004) and 3T3-
E1 (Bennett et al, 2002) respectively) cells have also been used to gain a better 
understanding of the differentiation of mesenchymal precursors.  While the precursor 
cell lines allow for a more simplified system, enabling the study of one particular 
differentiation pathway, they do not account for the potential for differentiation 
lineage interplay.  The use of the bi- and multipotent cell lines begin to address this 
issue.  Immortalised human cell lines, such as SV-HFO (Eijken et al, 2008) are also 
used, which can alleviate the problems associated with using murine models, yet as 
with all cell lines they are likely to behave abnormally due to prolonged in vitro 
culture.  Human MSCs from a variety of sources are being increasingly utilised 
(Baksh et al, 2007a; Boland et al, 2004; Krause et al, 2010; Liu et al, 2009) allowing 
for the study of lineage commitment decisions towards multiple cell types in a 
human primary cell culture.  While MSCs clearly offer many advantages over 
murine cell lines in their translatability into human medicine, there are disadvantages 
to their use in experimental procedures.  Firstly there is the problem of donor 
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variation (Frank et al, 2002; Phinney et al, 1999; Siddappa et al, 2007).  As MSCs 
are a primary cell line, they are likely to differ in their properties between donors, 
both in the proliferation rate and capacity to differentiate toward particular lineages.  
Furthermore, as MSCs are solely selected by their adherence to plastic, the resulting 
cell population is often heterogeneous, containing multipotent stem cell, but also a 
population of less potent, early lineage committed cells (Minguell et al, 2001).  
Together, these factors cause a difficulty in accurate reproduction between donors, in 
particular when combining absolute values.  Therefore comparisons between donors 
are often limited to trends.  Therefore it is also important to compare results from 
multiple donors to mitigate for the heterogeneity.  MSCs also have poor transfection 
efficiencies (Baksh et al, 2007b), and cannot be used to generate stable lines without 
first generating an immortalised cell line (Abdallah et al, 2005), making the use of 
reporter assays and over-expression studies challenging. 
The use of such a range of cell types has created difficulties of its own, with the 
culture conditions and requirements for differentiation varying with each cell type.  
This has lead to discrepancies in the findings between different groups using 
different cell models.  While studies in the murine cell lines has repeatedly reported 
increases in osteoblastic genes in response to canonical Wnt signalling (Bennett et al, 
2005; Jackson et al, 2005; Kulkarni et al, 2006) reports using human MSCs have 
demonstrated reductions in osteogenesis and increases in MSC proliferation in 
response to increased signalling (Baksh et al, 2007a; Boland et al, 2004; Liu et al, 
2009).  In this chapter the combination of the potent canonical Wnt activator AR28 
(Characterised in chapter 3) is used in combination with human MSCs to gain a 
more thorough understanding of the effect of canonical Wnt stimulation on the 
tri-lineage differentiation of MSCs.  
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4.2 Aims 
The general aims of the work presented in this chapter are to identify the effect of 
induced canonical Wnt signalling, by AR28, on the differentiation of human MSCs 
to gain a better understanding of the way in which AR28 increases bone mass in 
mice. 
More specifically the aims are to: 
 Characterise the effect of AR28 on CFU-F formation. 
 Identify the effect of AR28 on the adipogenic differentiation of MSCs, in 
order to confirm the inhibitory effect of canonical Wnt signalling on this 
process.  
 Determine the effect of AR28 on the osteogenic differentiation of MSCs 
using both the classical osteogenic media, and a milder stimulus by the 
exclusion of dexamethasone, to gain a better understanding of the role of Wnt 
signalling in osteogenic commitment. 
 Identify the effect of AR28 on chondrogenic differentiation of MSCs cultured 
as micromass pellets. 
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4.3 Methods 
4.3.1 CFU-F assay 
MSCs were counted and seeded at 10 cells/cm
2
 in 96 well plates in DMEM, 20% 
hyclone FBS (Thermo Scientific, Waltham, MA, USA), and 1% P/S.  Cells were 
allowed to attach overnight prior to AR28 treatments.  After 4 days, the media was 
replaced (containing standard FBS) and every 3-4 days thereafter.  The cells were 
cultured for approximately 2 weeks or until discrete colonies could be identified 
under the microscope.  The colonies were washed 2 times in PBS and fixed in 95% 
ethanol for 5 minutes.  The ethanol was removed and the cells stained for 30 minutes 
in 0.5% Crystal Violet (in 95% ethanol).  The Crystal Violet was removed and the 
plates washed in tap water to remove excess stain.  The plates were then allowed to 
dry before imaging on a light box. 
4.3.2 MTT assay 
MSCs were seeded at 1x10
4
 or 2x10
4
 cells/cm
2
 in 96 well plates, and allowed to 
attach overnight.  Treatments were applied in replicates of 6, and replaced every 3-4 
days.  The cells were cultured for 4 or 7 days before the media was removed and 
replaced with 100 µl basal media plus 25 µl 5 mg/ml MTT (in PBS).  Media and 
MTT was also added to 6 well with no cells as background controls.  The samples 
were cultured at 37ºC, 5% CO2 for 2 hours to allow the cells to convert the soluble 
MTT into insoluble formazan.  The media/MTT was then removed and formazan 
solubilised by 30 minutes incubation in acidic isopropanol (0.04M HCl in 100% 
isopropanol).  Once in solution, the absorbance was measured at 570 nm.  The mean 
blank value was subtracted from the sample absorbance readings, and presented as 
the mean absorbance ± standard deviation for each treatment. 
4.3.3 p-Nitrophenyl Phosphate (pNPP) alkaline phosphatase assay. 
At the desired time point cells, cultured in 96 well plates, were washed with 0.2M 
Carbonate Buffer (0.2M Na2CO3, 0.2M NaHCO3, pH 10.2), and lysed in 150μl lysis 
buffer (0.1% Triton X-100 in carbonate Buffer).  Cells were then freeze-thawed (-
80°C/37°C) 3 times and stored at -80°C.  Upon thawing, the cells were pipetted up 
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and down to ensure full lysis and 50μl transferred to both a new 96 well plate for the 
pNPP assay, and a black 96 well plate for the picogreen assay. 
4.3.3.1 pNPP assay 
For alkaline phosphatase (ALP) activity, standards were generated using p-
nitrophenol (pNP) diluted in 0.2M carbonate Buffer, and 100μl added per well of the 
clear plate.  50μl of working substrate (1 stock substrate: 2 dH2O. [Stock substrate = 
10mg pNPP, 9ml 0.2M carbonate buffer, 1ml 100mM MgCl2]) was then added to 
each sample well and incubated at 37°C for up to 1 hour before the absorbance at 
405nm was measured.   
4.3.3.2 Picogreen assay 
To measure the DNA content, the wells were treated with Quant-iT picogreen 
reagent (Invitrogen, Carlsbad, CA, USA).  50 µl of picogreen working reagent (50:1, 
Tris-EDTA : picogreen) was added to each sample and salmon sperm DNA 
standards.  The fluorescence was then measured using a plate reader (458 nm 
excitation and 538 nm emission).   
Standard curves were created for both pNP and DNA and the sample concentrations 
calculated.  The number of nmoles of pNP produced per minute of incubation could 
then be calculated for each well before normalising to DNA to give 
nmoles pNP/min/µg DNA. 
4.3.4 Alkaline Phosphatase Enzyme Histochemistry and von Kossa staining 
At the desired time point the cells, cultured in 24 well plates, were washed with PBS, 
followed by treatment with ALP reagent mix (0.2mg/ml naphthol AS-MX in 1% 
N,N-dimethylformamide diluted in 0.1M Tris (base) pH 9.2, plus 1mg/ml Fast Red 
TR).  Cells were then washed in PBS before fixation with 4% paraformaldehyde for 
5 mins, followed by single washes in PBS and dH2O.  Mineralisation was visualised 
using the von Kossa technique with the addition of 1% silver nitrate solution and left 
on a light box for 30 mins.  Cells were subsequently washed with dH2O, treated with 
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2.5% sodium thiosulphate for 5 minutes and washed again with dH2O, before storage 
in 20% glycerol in PBS and imaged using bright field microscopy. 
4.3.5 Alizarin Red S staining 
Cells were cultured in 24 well plates and treated as described.  Calcification of 
osteogenic monolayers was visualised using Alizarin Red Staining. Cells were 
washed with PBS followed by fixation with 4% PFA for 15 minutes.  The cells were 
then washed 3 times in PBS before staining with 40mM Alizarin Red S solution 
(pH4.2) for 20min at room temperature.  The cells were finally washed three times in 
PBS, followed by washes in tap water to remove non-specific staining.  Plates were 
allowed to dry prior to imaging. 
4.3.6 Oil Red O staining 
Cells were cultured in 96 well plates and treated as described.  Lipid droplets were 
visualised using Oil Red O staining.  Cells were washed with PBS followed by 
fixation with 4% paraformaldehyde for 10 mins.  The cells were then washed once in 
dH2O and incubated in 60% isopropanol for 5 mins.  The isopropanol was removed 
and followed by an incubation in Oil Red O staining solution (0.3% Oil Red O in 
60% isopropanol) for 10 mins, washed once in 60% isopropanol and 3 times with 
dH2O.  The samples were stored in 20% glycerol in PBS and imaged using bright 
field microscopy.  For quantification, Oil Red O was extracted using 100% 
isopropanol (50μl/well) for 10 minutes and the absorbance measured (490nm). 
4.3.7 FABP5/BODIPY staining 
Cells, cultured in glass bottom 96 well plates, were fixed at the desired time point in 
4% paraformaldehyde for 15 min, followed by washing in PBS.  The cells were then 
blocked in PBS supplemented with 1.1% BSA and 0.2% Triton-X-100 for 30 
minutes at room temperature.  Anti-FABP5 (Table 4.3.1) was added overnight at 4°C 
in blocking buffer.  The cells were washed in blocking buffer before addition of 
Alexa Flour 647 donkey anti-goat IgG and Hoechst 33342 (Table 4.3.1) in blocking 
buffer for 1 hour at room temperature.  The cells were washed three times in PBS 
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followed by BODIPY (Table 4.3.1) staining in PBS for 40 minutes at room 
temperature.  Cells were washed and stored in PBS at 4°C.  Images were taken using 
an automated ImageXpress 5000A (Molecular Devices) and analysed using 
Definiens analyzer software. 
Table 4.3.1. FABP5/BODIPY antibody and stain concentrations 
 
Antibody/stain Host 
Concentration
/dilution 
Supplier 
Catalogue 
No. 
Anti-human 
FABP5 
Goat 5 µg/ml 
R&D 
Systems 
AF3077 
Alexa Flour 647 
anti-goat IgG 
Donkey 1:500 Invitrogen A21447 
Hoechst 33342 N/A 1 µM Invitrogen H3570 
BODIPY N/A 200 nM Invitrogen D3933 
 
4.3.8 Mitomycin C treatment 
MSCs were seeded at 2x10
4
 cells/cm
2
 in 24 well plates and allowed to adhere 
overnight.  The media was removed and replaced with basal media containing 
10 µg/ml mitomycin C (Sigma Aldrich, St. Louis, MO, USA).  Cells were incubated 
for 2 hours before removal of the mitomycin C.  The cells were washed twice with 
PBS before addition of osteogenic (excluding dex) media to the cells. 
4.3.9 Cell TraceTM CFSE assay 
4.3.9.1 Optimisation 
MSCs were trypsinised and split into 4 tubes of 1.5x10
5
 cells.  One sample was 
seeded into a single well of a 6 well plate for a no CFSE control.  The remaining 
three were resuspended at 5x10
5
 cell/ml (300 µl) in PBS + 5% FBS.  Cell Trace
TM
 
CFSE stock solution (Invitrogen, Carlsbad, CA, USA) (5 mM) was added to the cells 
at 10, 20 and 30 µM, mixing whilst adding.  Samples were incubated for 10 minutes 
at 37ºC before quenching with 3 ml cold PBS + 5% FBS and incubating at 4ºC for 5 
minutes.  Samples were then centrifuged and washed in warm PBS + 5% FBS 3 
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times before resuspension in basal media and seeded into wells of a 6 well plate.  
After 24 hours of culture, cells were detached from culture using trypsin and 
analysed by flow cytometry using CyAn
TM
 ADP Analyzer (Beckman Coulter, 
Fullerton, CA, USA) at the appropriate excitation and emission wavelengths and 
analysed using Summit software. 
4.3.9.2 Proliferation assay 
MSCs were trypsinised and counted.  A sample of cells was seeded back into a well 
of a 6 well plate for a no CFSE control.  The remaining cells were resuspended at 
5x10
5
 cells/ml in PBS + 5% FBS and Cell Trace
TM
 CFSE stock solution (5 mM) 
added to a final concentration of 20 µM.  Cells were incubated at 37ºC for 10 
minutes before quenching with 10x the volume PBS + 5% FBS and incubated at 4ºC 
for 5 minutes.  The cells were then centrifuged and washed in warm PBS + 5% FBS 
3 times before resuspension in basal media and seeded into wells of a 6 well plate at 
2x10
4
 cells/cm
2
, and allowed to adhere overnight.  Samples were then cultured for 7 
days in the presence of a combination of media and AR28 conditions.  The cells 
were then detached using trypsin and analysed by flow cytometry using CyAn
TM
 
ADP Analyzer (Beckman Coulter, Fullerton, CA, USA) at the appropriate excitation 
and emission wavelengths and analysed using Summit software. 
4.3.10 Ki67 Immunocytochemistry 
Prior to fixation, MSCs to be probed for Ki67 were stained by ALP enzyme 
histochemistry (Section 4.3.4).  Cells cultured on coverslips in 24 well plates were 
fixed with 4% paraformaldehyde for 15 min, before blocking in PBS + 10% goat 
serum + 0.1% triton X-100 for 2 hours at RT.  Incubation with Anti-Ki67 (Abcam) at 
1:200 in blocking buffer was performed overnight at 4°C.  The cells were washed in 
PBS before addition of the Goat anti-rabbit IgG Alexafluor 488 (Invitrogen, 
Carlsbad, CA, USA) secondary antibody at 1:500.  Samples were incubated for 2 
hours at 4°C in the dark.  The secondary antibody was removed and the samples 
washed 3 times in PBS.  Coverslips were mounted on slides using VECTASHIELD 
mounting medium with DAPI (Vector laboratories, Burlingame, CA, USA).   
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4.4 Results 
4.4.1 AR28 reduces the CFU-F capability of MSCs 
One characteristic of MSCs is their capacity to form colonies from single cells, 
which is measured as the CFU-F capability of the population.  To identify how 
AR28 affects the CFU-F formation, MSCs were seeded at clonal density (10 
cells/cm
2
, i.e. 960 cells/well of a 6 well plate), and cultured for 2 weeks before 
fixation and staining with crystal violet to visualise colonies.  A representative donor 
is presented in Figure 4.4.1.  Untreated cells formed an average of ~10 colonies per 
well, which equates to a CFU-F value of ~1%.  The vehicle control had no 
significant effect on CFU-F values, nor did the lowest concentration of AR28, 
0.05 µM.  However, the higher concentrations of AR28 generated a dose-dependent 
decrease in number of colonies formed, implying that AR28 has a negative effect of 
the CFU-F capacity of MSCs. 
4.4.2 AR28 inhibits adipogenic differentiation of MSCs 
In order to study the effect of AR28 administration on the adipogenic differentiation 
of MSCs, bone marrow (BM) MSCs and human adipose derived stem cells (hADSC) 
were seeded at confluency and induced to form adipocytes.  These samples were 
then also treated with either vehicle control (DMSO) or AR28 at varying 
concentrations for 15 days before fixing and staining with Oil Red O to identify lipid 
droplet formation.  Both the BM MSCs and hADSCs formed lipid droplets in 
response to the adipogenic media (Figure 4.4.2 A and Figure 4.4.3 A), which was 
attenuated in response to AR28 treatment.  Both the number of lipid droplets and 
size of the droplets were reduced in AR28-treated samples at all concentrations, but 
0.5 µM AR28 was required to cause total inhibition.  The Oil Red O was extracted 
out of the droplets by incubation in 100% isopropanol, allowing for quantification of 
the staining by absorbance at 450 nm (Figure 4.4.2 B and Figure 4.4.3 B).  The BM 
MSCs showed significant reductions in Oil Red O with as little as 0.05 µM AR28, 
with absorbance values being reduced to basal levels by 0.5 µM AR28.  The 
hADSCs however, did not show significant reductions in absorbance with the lower 
concentrations, but still reduced to basal levels with 0.5 µM AR28.  
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Figure 4.4.1. AR28 inhibits CFU-F capability of BM MSCs 
A) Images of a representative donor (K57) showing the effect of AR28 on the 
CFU-F capability of MSCs.  MSCs were seeded at clonal density and allowed to 
attach before AR28 administration at the concentration given.  The MSCs were 
then cultured for approximately 2 weeks to allow colonies to form and stained 
with crystal violet before imaging. B) Bar chart showing the number of CFU-F 
colonies for each treatment.  Values given as mean ± stdev, n=3. 
A 
B 
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Figure 4.4.2. AR28 inhibits adipogenesis of BM MSCs 
Oil Red O staining of a representative MSC donor (FH429) after 15 days 
adipogenic treatment with AR28 at concentrations shown, or DMSO control.  A) 
Brightfield microscopy images of Oil Red O staining showing lipid droplet 
accumulation.  B) Quantification, by absorbance at 490 nm, of Oil Red O staining 
after solubilisation in 100% isopropanol.  Values given as mean ± stdev. n=6 
(independently treated technical replicates), * p<0.05, ** p<0.005, *** p<0.001.  
Statistical significance is relative to vehicle control, by Mann-Whitney U and 
Kruskal-Wallis tests. 
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Figure 4.4.3. AR28 inhibits adipogenesis of hADSCs 
Oil Red O staining of hADSCs after 15 days adipogenic treatment with AR28 at 
concentrations shown, or DMSO control.  A) Brightfield microscopy images of 
Oil Red O staining showing lipid droplet accumulation.  B) Quantification, by 
absorbance at 490 nm, of Oil Red O staining after solubilisation in 100% 
isopropanol.  Values given as mean ± stdev. n=6 (independently treated technical 
replicates), * p<0.05, ** p<0.005, *** p<0.001.  Statistical significance is relative 
to vehicle control, by Mann-Whitney U and Kruskal-Wallis tests. 
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While these results demonstrate changes in Oil Red O staining within the population 
they give no information into cell number, and the percentage of cells that have 
become adipogenic.  In order to gain some understanding of this an alternative high 
content approach was taken.  hADSCs were treated with adipogenic supplements as 
previously described for up to 7 and 14 days, and were then immuno-stained for 
FABP5 (adipocyte marker), and co-stained with BODIPY (lipid droplets) and 
Hoecsht 33342 (nuclei).  Three colour images were acquired automatically, allowing 
for 4 images to be taken from each of the 6 independently treated replicates. Using 
Definiens automated image analysis software (Figure 4.4.4) and defined thresholds 
the number of nuclei within FABP5/BODIPY double positive areas could be 
calculated, allowing for the evaluation of the percentage of double positive cells in 
response to AR28 treatments.  The use of a half log serial dilution allowed for a 
broad range of AR28 concentrations to be analysed, identifying the key range in 
concentrations for inhibition of adipogenesis as being ~50-500 nM, similar to that 
identified by Oil  Red O staining.  Under adipogenic conditions, approximately 50-
60% of the cells expressed both FABP5 and contained lipid droplets by 14 days, 
which was reduced to ~20% with 200 nM AR28, and completely abolished with 
632 nM AR28 (Figure 4.4.5 A).  Interestingly, the lower concentrations (2-20 nM 
AR28) at 7 days gave a small but significant increase in adipogenesis, but this was 
no longer seen by the later time point.  This same pattern was detected in a separate 
independent experiment (results not shown).  The second piece of information 
available from this work is the cell number in response to AR28 treatment.  At day 7 
there was no effect of AR28 on cell number, yet by day 14, the adipogenic 
conditions had reduced cell numbers compared to the basal media controls (Figure 
4.4.5 B).  Furthermore, treatment with 63 and 200 nM AR28 was able to partially 
rescue this decrease in proliferation, resulting in significant increases in cell number 
compared to vehicle control.  However, above these concentrations AR28 has a 
detrimental effect on cell number causing greatly reduced numbers of cells at 14 
days, suggesting a toxic effect of prolonged exposure to high concentrations of 
AR28.   
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Figure 4.4.4. Schematic showing image analysis process performed by 
Definiens software.  
Definiens analysis software separates the flourescence channels, separating the 
different antibody staining, allowing threshold levels to be applied to each marker 
independently, marking positive and negative regions.  These threshold maps are 
then recombined with nuclei positional information from Hoecsht 33342 staining 
to identify the percentage of FABP5/BODIPY double positive cells within the 
image. 
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Figure 4.4.5. High content analysis of adipogenesis and the effect of AR28. 
FABP5 and BODIPY analysis of 7 and 14 day adipogenic hADSC cultures in the 
presence of AR28 at the concentration given or DMSO control using Definiens 
analyses of fluorescence microscopy imaging.  A) Bar chart showing the number 
of FAPB5/BODIPY double positive cells in response to different AR28 
concentrations.  B) Bar chart showing the total number of nuclei in response to 
different AR28 concentrations.  Values given as mean ± stdev., n=6 
(independently treated technical replicates), * p<0.05, ** p<0.005, *** p<0.001.  
Statistical significance is relative to vehicle control at appropriate time point 
unless stated otherwise, by Mann-Whitney U and Kruskal-Wallis tests. 
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4.4.3 AR28 inhibits classical dexamethasone induced osteogenesis 
In a similar manner, to identify the effect of AR28 on osteogenic differentiation of 
MSCs, cells were cultured in the presence of classical osteogenic media containing 
β-glycerophosphate, L-ascorbic acid and dexamethasone (dex).  Initial analysis of 
osteogenesis was carried by measurement of alkaline phosphatase (ALP) activity per 
well, normalised to DNA content.  Multiple seeding densities of 5x10
3
, 7.5x10
3
 and 
1x10
4
 cells per well of a 96 well plate were tested in combination with the addition 
of AR28 to the culture (Figure 4.4.6).  All three seeding densities allowed for the 
osteogenic differentiation of MSCs in response to osteogenic media.  Similarly they 
all responded to AR28 in the same manner, with a dose-dependent inhibition of ALP 
activity relative to the osteogenic vehicle control, implying reduced osteogenesis.  
AR28 at 0.5 µM was capable of completely inhibiting any increase in ALP activity, 
with lower concentrations causing intermediate levels of inhibition.  As the starting 
cell number had little effect on the osteogenic differentiation of MSCs, an 
intermediate number of 2x10
4
 cells/cm
2
 was selected for use in all further 
experiments.  At these cell seeding numbers, other MSC donors and hADSCs were 
analysed for AR28 effect on osteogenesis.  Again, AR28 prevented the increases in 
ALP activity caused by the osteogenic media in a dose-dependent manner (Figure 
4.4.7).  The degree of inhibition by the lower AR28 (0.05-0.1 µM) concentrations 
varied between donors, but as with adipogenesis, complete inhibition of osteogenesis 
was detected when 0.5 µM AR28 was administered. 
To study the patterning of ALP and mineralisation in AR28 treated cultures, an 
imaging approach was taken.  MSCs were cultured in osteogenic media for up to 
three weeks, before ALP enzyme histochemistry and von Kossa (vK) staining were 
performed.  As seen with the ALP activity assay above, ALP was clearly reduced in 
cultures containing AR28 in a dose-dependent manner in all donors tested (Figure 
4.4.8).  Furthermore, while the degree of vK staining (marking the phosphate of the 
mineralised matrix) varied between donors, it was also reduced by AR28 treatment 
in all donors. 
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Figure 4.4.6. AR28 inhibits osteogenic induced ALP activity irrespective of 
cell density. 
MSC (FH405) seeded in 96 well plates at A) 5x10
3
, B) 7.5x10
3
 or C) 1x10
4
 
cell/well, were cultured in osteogenic  (incl. dex) conditions for up to 12 days in 
the presence of AR28 at the concentrations shown or DMSO control.  ALP 
activity normalised to cell number (given as nmoles pNP/min/µg DNA) was 
calculated at 4, 8 and 12 days. Values given as mean ± stdev., n=6 (independently 
treated technical replicates), * p<0.05, ** p<0.005, *** p<0.001.  Statistical 
significance is relative to vehicle control at appropriate time point, by Mann-
Whitney U and Kruskal-Wallis tests. 
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Figure 4.4.7. AR28 inhibits osteogenic induced ALP activity in both BM 
MSCs and hADScs. 
A) MSC (FH429) or B)  hADScs seeded in 96 well plates at 2x10
4 
cells/cm
2
, were 
cultured in osteogenic  (incl. dex) conditions for up to 12 days in the presence of 
AR28 at the concentrations shown or DMSO control.  ALP activity normalised to 
cell number (given as nmoles pNP/min/µg DNA) was calculated at 4, 8 and 12 
days. Values given as mean ± stdev., n=6 (independently treated technical 
replicates), * p<0.05, ** p<0.005, *** p<0.001.  Statistical significance is relative 
to vehicle control at appropriate time point, by Mann-Whitney U and Kruskal-
Wallis tests. 
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The calcium deposition in the mineralised matrix was also studied using Alizarin 
Red S (ARS) staining (Figure 4.4.9).  In this case final mineralisation at 21 days 
appeared unaffected by AR28 treatment.  However, early time points showed 
increases in small amounts of calcium deposition in the matrix upon AR28 
treatment, giving a very different picture of mineralisation to the vK staining which 
was abolished by AR28. 
It was proposed that the time at which MSCs are subjected to canonical Wnt 
signalling may be important in generating positive or negative effects on 
osteogenesis, therefore MSCs were treated with four day pulses of 0.5 µM AR28 at 
different time points during osteogenic differentiation (Figure 4.4.10).  Osteogenesis 
was then measured by ALP activity.  As previously shown, AR28 addition to the 
culture for the entire period prevented the increases in ALP activity in response to 
osteogenic differentiation.  However, this process was reversible, as when AR28 was 
added for the first 4 days of culture, the increase in ALP activity was delayed, but 
osteogenesis resumed at the normal rate upon AR28 removal, almost reaching 
control levels by 16 days.  When AR28 was added at later points throughout the 
differentiation process, increases in ALP activity were halted, but resumed to some 
degree after AR28 removal.  The ALP activity results have been plotted relative to 
DNA content, therefore while increases in ALP activity were halted upon AR28 
addition, the cells continued to proliferate, causing the reduced relative ALP activity 
per cell.  It is unlikely that the levels of ALP expression within the cells already 
expressing ALP is reduced by AR28, but that the percentage of cells within the 
proliferating population that express ALP is reduced.  However, one cannot say for 
certain from this experiment. 
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Figure 4.4.8. ALP enzyme histology and von Kossa staining of osteogenic 
induced MSCs in the absence and presence of AR28. 
MSCs (A) FH408, B) FH429) were cultured for 14 or 21 days in osteogenic (Incl. 
dex) conditions, with AR28 at concentrations given, or DMSO control.  Samples 
were stained for ALP (pink) and von Kossa (brown/black) and imaged by 
brightfield microscopy.  Representative images shown. 
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Figure 4.4.9. Alizarin Red S staining of osteogenic induced MSCs in the 
absence and presence of AR28. 
MSCs (A) K16, B) FH408) were cultured for 7, 14 or 21 days in osteogenic (Incl. 
dex) conditions, with AR28 at concentrations given, or DMSO control.  Samples 
were stained Alizarin Red S and imaged by brightfield microscopy.  
Representative images shown. 
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Figure 4.4.10. ALP activity in osteogenic induced MSCs with pulse 
treatments with AR28. 
MSCs (FH367) were cultured in basal (blue bars) or osteogenic (Incl. dex) 
conditions for up to 16 days, with the addition of 0.5 µM AR28 for the period 
indicated (green bars) or DMSO control (red bars).  ALP activity normalised to 
cell number (given as nmoles pNP/min/µg DNA) was calculated at 4, 8, 12 and 
16 days. Values given as mean ± stdev., n=6 (independently treated technical 
replicates), * p<0.05, ** p<0.005, *** p<0.001.  Statistical significance is relative 
to vehicle control at appropriate time point unless, by Mann-Whitney U and 
Kruskal-Wallis tests. 
(Similar results from donor FH388 not shown) 
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4.4.4 AR28 enhances dexamethasone-independent osteogenesis 
It has been noted in the literature that activation of the canonical Wnt signalling 
pathway using BIO or a PPARγ inhibitor can have a positive osteogenic effect when 
added to a mild osteogenic stimulus, which excludes dex from the osteogenic culture 
medium (Krause et al, 2010).  However, BIO has been shown to have off-target 
effects, and poor specificity (Liu et al, 2011; Meijer et al, 2003), and PPARγ 
inhibition indirectly stimulates canonical Wnt signalling and will have many 
unknown effects.  Therefore, to test whether the more potent and specific canonical 
Wnt stimulator, AR28, could have a positive effect on early osteogenesis, MSCs 
were treated as previously, but with the exclusion of dex from the osteogenic culture 
medium.  Under these conditions, staining of the cultures revealed very little ALP, 
vK or ARS staining in the control differentiation samples, which varied depending 
on donor.  However, when treated with AR28, small increases in ALP and ARS 
staining could be detected.  More specifically, MSCs cultured in mild osteogenic 
media showed very little ALP staining, present in varying amounts depending on 
donor, in some cases just in a few cells throughout the culture (Figure 4.4.11 A), or 
evenly throughout the culture at low levels (Figure 4.4.11 B+C).  However, 
irrespective of the osteogenic control ALP levels, increases in ALP could be seen 
upon AR28 treatment at 14 and 21 days.  Again the extent of staining varied between 
donors, and different AR28 concentrations had optimal effects.  For example FH408 
had increased ALP with 0.05 and 0.1 µM AR28, but reduced by 0.5 µM, while 
FH429 and K16 showed highest ALP with 0.5 µM AR28.  No vK staining could be 
detected in any of these cultures suggesting that dex is required for osteogenic 
maturation and phosphate deposition.  
ARS staining of parallel cultures showed a similar pattern, with small amounts of 
calcium deposition in the control mild osteogenic stimulus.  Interestingly donor 
FH429, which generated the strongest ALP staining in these conditions, also 
displayed the greatest calcium deposition.  Upon AR28 addition to this culture 
system, clear increases in calcium deposition could be detected by ARS staining, in a 
dose-dependent manner, with the greatest increases detected with 0.5 µM AR28 for 
all three donors (Figure 4.4.12). 
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Figure 4.4.11. ALP enzyme histology and von Kossa staining of MSCs 
cultured in mild osteogenic stimuli (excluding dex) with and without AR28 
addition. 
MSCs (A) FH408, B) FH429, C) K16) were cultured in mild osteogenic 
(excluding dex) conditions with AR28 at concentrations given, or DMSO control.  
After 14 or 21 days cultures were stained for ALP (pink) and von Kossa 
(brown/black) and imaged by brightfield microscopy.  “cells detached” indicates 
samples that had contracted into pellets. 
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Figure 4.4.12. Alizarin Red S staining of MSCs cultured in mild osteogenic 
stimuli (excluding dex) with and without AR28 addition. 
MSCs (A) FH408, B) FH429, C) K16) were cultured in mild osteogenic 
(excluding dex) conditions with AR28 at concentrations given, or DMSO control.  
After 14 or 21 days cultures were stained with Alizarin Red S and imaged by 
brightfield microscopy.  “cells detached” indicates samples that had contracted 
into pellets. 
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Figure 4.4.13. ALP activity assays of MSCs cultured in mild osteogenic 
stimuli (excluding dex) with and without AR28 addition. 
A-B) MSCs (FH408) were cultured in mild osteogenic (excluding dex) conditions 
(grey bars) with AR28 at concentrations given, or DMSO control.  Basal (light 
grey bars) or osteogenic (including dex) (black bars) conditions were also 
performed as controls.  After 14 days A) ALP activity (given as nmoles pNP/min) 
and B) ALP normalised to cell number (given as nmoles pNP/min/µg DNA) were 
calculated.  C) (FH388) and D) (K16) show ALP activity (nmoles pNP/min) of 
two other donors from similar experiments.  Values given as mean ± stdev., n=6 
(independently treated technical replicates), * p<0.05, ** p<0.005, *** p<0.001.  
Statistical significance is relative to mild osteogenic vehicle control, by Mann-
Whitney U and Kruskal-Wallis tests. 
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It is also worth noting that in these mild osteogenic conditions, AR28 caused very 
confluent layers to form, likely through increased proliferation.  In the later time 
points, this can cause the sheets to contract around the circumference of the well, and 
eventually round up into a pellet (identified in Figure 4.4.11 and Figure 4.4.12 as 
“cells detached”).   
ALP activity assays were also performed using these mild osteogenic stimuli, 
however the absorbance readings were very low, making detection of the small 
changes in activity very difficult.  Small but significant increases in ALP activity 
within treated wells could be detected at AR28 concentrations of 0.05 and 0.1μM in 
one donor (FH408) (Figure 4.4.13 A), but these increases were not apparent when 
normalised to DNA due to increased cell number in AR28 treated samples (Figure 
4.4.13 B).  Small changes in ALP activity could be seen in another donor (FH388) 
(Figure 4.4.13 C), while in another (K16) no changes in ALP were detected (Figure 
4.4.13 D). 
4.4.5 Increased cell number caused by AR28 is important in the increased 
differentiation in response to mild osteogenic stimulation 
As alluded to previously, AR28 appeared to cause increased cell numbers when 
added to the mild osteogenic culture medium.  To study the proliferation rate further, 
MTT assays were performed.  The MTT assay uses the conversion of the water 
soluble MTT (3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide) to an 
insoluble formazan by mitochondrial proteins, which can then be solubilised and the 
concentration determined by measuring the absorbance at 570nm.  The rate of MTT 
conversion can then be used as an indirect measure of cell number.  The effect of 
AR28 on cell number was analysed by this method in basal, mild osteogenic 
(excluding dex) and osteogenic (including dex) medium at both 1x10
4 
and 2x10
4
 
cells/cm
2 
after 4 and 7 days.  Significant increases in MTT conversion were detected 
in all media and cell densities at both time points with AR28 treatment in a dose-
dependent manner (Figure 4.4.14 and Figure 4.4.15).  The difference between the 
DMSO control and AR28 treatment was greatest in the mild osteogenic media, yet 
even in basal media, where little increase in MTT conversion was detected over time 
in control samples, 0.5 µM AR28 was able to generate significant (p<0.05) increases  
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Figure 4.4.14. MTT assay of donor FH429 in response to AR28 in basal and 
osteogenic media. 
MSCs (FH429) were seeded at A) 1x10
4
 or B) 2x10
4
 cells/cm
2
 and cultured in 
Basal, mild osteogenic (Excl. dex) or osteogenic (Incl. dex) conditions with AR28 
at the concentration given, or DMSO control.  After 4 or 7 days the cultures were 
assayed for mitochondrial activity by MTT conversion to formazan.  This was 
then solubilised and quantified by measuring the absorbance at 570 nm, and 
subtracting the blank value.  Values given as mean ± stdev., n=6 (independently 
treated technical replicates), * p<0.05, ** p<0.005, *** p<0.001.  Statistical 
significance is relative to vehicle control at appropriate conditions and time point, 
by Mann-Whitney U and Kruskal-Wallis tests. 
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Figure 4.4.15. MTT assay of donor K57 in response to AR28 in basal and 
osteogenic media. 
MSCs (K57) were seeded at A) 1x10
4
 or B) 2x10
4
 cells/cm
2
 and cultured in 
Basal, mild osteogenic (Excl. dex) or osteogenic (Incl. dex) conditions with AR28 
at the concentration given, or DMSO control.  After 4 or 7 days the cultures were 
assayed for mitochondrial activity by MTT conversion to formazan.  This was 
then solubilised and quantified by measuring the absorbance at 570 nm, and 
subtracting the blank value.  Values given as mean ± stdev., n=6 (independently 
treated technical replicates), * p<0.05, ** p<0.005, *** p<0.001.  Statistical 
significance is relative to vehicle control at appropriate conditions and time point, 
by Mann-Whitney U and Kruskal-Wallis tests. 
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Figure 4.4.16. DNA content of MSC cultures in response to AR28 in basal 
and osteogenic conditions. 
MSCs (FH408) were seeded at 2x10
4
 cells/cm
2
 and cultured in Basal, mild 
osteogenic (Excl. dex) or osteogenic (Incl. dex) conditions with AR28 at the 
concentration given, or DMSO control.  After 4, 7 and 14 days the cultures were 
assayed for DNA content by picogreen analysis.  Fluorescence was measured and 
the NDA concentration calculated from a standard curve.  Values given as mean ± 
stdev., n=6 (independently treated technical replicates), * p<0.05, ** p<0.005, 
*** p<0.001.  Statistical significance is relative to vehicle control at appropriate 
conditions and time point, by Mann-Whitney U and Kruskal-Wallis tests. 
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 with 4 days of treatment.  These increases in cell number were confirmed by DNA 
content experiments over longer time periods of 2 weeks, which demonstrated clear 
increases in DNA content per well of cells treated with AR28.  As in the MTT 
assays, increases in cell number could be detected in basal media and standard 
osteogenic media, however the largest increases were present in mild osteogenic 
conditions (Figure 4.4.16).  After 7 days, the increases in DNA are dose dependent 
with the greatest increases with 0.5 µM AR28, but by 14 days 0.5 µM AR28 appears 
to be having a detrimental effect on cell number.  This is similar to the cell death 
caused by the higher concentrations of AR28 during the adipogenic differentiation 
described above in which prolonged periods of treatment can begin to reduce cell 
number.
  
Figure 4.4.17. Mitomycin C treatment inhibits the proliferation of MSCs 
MSCs (FH429) were treated for 2 hours with 10 µg/ml mitomycin C followed by 
culture in mild osteogenic (Excl. dex) conditions for 7 days.  Cultures were then 
assayed for MTT conversion into formazan, which was solubilised and quantified 
by measuring the absorbance at 570 nm.  Without mitomycin C treatment MSCs 
were able to proliferate over the 7 day period.  Mitomycin C treatment prevented 
this increase in MTT conversion.   Values given as mean ± stdev., n=6 
(independently treated technical replicates), * p<0.05, ** p<0.005, *** p<0.001.  
Statistical significance is relative to vehicle control at appropriate conditions and 
time point, by Mann-Whitney U and Kruskal-Wallis tests. 
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4.4.5.1 Mitomycin C treatment prevents AR28 induced osteogenesis 
It was therefore proposed that the increases in mineralisation were dependent on 
elevated cell numbers.  To test this hypothesis, MSCs were treated with mitomycin C 
to inhibit their proliferation (Figure 4.4.17), and subjected to the mild differentiation 
stimulus with and without AR28 addition.  As in previous studies, AR28 caused 
increases in Alizarin Red S staining by 7 and 14 days, however when proliferation 
was inhibited this increase in mineralisation was blocked (Figure 4.4.18).  
Furthermore, the increased mineralisation detected was not solely due to an increase 
in total cell number, as simply doubling the initial seeding density had no effect on 
Alizarin Red S staining (Figure 4.4.18).  It is worth noting that after mitomycin C 
treatment, the cells appeared more sensitive to the toxic effects of AR28, and by 14 
days mitomycin C had a clear effect on cell death with 0.5 µM AR28. 
Similar experiments were performed in which MSCs were pre-treated with 
mitomycin C to prevent proliferation, and subjected to mild osteogenic induction 
with and without AR28, and analysed by ALP enzyme histochemistry and vK 
staining.  Images from two donors are shown in Figure 4.4.19.  A third donor (K9) 
showed very little staining after 14 days and a particularly high sensitivity to the 
toxic effects of AR28 after mitomycin C treatment.  Both FH402 and K16 showed 
increases in ALP in response to AR28 treatment in combination with the mild 
osteogenic stimulus after 14 days, however the effect of mitomycin C treatment is 
less clear.  A higher AR28 concentration, at 0.5 µM, caused fairly severe cell death 
in the mitomycin C treated cultures as mentioned above. A concentration of 0.1 µM 
AR28 was less toxic to the cells and allowed for the analysis of the effects of 
mitomycin C and AR28 treatment on ALP activity.  Mitomycin C had no clear effect 
on AR28 induced ALP activity in FH402 cells (Figure 4.4.19 A), but appeared to 
increase the intensity, but not the area of the staining in donor K58 samples (Figure 
4.4.19 B).   
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Figure 4.4.18. Mitomycin C treatment inhibits AR28 induced increase in 
Alizarin Red S staining of MSCs cultured in mild osteogenic conditions. 
Representative donor (FH429) of MSCs seeded at 2x10
4
 cell/cm
2
 treated with 
10 µg/ml mitomycin C for 2 hours followed by mild osteogenic (Excl. dex) 
differentiation for 7 and 14 days, with AR28 at concentrations given, or DMSO 
control.  DMSO controls were also performed with MSCs seeded at 4x10
4
 
cells/cm
2 
followed by mild osteogenic (Excl. dex) differentiation.  Samples were 
stained with Alizarin Red S and imaged using brightfield microscopy. 
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Figure 4.4.19. The effect of mitomycin C treatment on AR28 induced 
increase in ALP staining of MSCs cultured in mild osteogenic conditions. 
Two MSC donors (A) FH402 and B) K58) were seeded at 2x10
4
 cell/cm
2
 treated 
with 10 µg/ml mitomycin C for 2 hours followed by mild osteogenic (excluding. 
dex) differentiation for 7 and 14 days, with AR28 at concentrations given, or 
DMSO control.  Samples were stained for ALP and imaged using brightfield 
microscopy. 
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4.4.5.2 CFSE analysis of AR28 induced proliferation 
The above results demonstrate that treatment with AR28 results in increased cell 
numbers when cultured in the mild osteogenic stimulus, and that this was important 
for the initial increase in ARS staining.  In order to demonstrate an increase in 
proliferation rate is responsible for this increase in cell number a carboxyfluorescein 
diacetate, succinimidyl ester (CFSE) incorporation assay was devised, to allow the 
measurement of cell divisions within the cell population over time by flow 
cytometry.   
CFSE assays identify the number of cell divisions a cell undergoes through the 
incorporation of the fluorescent CFSE dye, which halves in intensity at each cell 
division.  Therefore by measuring the fluorescence intensity over time it is possible 
to identify the rate of proliferation within a population of cells.  Initially, three CFSE 
concentrations were tested for the incorporation and fluorescence signal generated.  
Concentrations of 10, 20 and 30 µM CFSE all generated a positive shift in 
fluorescence in a dose-dependent manner (Figure 4.4.20 A). A concentration of 
20 µM CFSE was chosen to take forward for the remainder of the experiments, as 
overly high concentrations of CFSE can reduce the proliferation of cells.  In addition 
to this, DMSO is known to cause permeation of cell membranes (Da Violante et al, 
2002), therefore DMSO was tested at 0.2% (final concentration used in AR28 
treatments) for its effect of CFSE reduction.  No differences were detected between 
control cultures and DMSO-treated cultures (Figure 4.4.20 B).  Therefore to study 
the effect of the mild osteogenic stimulus and AR28 on the rate of proliferation, 
MSCs were treated with CFSE, allowed to adhere to plastic and then treated with a 
combination of mild osteogenic and AR28 concentrations.  The cultures were then 
grown for 7 days prior to fluorescence analysis by flow cytometry. 
A control sample, treated with 0.5% FBS basal culture medium was used as a 
non-proliferating control, allowing the treated samples to be compared to this 
fluorescence intensity.  Cells cultured in basal media showed very little change in 
fluorescence compared to the non-proliferating controls.  This is likely due to the 
cells being seeded at confluency for all osteogenic experiments, causing contact 
inhibition.  Cells in the mild osteogenic stimulus, however, showed a reduction in 
138 
 
Figure 4.4.20. CFSE proliferation assay optimisation 
A)  MSCs (K9) were treated with 10, 20 or 30 µM Cell Trace
TM
 CFSE, and 
allowed to adhere for 24 hours.  The cells were then detached and analysed by 
flow cytometry for fluorescence.  B)  MSCs (K16) were treated with 20 µM Cell 
Trace
TM
 CFSE and allowed to attach overnight.  A portion of the cells were 
arrested at parent generation by FBS reduction, and the remainder were treated as 
stated and cultured for a further 5 days.  The cells were then detached and 
analysed by flow cytometry for fluorescence. 
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Figure 4.4.21. AR28 increases the rate of cell division of MSCs in mild 
osteogenic conditions 
MSCs (K16) were treated with Cell Trace
TM
 CFSE and allowed to adhere 
overnight.  A portion of the cells were arrested at parent generation by FBS 
reduction, and the remainder were treated as stated and cultured for a further 7 
days.  The cells were then detached and analysed by flow cytometry for 
fluorescence. A) Histogram showing autofluorescence levels in none-CFSE 
treated MSCs (black) relative to CFSE fluorescence in growth arrested CFSE 
treated MSCs (grey).  B)  Histogram showing the reduction in fluorescence due to 
proliferation in basal (blue) and mild osteogenic (excluding dex) (red) conditions.  
C)  Histogram showing the effect of AR28 treatment (0.1 µM: yellow, 0.5 µM: 
light blue) on fluorescence intensity in mild osteogenic (excluding dex) 
conditions. 
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 fluorescence intensity, with a negative shift of the peak.  This was further enhanced 
by the addition of AR28 at 0.5 µM (Figure 4.4.21).  Unfortunately, the resolution of 
the peaks is relatively poor due to the fairly broad non-proliferating peak which is 
indicative of non-uniform incorporation of CFSE into the cells, likely due to the 
heterogeneous population of cells.  It is possible to sort the cells after CFSE 
incorporation to select cells with a narrower range of fluorescence, which should 
allow for greater resolution.  However, this may inadvertently select for a particular 
population of cells, potentially excluding the osteogenic precursors.  Despite the 
poor resolution obtained, this assay was able to identify an increase in proliferation 
with AR28 exposure within the cell population, compared to controls, indicated by 
the negative shift in fluorescence, thus demonstrating that the increase in cell number 
in AR28 treated cultures is due, at least in part, to an increase in cell division and 
proliferation. 
4.4.5.3 Ki67 analysis of AR28 induced proliferation 
An alternative approach to study the proliferation of cells is by the use of Ki67 
immunocytochemistry.  Ki67 is a cellular protein associated with cells within the cell 
cycle, but is absent in cells in G0 (Gerdes et al, 1984), and can therefore be used to 
identify proliferating cells within the population.  The advantage of this method is 
that it can be performed after any length of time and be co-stained with ALP enzyme 
histochemistry and DAPI.  MSCs were cultured in the mild osteogenic stimulus, 
with and without AR28 for two weeks, before staining for ALP, Ki67 and DAPI.  As 
shown previously, the mild osteogenic media generated some small increases in ALP 
staining, but this was increased with AR28 treatment (Figure 4.4.22 A).  Again this 
increase in ALP occurred alongside an increase in cell number clearly visible from 
the images.  The nuclei in the images could also be quantified through the 
measurement of the total area of DAPI staining (Figure 4.4.22 B) using Image J 
software as a readout of cell number.  The area of DAPI staining increased 
dramatically with AR28 treatment compared to controls, in a dose-dependent 
manner, with the greatest DAPI area observed with 0.5 µM AR28.  The number of 
nuclei could not be calculated using the software as the cells become too confluent, 
preventing the software from identifying individual nuclei. 
141 
 
Figure 4.4.22. Ki67 staining of AR28 treated MSCs in mild osteogenic 
conditions 
MSCs cultured in mild osteogenic (Excl. dex) conditions from 14 days with 
AR28 concentrations as stated or DMSO control.  A) Samples were stained for 
ALP (red), Ki67 (green) and DAPI (blue), and imaged by fluorescence 
microscopy. B) Total area of DAPI staining/image was calculated using Image J 
and the mean ± stdev plotted.  C) The number of Ki67 positive nuclei per image 
were manually counted and the mean ± stdev plotted.  n=6 (total of 6 images from 
2 independently treated technical replicates). 
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The number of cells expressing the Ki67 protein were manually counted in each 
image, and the mean plotted (Figure 4.4.22 C).  On average, less than one cell per 
image expressed Ki67 when cultured in basal media, however this increased to 
approximately 10 cells per image in the mild osteogenic media.  Furthermore, AR28 
at 0.05 and 0.1 µM increased the number of cells expressing Ki67 further to around 
17 cells per image.  The number of Ki67-expressing cells varied greatly between 
images with these AR28 treatments, demonstrated by the large error bars, making it 
difficult to determine whether this increase in staining was significant from this 
single experiment.  In addition to this, 0.5 µM AR28, which resulted in the greatest 
number of cells, only had an average of six Ki67 positive cells per image.  This 
highlights the limitation of this fixed end point assay, where only the cells that are in 
the cell cycle at the end of the two week period are detected, and not any of the cells 
that have undergone mitosis previously.   
Another aim of this assay was to identify which cells were proliferating and in 
particular, if the ALP-expressing osteogenic precursor cells were induced to 
proliferate to a greater extent than other cell populations.  However, the Ki67 
positive cells do not appear to fall primarily in either ALP-positive or negative areas, 
but are split between both populations.  Therefore, while these results backed up 
those performed previously, showing that AR28 can cause increased ALP staining in 
mild osteogenic conditions, and that this increase in accompanied by an increase in 
cell number, it did not provide any additional information due to the nature of the 
fixed end point, and was therefore not repeated in other donors.  
4.4.6 Pre-treatment with AR28 can increase osteogenesis, but not adipogenesis 
To study whether the treatment of the MSC population with AR28 prior to 
differentiation had any effect on the propensity for the cells to form osteoblasts or 
adipocytes MSCs were treated for 7 days in basal media with or without AR28, 
before the switch to differentiation conditions and removal of AR28. 
AR28 pre-treatment of MSCs in this manner caused clear increases in osteogenesis 
compared to non-pre-treated controls when differentiated with both the classical and 
mild osteogenic media.  ALP and vK staining of the cultures showed increases in 
143 
 
Figure 4.4.23. Pre-treatment of MSCs with AR28 increases ALP and von 
Kossa staining upon osteogenic induction 
A)  Schematic of AR28 pre-treatment experiment, showing 7 days of AR28 
treatment in basal media before removal of AR28 and addition of osteogenic 
conditions for a further 14 days.  B)  Representative donor (FH429) of MSCs pre-
treated for 7 days with AR28 or DMSO as stated, followed by a further 7 or 14 
days treatment in either mild (-dex) or standard (+ dex) osteogenic conditions.  
Samples were then stained for ALP and von Kossa and imaged by brightfield 
microscopy. 
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ALP and vK staining in classical differentiation media in response to 0.5 and 1 µM 
AR28 pre-treatment, while the mild osteogenic media was only able to increase ALP 
staining with no visible vK staining (Figure 4.4.23).  To gain a quantifiable measure 
of osteogenic differentiation, pNPP ALP activity assays were performed in samples 
after AR28 pre-treatment followed by culture in the mild osteogenic stimulus for up 
to 14 days.  Significant increases in ALP activity could be detected at both 7 and 14 
days after osteogenic media exchange when pre-treated with 0.5 µM AR28, 
compared to non-pre-treated controls (Figure 4.4.24).  Unlike in the ALP enzyme 
histochemistry analysis of pre-treatment in 24 well plates above, 1 µM AR28 did not 
cause any measurable increase in ALP activity compared to vehicle controls.  
Similarly, MSCs pre-treated with AR28 followed by mild osteogenic stimulus were 
stained with ARS to identify calcium deposition.  As seen with the ALP enzyme 
histochemistry and vK staining, AR28 pre-treatment caused an increase in ARS 
staining of the cultures compared to the DMSO pre-treated controls (Figure 4.4.25).   
The optimal concentration varied between donors, 1 µM pre-treatment causing 
strong mineralisation in one donor, while 0.5 µM AR28 caused the greatest increase 
in another. 
Figure 4.4.24. Pre-treatment of MSCs with AR28 increases ALP activity 
upon mild osteogenic induction 
Representative donor (FH452) of MSCs pre-treated for 7 days with AR28 or 
DMSO as stated, followed by a further 7 or 14 days treatment in mild osteogenic 
(excluding dex) conditions.  Samples were then assayed for ALP activity 
normalised to cell number (given as nmoles pNP/min/µg DNA).  Values given as 
mean ± stdev., n=6 (independently treated technical replicates), * p<0.05, ** 
p<0.005, *** p<0.001.  Statistical significance is relative to vehicle control at 
appropriate conditions and time point, by Mann-Whitney U and Kruskal-Wallis 
tests. 
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Figure 4.4.25. Pre-treatment of MSCs with AR28 increases Alizarin Red S 
staining upon osteogenic induction 
Representative donors (A) FH408 and B) FH429) of MSCs pre-treated for 7 days 
with AR28 or DMSO as stated, followed by a further 7 or 14 days treatment in 
mild osteogenic (Excluding. dex) conditions.  Samples were then stained with 
Alizarin Red S and imaged by brightfield microscopy. 
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In contrast to the positive effect of pre-treating MSCs with AR28 on osteogenesis, 
adipogenesis was not increased.  Cultures were treated as above, except the 
differentiation media was exchanged for adipogenic media.  Adipogenesis was 
identified by Oil Red O staining followed by bright field microscopy.  MSCs pre-
treated with the vehicle control, DMSO, were able to differentiate into adipocytes, 
showing clear Oil Red O positive lipid droplets forming over 14 days after media 
exchange.  Unlike with osteogenesis pre-treatment with AR28 reduced the capacity 
of the MSCs and hADSCs to differentiate into adipocytes, with reduced lipid droplet 
formation (Figure 4.4.26).    
4.4.7 AR28 and chondrogenesis 
Finally, the effect of AR28 on chondrogenesis was studied.  MSCs were cultured as 
micromass pellets and subjected to chondrogenic media with or without AR28 for 21 
days.  The pellets were then sectioned before staining for the chondrogenic markers, 
glycosaminoglycans (GAGs) and type II collagen.  Chondrogenic conditions cause 
an increase in alcian blue staining for GAGs compared to non-chondrogenic cultures.  
AR28 appeared to have little effect on this increase in GAG staining (Figure 4.4.27).  
In addition, no increases in Collagen II could be detected in chondrogenic media by 
immunocytochemistry. 
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Figure 4.4.26. Pre-treatment of MSCs with AR28 reduces lipid droplet 
formation upon adipogenic induction 
Bone marrow MSCs (A) FH399 B) K9) and C) hADSCs pre-treated for 7 days 
with AR28 or DMSO as stated, followed by a further 7 or 14 days treatment in 
adipogenic conditions.  Samples were then stained by Oil Red O to identify lipid 
droplet formation and imaged by brightfield microscopy. 
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Figure 4.4.27. AR28 treatment has no effect on GAG production in 
chondrogenic micromass pellets. 
MSCs (FH452) were cultured in micromass pellets in chondrogenic conditions for 
21 days in the presence of AR28 at concentrations stated, or DMSO control.  
Control pellets in basal and chondrogenic conditions alone were also generated.  
Pellets were cryosectioned at 10 µm and stained with Alcian blue to identify 
GAG levels.  Samples were imaged using brightfield microscopy. 
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4.5 Discussion 
AR28 has been demonstrated to enhance bone mineral density (BMD) in mice 
(Gambardella et al, 2011), and therefore the overall aim of this part of the project 
was to use in vitro studies in human MSCs to gain a better understanding of the 
processes underlying this increase in BMD.  Results presented in chapter 3 
demonstrated the suitability of AR28 as a pharmacological Wnt manipulator in in 
vitro cell culture, and MSCs in particular.  To further demonstrate the capacity of 
AR28 to functionally stimulate canonical Wnt signalling and affect cell fate, AR28 
was used to study the activation of canonical Wnt signalling during MSC adipogenic 
differentiation.  Canonical Wnt signalling is widely considered a strong inhibitor of 
adipogenesis (Bennett et al, 2002; Liu et al, 2009), with the inhibition of canonical 
Wnt signalling required for adipogenesis to occur (Li et al, 2007).  Activation of the 
canonical Wnt pathway by AR28 complemented these in vitro results, with clear 
dose-dependent inhibition of differentiation identified over a two week period, 
compared to controls and a corresponding increase in proliferation, when assayed by 
lipid droplet formation or FABP5/BODIPY co-staining.  Interestingly, when 
compared to the effect of recombinant Wnt3a ligand in published studies (Liu et al, 
2009), AR28 concentrations of 0.05-0.5 µM generated similar levels of inhibition to 
5-100 ng/ml Wnt3a, again suggesting potent activation of the canonical Wnt 
signalling pathways, allowing the use of low AR28 concentrations.  The actions of 
AR28 can be compared to those of another GSK3β inhibitor, CHIR99021.  Work 
carried out in the preadipocyte cell line 3T3-L1 showed inhibition of adipogenesis 
with CHIR99021 concentrations of 0.3-1 µM (Bennett et al, 2002), slightly higher 
than that of AR28 in our studies.   
These results confirm the inhibitory effect of canonical Wnt stimulation on 
adipogenic differentiation, demonstrating the versatility of AR28 as a variable 
canonical Wnt stimulator.  However, the combination of AR28 as a specific variable 
Wnt stimulator, and the novel FABP5/BODIPY high content approach allowed for 
the identification of small changes in adipogenesis in response to low level Wnt 
activation.  While Oil Red O staining of cultures is a clear readout for adipogenesis 
and can be quantified to some degree by measurement of the absorbance of the 
solubilised staining, it is not very sensitive.  Other approaches commonly used are 
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the analysis of mRNA expression levels by RT-PCR and RT-qPCR (Fu et al, 2005) 
or protein levels by SDS-PAGE and western blot (Bennett et al, 2002; Li et al, 
2007).  While these are powerful tools, allowing a quantifiable analysis of up-
regulated gene or protein expression of the cell population, they do not allow for the 
analysis of changes in protein levels on a cell by cell basis.  The development of the 
high content immunocytochemistry and imaging technique allows for changes in 
protein expression to be analysed on a cell by cell basis in a quantifiable manner.  
This offers multiple advantages over whole population analysis techniques such as 
qPCR and western blot, making it possible to identify different populations within 
the culture, and therefore percentages for positive and negative populations, similar 
to that of flow cytometry.  Clearly, the high content method does not allow for such 
large numbers of cells to be analysed as during flow cytometry, but it does generate 
information about cell patterning within the population and total cell numbers.  
Therefore, this high content screening method provides an invaluable tool in the 
study of cell differentiation, and with some optimisation and identification of good 
protein markers for other lineages, could be used not only to study single lineage 
differentiation, but dual differentiation studies in which multiple populations of cells 
are developing within the population. 
As mentioned above, the increased sensitivity of the high content technique 
generated new intriguing results regarding the effects of very low level Wnt 
signalling on the adipogenic differentiation of MSCs.  Unlike previous studies, very 
mild stimulation of the canonical Wnt signalling pathway by AR28 was 
advantageous for adipogenesis, generating small but significant increases in 
adipogenesis compared to untreated controls.  While these increases were detected 
on two independent assays, in order to fully confirm and understand the mechanisms 
behind this increase, multiple donors and other techniques must be used.  One 
potential mechanism to consider is the effect of canonical Wnt signalling on MSC 
proliferation.  Observations from the work presented in this chapter (4.4.5) and that 
performed by Boland et al. (Boland et al, 2004) implicate a role of canonical Wnt 
signalling in enhancing the proliferation of MSCs.  Therefore the low level AR28 
treatment may cause small increases in MSC and early adipogenic precursor cell 
numbers, whilst not generate a strong enough canonical Wnt response to prevent the 
progression of adipogenic differentiation. 
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The work focusing on adipogenic differentiation demonstrated the ability of AR28 to 
manipulate the degree of canonical Wnt signalling within cells, allowing for the use 
of AR28 as a powerful tool for unlocking the poorly understood effects of canonical 
Wnt signalling on the chondrogenic and osteogenic differentiation of MSCs.  MSCs 
were cultured under chondrogenic conditions as micromass pellets and submitted to 
AR28 treatment to induce canonical Wnt signalling.  However, the effect of AR28 
on classical chondrogenic micromass cultures is inconclusive from these results.  
Published work suggests the inhibition of the onset of chondrogenesis by canonical 
Wnt signalling (See section 1.4.3.1), but under the conditions described here no 
reduction in GAG content after AR28 treatment could be detected.  However, the 
results here are from a single donor, and rely on the upregulation of GAGs in 
chondrocytes as a marker for chondrogenesis.  Analysis of the effects of AR28 on 
chondrogenesis must be performed on more donors, and analysed by other means 
looking into chondrocyte specific markers.  For example, RT-PCR could be utilised 
to identify the upregulation of specific genes, such as Sox9, Aggrecan, collagen II, 
IV and X, allowing not only the degree of chondrogenesis to be analysed, but also 
the stage at which AR28 may have an effect. 
In relation to osteogenesis, it was shown that activation of the canonical Wnt 
signalling pathway inhibits ALP and vK staining of MSCs when differentiated using 
the standard differentiation cocktail of β-glycerophosphate, L-ascorbic acid and 
dexamethasone.  This is in agreement with other work (Boland et al, 2004; de Boer 
et al, 2004; Liu et al, 2009) demonstrating a reduction in ALP and mineralisation in 
response to canonical Wnt signalling in standard osteogenic conditions.  The results 
from ARS staining were not as clear, with no reduction in calcium deposition in 
response to AR28 in these strong osteo-inductive conditions.  In fact there was an 
increase in the ARS staining at the earlier time points in particular, which then 
became masked at the later time points.  The reason for this difference in staining to 
that of the ALP and vK is not known.  One explanation for the discrepancies in ARS 
and vK staining involves the inhibition of ALP activity by AR28 treatment.  One 
role for ALP in is the hydrolysis of phosphomonoesters, including β-
glycerophosphate in vitro, into inorganic phosphate, a component of the mineralised 
matrix, whilst at the same time reducing mineralisation inhibitors such as 
pyrophosphate (Hessle et al, 2002).  Therefore, the strong inhibition of 
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dexamethasone induced ALP detected upon AR28 treatment, could reduce the levels 
of inorganic phosphate, preventing its incorporation into the matrix, whilst the strong 
mineralisation inducer dexamethasone is still able to cause calcium acquisition into 
the matrix by another route.  Indeed it would be interesting to study the effect of 
ALP inhibition, such as that by levamisole, on dexamethasone induced osteogenesis 
to see if these discrepancies in staining can be replicated.  Despite these 
discrepancies in vK and ARS staining, ARS staining did detect small early increases 
in calcium content, which may be explained by increased proliferation of the culture 
as discussed later in this section. 
Both the small early increase in ARS staining in response to AR28 and published 
literature proposing the enhancement of the early differentiation process, 
accelerating the cells though this osteoblast precursor stage in response to Wnt 
signalling (Eijken et al, 2008; Krause et al, 2010) led to the study of canonical Wnt 
stimulation under milder osteogenic inductive conditions.  This was achieved 
through the removal of dexamethasone, leaving both ascorbic acid and β-
glycerophophate to provide small osteo-inductive cues.  As expected, the removal of 
dex prevented the strong induction of osteogenesis, generating only low levels of 
ALP and ARS staining similar to that seen by Eijken et al (2008) and Krause et al 
(2010).  The addition of AR28 to this culture however increased both ALP and ARS 
staining over 21 days.  These increases in ALP are in agreement with those shown by 
Krause et al (2010), however our studies also identified an increase in mineralisation 
measured by ARS staining which previous publications did not.  However, no 
increases in vK staining were detected in these cultures, suggesting an increased 
sensitivity in ARS staining over that of vK.  ARS identified uniform increases in 
calcium content across the culture at early stages, however vK was only able to 
detect phosphate in the highly mineralised nodules formed in the presence of dex. 
These increases in both ALP and ARS were variable between donors, with some 
donors presenting strong mineralisation in response to AR28 while others only 
showed small increases.  This is likely due to the heterogeneity of the cell 
population, where some donor populations contain greater contributions of 
osteogenic precursors, generating different levels of response to osteogenic 
conditions.  This may also explain the difference between this work and previous 
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publications that used a different donor site, iliac crest aspirates, which are likely to 
result in similar but different MSC cell populations.  The difference could equally be 
due to the Wnt stimulant used.  Krause et al (2010) stimulated canonical Wnt using 
BIO or a PPARγ inhibitor, which are likely to generate smaller increases in 
canonical Wnt signalling than AR28.  Indeed in work presented here, the 
concentrations of BIO used in this publication were unable to generate increases in 
TCF reporter expression as great as AR28 (Chapter 3).  Krause et al. (2010) also 
indentified negative effects of BIO on cell viability and proliferation at the 
concentrations used in their assays, which is also likely to have affected cell 
behaviour.  Furthermore, PPARγ is a key regulator of adipogenesis, and therefore 
will regulate many other factors in addition to canonical Wnt signalling, and its 
inhibition would prevent the expression of adipogenic genes, potentially enhancing 
osteogenic precursor numbers and allowing increased osteogenesis in this manner. 
In addition to these results, drawing comparisons to previous publications, we have 
also shown that upregulation of canonical Wnt signalling by AR28 caused an 
increase in cell number, most notably in the mild osteogenic conditions.  This 
increase in cell number was necessary for the increase in ARS staining in response to 
AR28, and was, at least in part, due to an increased rate of proliferation, 
demonstrated by the mitomycin C and CFSE incorporation assays respectively.  The 
effects of Wnt signalling on proliferation complements work of Boland et al (2004), 
who demonstrated increases MSC numbers upon Wnt3a treatment in basal or 
osteogenic conditions, where both increased proliferation and decreased apoptosis 
were detected.  The method by which AR28 increases proliferation in this situation is 
unknown, but two likely candidates are the cell cycle protein Cyclin D1 and the 
transcription factor c-myc.  Cyclin D1, a known effecter of Wnt signalling, is 
transcribed in response to TCF/LEF1 transcription factor activity (Shtutman et al, 
1999) and can stimulate cell proliferation in vitro (Biliran et al, 2005).  C-myc is 
another gene that is directly up regulated by canonical Wnt signalling and TCF/LEF1 
activity (He et al, 1998), and is also linked to increased proliferation and cell cycle 
progression (Bennett et al, 1994).  The involvement of these proteins could be tested 
by the study of mRNA levels by RT-PCR and western blot, identifying any increases 
in gene expression in response to increased canonical Wnt signalling. 
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The cell number and proliferation assays used provided valuable data, showing 
increased cell number due to increased proliferation in the entire culture, however 
they were unable to identify if any particular cell type was being affected 
preferentially.  The combination of the staining pattern of ALP in mild osteogenic 
conditions treated with AR28, showing activity in discrete groups of cells, and 
increased cell number are suggestive of an increase in the proliferation of the 
osteogenic precursor cells.  This would lead to an increased osteogenic precursor 
pool, ultimately leading to increased osteogenesis.   The importance of proliferation 
in AR28 enhanced osteogenesis was supported by mitomycin C treatment 
experiments which demonstrated the requirement of proliferation for increased ARS 
staining in mild osteogenic media.  However, there was no clear reduction in ALP 
activity upon mitomycin C treatment.  The reason for this is unknown, however one 
area of research which may provide some reasoning is that of the interplay between 
cell cycle arrest and differentiation (Myster & Duronio, 2000).  It is possible that the 
inhibition of proliferation by mitomycin C caused the spontaneous differentiation 
and maturation of osteoblast precursors, masking any effects of proliferation rate on 
increased differentiation. 
The proposition that AR28 can increase the proliferation of osteogenic precursors is 
supported by the AR28 pre-treatment experiments, in which one week treatment of 
the heterogeneous MSC population prior to differentiation induction, caused 
enhancement of osteogenesis, but a reduction in adipogenesis.  These findings 
indicate that AR28 does not simply cause an increase in multipotent MSC number, 
but that the effect is specific for osteogenesis.  These findings share similarities to 
those by Gambardella et al (2011) who identified in vivo amplification of 
mesenchymal progenitors upon AR28 administration (Gambardella et al, 2011).  
However, in vivo studies showed that these increases in progenitor numbers 
ultimately led to increased osteoblast cell number, with no increase in adipocytes, 
implying a preference of these amplified precursors for osteogenesis.  However, 
more detailed work studying the proliferation of cells within the MSC population is 
required to confirm this hypothesis and fully understand the role of canonical Wnt 
signalling in MSC lineage commitment.   
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While increased proliferation of osteoprogenitors could explain the increases in 
osteogenesis in response to AR28 pre-treatment, it is likely not the only factor at 
play as only small increases in cell number were detected after 7 days in basal media, 
and this would not cause a reduction in adipogenesis.  Furthermore, this inhibitory 
affect on adipogenesis provides a clue to an alternative mechanism for increased 
osteo-induction.  Canonical Wnt signalling is known to reduce adipogenesis, as has 
been shown here, and does this primarily through the inhibition of PPARγ (Okamura 
et al, 2009).  There is also evidence in the literature for the importance of PPARγ as 
a key transcription factor in the determination of osteogenic differentiation, where 
knockouts in ES cells resulted in spontaneous osteogenesis (Akune et al, 2004), and 
inhibition by canonical Wnt signalling in ST2 cells caused increased osteogenic gene 
expression (Kang et al, 2007).  It is possible therefore, that AR28 pre-treatment can 
increase the number of precursor cells through increased proliferation, whilst at the 
same time priming them for osteogenesis through the inhibition of PPARγ.  
Additionally this reduction in PPARγ would lead to a reduction in the number of 
adipogenic precursor cells within the MSC population causing the reduction/delay of 
adipogenic differentiation. 
The results in this chapter also feed into the important medical field of 
glucocorticoid (GC)-induced osteoporosis.  Long-term exposure to glucocoriticoids 
is reported to reduce the BMD of patients and increase the fracture risk (de Vries et 
al, 2007).  This process is thought to be in part due to increased adipogenesis, but 
also the inhibition of osteoblast precursor proliferation, alongside increased terminal 
differentiation and apoptosis of osteoblasts, leading to reduced osteoblast numbers 
and mineral deposition (Walsh et al, 2001; Weinstein et al, 1998).  Canonical Wnt 
signalling has been identified as a key player in GC-induced osteoporosis, through 
the identification of reduced Wnt upon GC administration (Wang et al, 2008) and the 
rescue of GC-induced osteoporosis by GSK3β inhibition by BIO (Wang et al, 2009).  
The results presented here indicate the importance of proliferation in the early stages 
of osteogenic differentiation, and the ability of canonical Wnt signalling to enhance 
this.  Yet, canonical Wnt signalling inhibits the dexamethasone-induced osteogenic 
and adipogenic differentiation and maturation of MSCs.  Therefore, induced 
canonical Wnt signalling has the potential to reduce GC-induced osteoporosis 
through the prevention of final maturation and apoptosis of osteoblasts, increasing 
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the number of osteoblast precursors, likely through increased proliferation, and 
prevention of adipogenic differentiation.  This would prevent the depletion of the 
osteogenic progenitor pool, allowing for the maintenance of bone density.   
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Chapter 5: Role of Wnt in dual lineage 
commitment 
5.1 Introduction 
Several groups have proposed a hierarchical model for the differentiation of MSCs, 
progressing through a range of cell types capable of self renewal, but with a gradual 
reduction in potency.  Muraglia et al. (2000) proposed a model in which tripotential 
MSCs spontaneously progressed toward the osteogenic lineage.  The adipogenic 
lineage was the first to diverge, causing the loss of adipogenic capacity, creating 
osteo-chondro progenitors, which progress together before branching into osteogenic 
and chondrogenic-specific lineages prior to terminal differentiation.  More recently a 
similar, but more complex model has been derived, which incorporated myoblastic 
and fibroblastic potential into the hierarchical model (Sarugaser et al, 2009).  This 
model expanded on that of Muraglia et al. (2000), and proposed the final, default cell 
type to be that of the fibroblast, with myocytes suggested to be very first cell type to 
diverge (Figure 5.1.1).  This model also highlights the existence of osteo-adipo 
progenitors, a proposition supported by various lines of work, which demonstrated 
clonal lines with lineages restricted to osteogenic and adipogenic differentiation 
(Pittenger et al, 1999; Sarugaser et al, 2009).  The very nature of this progressive 
hierarchical model dictates the need for signalling inputs to regulate the progression 
down a particular pathway, and manipulation of cell signalling pathways such as 
BMPs and Wnts, either endogenously or through extrinsic administration, is likely to 
alter commitment decisions.  Indeed, Liu et al. (2009) demonstrated a role for 
canonical Wnt signalling in the progression toward osteoblasts in preference to 
adipocytes.  Similarly, BMPs have been shown to stimulate MSCs to form both 
osteoblasts (Cheng et al, 2003; Lee et al, 2000; Sampath et al, 1992) and 
chondrocytes, suggestive of the directing of commitment towards an osteo-chondral 
progenitor phenotype.  Furthermore, canonical Wnt signalling has been shown to 
increase BMP-induced osteogenesis in mouse models (Chen et al, 2007b) and cell 
lines (Tang et al, 2009), yet reduce chondrogenesis (Fischer et al, 2002).  Canonical 
Wnt signalling has also been shown to be important in the regulation of the switch 
from chondrogenic to osteogenic differentiation during development by conditional 
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Figure 5.1.1. Schematic of the hierarchical differentiation of MSCs 
MSCs spontaneously progress toward the fibroblastic lineage, maintaining their 
capacity to renew but gradually lose potential as they progress.  The myocyte 
lineage is the first to diverge, causing the loss of myogenic capacity, followed by 
the divergence of adipocytes.  Osteo-Chondro progenitors, progress together 
before branching prior to terminal differentiation or continuing to the default 
fibroblastic lineage.  The potency of the progenitors is denoted by the initials in 
blue. (E.g. COF: Chondrogenic, Osteoblastic and Fibroblastic potential.) M: 
Myogenic, A: Adipogenic, C: Chondrogenic, O: Osteoblastic, F: Fibroblastic 
Adapted from Sarugaser et al. (2009) 
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β-catenin knock out and Wnt14 over-expression studies in mouse models (Day et al, 
2005; Hill et al, 2005).  Increased canonical Wnt signalling within the progenitor 
cells promoted osteogenesis and chondrocyte hypertrophy whilst blocking 
chondrocyte differentiation.  Conversely, canonical Wnt inhibition resulted in 
increased cartilage formation at the expense of osteogenesis.  However, the in vitro 
studies of BMP-induced osteogenesis and chondrogenesis have only been performed 
in mouse cell lines with independent analysis of the two differentiation pathways in 
response to canonical Wnt signalling, however to study the role of these signalling 
pathways in this bi-lineage environment both differentiation processes should ideally 
be studied simultaneously.  
One method suited to the simultaneous analysis of different differentiation pathways 
is quantitative reverse transcriptase PCR (qPCR).  This quantitative approach allows 
for the study of a whole array of gene expression profiles in a single sample, 
permitting the identification of expression levels of osteogenic genes, such as Runx2 
and ALP, and chondrogenic genes, such as Sox9, Aggrecan and Col2a1, within a 
single differentiating sample.  The use of such a technique also allows for the 
identification of the point at which the differentiation process is affected, through the 
identification of differentiation stage-specific genes. 
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5.2 Aims 
The general aims of the work presented in this chapter are to identify the effect of 
stimulated canonical Wnt signalling, by AR28 administration, on the differentiation 
of MSCs cultured in conditions capable of stimulating multiple lineages 
simultaneously. 
More specifically the aims are to: 
 Characterise the effect of AR28 on the osteogenic and adipogenic 
differentiation of MSCs cultured in an osteo/adipogenic induction medium. 
 Characterise the effect of AR28 on the osteogenic differentiation of MSCs 
cultured with BMP2. 
 Use cell lines to model the effect of BMP2 and AR28 on Sox9 activity and 
stability. 
 Characterise the effect of AR28 on the simultaneous osteogenic and 
chondrogenic differentiation of MSCs cultured in BMP2, using reverse 
transcription real time PCR. 
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5.3 Methods 
5.3.1 Dual differentiation studies 
MSCs or hADSCs were seeded at 2x10
4
 cells/cm
2
 and allowed to adhere overnight.  
Cells were then cultured in adipogenic/osteogenic dual differentiation conditions 
(Liu et al, 2009) comprised of 50:50 adipogenic:osteogenic medium (2.2.1.6) with 
AR28 at concentrations stated.  Cells were cultured for the desired length of time 
with media change every three or four days. 
5.3.2 BMP2-induced osteogenesis 
MSCs were seeded at 2x10
4
 cells/cm
2
 and allowed to attach overnight.  Cells were 
then cultured in Basal media (2.2.1.6) with the addition of 100 ng/ml recombinant 
BMP2 and AR28 at concentrations stated.  Media was changed every three or four 
days. 
5.3.3 Differentiation marker assays 
For the osteogenic assays, ALP enzyme histochemistry, von Kossa staining and ALP 
activity assays were performed as previously described in sections 4.3.3 and 4.3.4. 
For the adipogenic assays, Oil Red O staining and absorbance and FABP5/BODIPY 
staining, were performed as described previously in sections 4.3.6 and 4.3.7. 
5.3.3.1 ELF97 staining 
hADSCs were cultured in glass bottom 96 well plates and treated as described.  Cells 
were fixed in 4% paraformaldehyde for 15 min, followed by washing in PBS.  
Samples were permeabalised in PBS-0.2%Tween 20 for 10 minutes, and washed in 
PBS for 10 minutes.  The PBS was removed completely from the wells, and 50 µl of 
100 µM ELF97 substrate (Invitrogen, Carlsbad, CA, USA) diluted in enhancing/AP 
buffer (100 mM Tris-HCl, 50 mM MgCl2, 100mM NaCl) was added.  The cells were 
then incubated for 30secs-5minutes for optimisation, or 1 minute for subsequent 
assays.  Samples were then washed in stop/wash buffer (25 mM EDTA, 5 mM 
Levamisol in PBS) for 10 minutes followed by 2 washes for 5 minutes.  Samples 
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were washed and stored in PBS at 4°C.  Images were taken using an automated 
ImageXpress 5000A (Molecular Devices).  Post-acquisition image analysis was 
performed using the granularity application module of MetaXpress analysis software 
(Molecular Devices) to identify granules between 2 and 30µm in diameter.  Samples 
were subsequently stained with Hoechst33342 at 1 µM for 10 minutes at room 
temperature.  The same areas of the sample wells were imaged to identify the nuclei, 
and analysed using the count nuclei application module (MetaExpress). 
5.3.4 Sox9 Reporter assays 
C3H10T1/2 cells were seeded in white opaque 96 well plates at 1x10
4
 cells/well 
(without antibiotics), and allowed to adhere overnight.  Cells were then transfected 
with the 4Col2E-Luc reporter and Sox9 over-expression plasmids in combination 
with the pCMV-Renilla plasmids using Lipofectamine as described in section 
2.2.3.1.  Optimised conditions are given in Table 3.3.3.  After 24 hours the cells 
were treated with AR28 or DMSO vehicle control and 300 ng/ml BMP2 as stated.  
After 48 hours the reporter activity was assayed using the Dual Glo Luciferase assay 
system (2.2.4) 
Table 5.3.1. Optimised transfection  conditions for C3H10T1/2 in 96 well plates 
DNA/Reagent Amount/well 
4Col2E-Luc 30 ng 
pCMV-Renilla 3 ng 
pRK5-Sox9 25 ng 
Plus Reagent  0.3 µl 
Lipofectamine Reagent 0.3 µl 
DMEM 4 µl 
DMEM for final dilution 32 µl 
 
5.3.5 Western Blot analysis of Sox9 and β-catenin  
C3H10T1/2 and HEK293 cells were seeded at 1.25x10
5
 cells/well (12 well plate) 
and 2x10
5
 cells/well (24 well plate) respectively and allowed to adhere overnight.  
Cells were then transfected using Lipofectamine or Lipofectamine LTX reagents as 
described in section 2.2.3.  Optimised conditions are given in Table 5.3.2. 
. 
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Table 5.3.2. Optimised transfection conditions for C3H10T1/2 and HEK293 
cells 
DNA/Reagent Amount/well 
C3H10T1/2 cells (12 well plate) 
pRK5-Sox9 600 ng 
Plus Reagent  4 µl 
Lipofectamine Reagent 4 µl 
DMEM 50 µl 
DMEM for final dilution 700 µl 
HEK293 cells (24 well plate) 
pRK5-Sox9 or empty pRK5 
plasmid DMA 
Combined to 
give 300 ng 
Plus Reagent  0.3 µl 
Lipofectamine LTX Reagent 1 µl 
Optimem 100 µl 
 
Total protein lysate samples were obtained and separated by SDS-PAGE and 
transferred to PVDF membranes as described in section 2.2.5. Antibody probing was 
performed using the primary antibody concentrations and appropriate HRP-
conjugated secondary antibodies given in Table 5.3.3.   
Table 5.3.3. Optimised Antibody concentrations for Western Blot analysis 
Target Conjugate Host Conc. Supplier Cat. No. 
β-catenin 
Purified 
IgG 
Mouse  0.25 µg/ml 
BD Transduction 
Laboratories 
610154 
Sox9 
Purified 
IgG 
Rabbit  0.4 µg/ml Abcam ab36748 
GAPDH 
Purified 
IgG 
Mouse  0.5 µg/ml Genetex 28245 
Anti-mouse 
IgG 
HRP Goat 0.1 µg/ml 
Santa Cruz 
Biotech 
SC-2005 
Anti-rabbit 
IgG 
HRP Swine 0.17 µg/ml DAKO P0399 
 
5.3.6 RNA extraction, reverse transcription and real-time PCR analysis 
5.3.6.1 Trizol extraction of RNA 
Cells were cultured in 6 well plates and treated according to the assay.  At 
appropriate time-points for RNA analysis, cultures were washed twice in PBS before 
direct lysis in the well with 0.5 ml Trizol
®
 (Invitrogen, Carlsbad, CA, USA) for 5 
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minutes at room temperature.  The cell lysate was passed through a pipette several 
times before being transferred to a clean eppendorf and stored at -80ºC.  Thawed 
samples were incubated for 5 minutes at room temperature before the addition of 
100 µl chloroform, and thorough mixing by vortexing for 15 seconds.  The samples 
were incubated at room temperature for a further 5 minutes before centrifugation at 
12,000g for 15 minutes at 4ºC.  The upper aqueous phase was transferred to a clean 
tube and mixed with 250 µl isopropanol before incubation at 4ºC for 30 minutes.  
The samples were centrifuged at 12,000g for 15 minutes at room temperature and the 
supernatant removed.  The RNA sample was then washed in 0.5 ml of 75% ethanol 
and centrifuged at 12,000g for 5 minutes.  The supernatant was fully removed and 
the pellet allowed to air dry.  The RNA was then resuspended in 12 µl Nuclease free 
H2O.  RNA was stored at -80ºC. 
5.3.6.2 DNase treatment of RNA 
DNase treatment was performed using the DNA-free
TM
 kit, (Invitrogen, Carlsbad, 
CA, USA).  1.2 µl of DNase I buffer and 1 µl of rDNase I was added to the RNA 
and mixed gently before incubation at 37ºC for 30 minutes.  1.2 µl of DNase 
inactivation reagent was then added to the sample and mixed well, followed by 
incubation at room temperature for 2 minutes, flicking occasionally to mix.  The 
samples were then centrifuged at 13,000g for 1 minute to pellet the inactivation 
reagent.  The supernatant was transferred to a clean tube and the RNA concentration 
measured using a NanoDrop 1000 Spectrophotometer (Thermo Scientific, Waltham, 
MA, USA).  RNA was stored at -80ºC. 
5.3.6.3 cDNA synthesis 
Reverse transcription was performed using Superscript II reverse transcriptase 
(Invitrogen, Carlsbad, CA, USA).  1 µg of RNA was combined with 1 µl Oligo dt 
primers (Invitrogen, Carlsbad, CA, USA) and 1 µl of 10 mM 2’-deoxynucleoside 
5’triphosphates (dNTPs) (Invitrogen, Carlsbad, CA, USA), and made up to 12 µl 
with nuclease free H2O.  Selected samples were prepared in replicate for no Reverse 
transcriptase controls.  Samples were incubated at 65ºC for 5 minutes, followed by 
chilling on ice for 2 minutes.  A prepared mix of 4 µl 1
st
 strand buffer, 2 µl 0.1 M 
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Dithiothreitol (DTT) and 1 µl nuclease free H2O was then added to each sample, and 
incubated at 42ºC for 2 minutes.  1 μl of SuperScript II reverse transcriptase was 
then added to each sample, except the no enzyme controls, where H2O was added 
instead, followed by incubation at 42ºC for 1 hour and 70ºC for 1 minute.  cDNA 
samples were then diluted with 30 µl nuclease free H2O and stored at -20ºC. 
5.3.6.4 Quantitative reverse transcription PCR 
Quantitative reverse transcription PCR (qPCR) was used to analyse changes in gene 
expression in response to various combinations of BMP2 and AR28.  qPCR 
reactions were set up as in Table 5.3.4 and run on a ABI Prism 7000. 
Table 5.3.4. qPCR reaction composition 
Volume Reagent 
5 µl cDNA Sample 
1 µl Forward Primer (20µM) 
1 µl Reverse Primer (20µM) 
12.5 µl SYBR Green Power (Invitrogen) 
5.5 µl dH2O 
 
Primer optimisation 
Primer optimisation was performed using either combined cDNA from osteogenic 
differentiation of MSCs for the osteogenic genes, or cDNA from homogenised 
cartilage for chondrogenic genes.  A 10-fold serial dilution of the sample was 
generated, producing a range of concentrations as follows; 1:0, 1:10, 1:100 and 
1:1000.  These cDNA concentrations were then analysed with the primer pairs in 
Table 5.3.5. Reaction mixes set up in triplicate as Table 5.3.4 in a 96 well plate 
format and run on an ABI Prism 7000.  Thermocycler settings were; 60ºC for 2 
minutes, 95ºC, followed by 40 cycles of 95ºC for 15 seconds and 50ºC for 1 minute.  
Each cycle was followed up by a dissociation stage of 95ºC for 15 seconds, 60ºC for 
20 seconds and 95ºC for 15 seconds.  Standard curves were generated from the CT 
values for each concentration and the gradient of the regression line determined.  The 
regression line gradients from each primer pair, including the house keeping gene, 
40S ribosomal protein S27a (RPS27A), to show the primer pairs were amplifying at 
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high efficiency that was conserved between primer pairs.  Dissociation curves were 
also generated to ensure the product amplification specificity. 
Reverse transcriptase real time PCR 
cDNA samples were diluted 1:5 for the genes of interest, and 1:100 for RPS27A, 
before combining into the reaction mix (Table 5.3.4) in triplicate in a 96 well plate 
format, and assayed using the ABI Prism 7000.  Thermocycler settings were; 60ºC 
for 2 minutes, 95ºC, followed by 40 cycles of 95ºC for 15 seconds and 60ºC for 1 
minute.  Results were analysed using 7000 system software and the 2
-ΔΔCt
 method 
(Livak & Schmittgen, 2001).  Threshold levels were set in the exponential phase of 
the amplification for each primer pair, and the CT values exported.  CT values for 
genes of interest were normalised to the RPS27A values, by subtraction of the mean 
RPS27A CT value for the particular cDNA sample, to give ΔCT.  The mean ΔCT of 
the day 4 control cDNA sample was then subtracted from the ΔCT making all 
samples relative to Day 4: No treatment, giving ΔΔCT.  2
-ΔΔCt
 was then calculated to 
give fold changes in gene expression.  Means were then calculated from the technical 
replicates.  Technical errors were given as CT ± standard deviation. 
Table 5.3.5. qPCR primer sequences 
Gene  Nucleotide sequence (3’-5’) 
RPS27A 
Forward TGGATGAGAATGGCAAAATTAGTC 
Reverse CACCCCAGCACCACATTCA 
Runx2 
Forward AGTGATTTAGGGCGCATTCCT 
Reverse GGAGGGCCGTGGGTTCT 
ALP 
Forward GGGAACGAGGTCACCTCCAT 
Reverse TGGTCACAATGCCCACAGAT 
Sox9 
Forward TTCCGCGACGTGGACAT 
Reverse TCAAACTCGTTGACATCGAAGGT 
Aggrecan 
Forward AGTATCATCAGTCCCAGAATCTAGCA 
Reverse AATGCAGAGGTGGTTTCACTCA 
Coll2A1 
Forward TTGCCTATCTGGACGAAGCA 
Reverse CGTCATTGGAGCCCTGGAT 
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5.4 Results 
5.4.1 Adipogenic and osteogenic dual lineage commitment 
5.4.1.1 ALP/vK and Oil Red O staining 
To study the effect of AR28 on the differentiation of MSCs towards osteoblasts and 
adipocytes simultaneously, MSCs were cultured in a 50:50 mix of osteogenic and 
adipogenic media for up to 14 days.  These cultures were also treated with AR28 
between 0.05-0.5 µM or a DMSO vehicle control.  Initial analysis of differentiation 
was performed by ALP/vK staining or Oil Red O for osteogenesis and adipogenesis 
respectively, and imaged by brightfield microscopy.  As controls, to ensure the MSC 
donor was capable of differentiating toward osteoblasts and adipocytes, standard 
single lineage differentiation was also preformed, showing strong osteogenic and 
adipogenic staining for the respective cultures (Figure 4.4.1 A).  The dual 
differentiation conditions, in the absence of AR28 were able to induce both 
osteogenic and adipogenic differentiation, shown by ALP/vK and Oil Red O staining 
(Figure 4.4.1 B).  Staining was performed in separate wells for osteogenic and 
adipogenic markers to allow for the two stains to be easily distinguished, however 
lipid droplet formation can be visualised in the ALP/vK stained cultures without Oil 
Red O staining.  This shows the two differentiated cell types in close proximity, with 
no separation of the two cell types to different areas of the culture.  AR28 addition at 
0.5 µM resulted in the complete inhibition of adipogenesis and osteogenesis in the 
dual lineage cultures, similar to the single lineage experiments (Chapter 4), however 
the lower concentration of 0.05 µM showed clear inhibition of adipogenesis, with no 
clear change in osteogenesis (Figure 4.4.1 B).   
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Figure 5.4.1. ALP/vK and Oil Red O staining of adipogenic and osteogenic 
dual lineage differentiation 
A) MSCs (FH390) were cultured in osteogenic or adipognic conditions for 12 
days and stained with ALP/vK or Oil Red O.   
B) MSCs (FH390) were cultured in Dual differentiation media (50:50 mix of 
osteogenic and adipogenic media) in the presence of AR28 or DMSO control as 
stated for 12 days.  Samples were then stained with ALP/vK or Oil Red O. 
Samples were imaged by brightfield microscopy. 
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5.4.1.2 Quantitative analysis of ALP activity and Oil Red O  
The staining and imaging technique used in the experiment described above is purely 
qualitative, making it difficult to identify small changes in osteogenesis throughout 
the well.  Therefore, quantitative assays were used to study both osteogenesis and 
adipogenesis in the dual lineage differentiation conditions.  Adipogenesis was 
studied using Oil Red O staining, and extraction followed by absorbance 
measurements at 490 nm.  As seen with Oil Red O staining and imaging, AR28 
clearly inhibited adipogenesis in both single and dual differentiation conditions at all 
concentrations used, although complete inhibition was not generated until 
concentrations of 0.5 µM were reached (Figure 5.4.2 A).  Interestingly, the donor 
used here generated an increase in Oil Red O in the presence of the osteogenic 
media, suggesting a propensity of this donor for adipogenesis. 
To study the degree of osteogenesis, the pNPP ALP activity assay was performed 
(Figure 5.4.2 B).  Adipogenic conditions reduced the ALP activity to below the basal 
levels for the MSCs within 7 days.  Single osteogenic differentiation induced a clear 
increase in ALP activity, which was reduced upon AR28 addition between 0.05-
0.5 µM in a dose-dependent manner, as discussed in Chapter 4.  Dual lineage 
conditions were also able to generate an increase in ALP activity, although to a 
lesser extent than by single osteogenic conditions.  Furthermore, AR28 has similar 
inhibitory effects on ALP activity in the dual lineage conditions, with inhibition at 
all concentrations used.   
5.4.1.3 High content analysis of FABP5/BODIPY double positive cells 
As only a small range of concentrations were used to study the effect of AR28 using 
the techniques described above, the high content FABP5/BODIPY staining 
technique was used to identify adipogenesis, while a method using Enzyme-
Labelled-Fluorescence (ELF) 97 was developed to study ALP activity.  These assays 
were performed using hADSCs, however previous findings (Chapter 4) showed very 
little difference between hADSCs and bone marrow derived MSCs in relation to the 
effect of canonical Wnt signalling on osteogenic and adipogenic differentiation.  
Consistent with the results described in MSCs, AR28 reduced the percentage of 
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Figure 5.4.2. pNPP assay and Oil Red O absorbance of adipogenic and 
osteogenic dual lineage differentiation  
A) MSC (FH429) seeded in 96 well plates, were cultured in adipogenic, 
osteogenic and dual lineage condition (50:50 mix) conditions for up to 14 days in 
the presence of AR28 at the concentrations shown or DMSO control.  Samples 
were stained with Oil Red O before solubilisation in 100% isopropanol and 
quantification by absorbance at 490 nm.  
B) MSC (FH429) seeded in 96 well plates, were cultured in osteogenic, 
adipogenic, and dual lineage condition (50:50 mix) conditions for up to 14 days in 
the presence of AR28 at the concentrations shown or DMSO control.  ALP 
activity normalised to cell number (given as nmoles pNP/min/µg DNA) was 
calculated at 7 and 14 days.  
Values given as mean ± stdev., n=6 (independently treated technical replicates), 
* p<0.05, ** p<0.005, *** p<0.001.  Statistical significance is relative to vehicle 
control at appropriate time point, by Mann-Whitney U and Kruskal-Wallis tests. 
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Figure 5.4.3. Definiens analysis of FABP5/BODIPY staining of Dual 
differentiation cultures 
FABP5 and BODIPY analysis of 7 and 14 day dual differentiation (50:50 mix of 
adipogenic and osteogenic media) hADSC cultures in the presence of AR28 at the 
concentration given or DMSO control using Definiens analyses of fluorescence 
microscopy imaging.  A) Bar chart showing the number of FAPB5/BODIPY 
double positive cells in response to different AR28 concentrations.  B) Bar chart 
showing the total number of nuclei in response to different AR28 concentrations.  
Values given as mean ± standard deviation, n=6 (independently treated technical 
replicates), * p<0.05, ** p<0.005.  Statistical significance is relative to vehicle 
control at appropriate time point unless stated otherwise, by Mann-Whitney U and 
Kruskal-Wallis tests. 
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FABP5/BODIPY double positive nuclei with concentrations as low as 63 nM, with 
complete inhibition of adipogenesis by 632 nM in dual lineage differentiation media, 
at all time point measured (Figure 5.4.3 A).  However, unlike single lineage 
conditions (Chapter 4) the dual lineage differentiation media did not generate a 
reduction in cell number relative to the basal media control (Figure 5.4.3 B).  This is 
likely due to the presence of proliferative osteogenic precursors in the culture, which 
as discussed in Chapter 4 appear to proliferate more rapidly upon AR28 treatment, 
presenting itself as increased cell number over time.  As discussed in chapter 4, 
higher AR28 concentrations of 632 nM and above resulted in a reduction in cell 
number.  
5.4.1.4 High content analysis of osteogenesis using the ELF-97phosphate 
The ELF-97 phosphate is hydrolysed by ALP, liberating the ELF97 alcohol, which 
forms a fluorescent precipitate.  This can then by visualised by fluorescence 
microscopy.  ELF97 is considered better than Fast Red TR, with lower diffusion 
after enzymatic conversion, allowing for greater resolution to be attained (Cox & 
Singer, 1999).  To optimise the time the ELF97 phophatase substrate was incubated 
with the cells, a range of incubation times (30 secs – 5 minutes) were performed on 
MSCs cultured in both basal and osteogenic conditions.  Images were then acquired 
by automated fluorescence microscopy (Figure 5.4.4).  Image analysis identified an 
incubation period of 1 minute was sufficient to create increases in fluorescence 
intensity, while not causing large non-specific ELF97 precipitates to form, and 
allowing differences between basal and osteogenic cultures to be detected. 
The optimised protocol was then used to identify the effect of a large range of AR28 
concentrations on osteogenesis induced by dual lineage conditions (Figure 5.4.5).  
The ELF97 staining presented itself in a highly localised punctate manner, owing to 
the low diffusion of the insoluble precipitate.  The punctate staining pattern allowed 
for the image analysis of ELF97 staining using a granularity assay, calculating the 
number of ELF97 foci and the total area of positive staining.  Additionally, the mean 
intensity of the ELF97 foci could be calculated.  Samples were also co-stained with 
Hoechst, allowing for the number of cells per image to be calculated, and therefore 
the relative ELF97 staining per cell. 
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Figure 5.4.4. ELF97 optimisation  
hADSCs were cultured in basal or osteogenic media for 21 days before 
optimisation of the ELF97 assay.  Substrate incubation time was optimised by 
performing a range of incubation periods stated.  Samples were imaged using 
fluorescence microscopy.  One minute incubation period was chosen as an 
optimal time, generating clear increases in ELF97 fluorescence, without large 
amounts of non-specific precipitation. 
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Figure 5.4.6. ELF97 Dual differentiation assay image analysis  
(Overleaf) 
Image analysis of hADSCs cultured for up to 21 days in dual differentiation 
media (50:50 mix of osteogenic and adipogenic media), with the addition of 
AR28 at concentrations stated or DMSO control, and assayed by ELF97, 
followed by fluorescence microscopy. Samples were co-stained with Hoechst, 
allowing for cell number to be calculated.  Image analysis was performed using a 
granularity application module (MetaExpress) due to the punctate staining, 
allowing A) the number of ELF97 positive foci per cell (No. granules/cell 
number), B) the area of ELF97 staining per cell (Granule area/cell number) and 
C) the mean intensity of the ELF97 staining (Mean granule intensity) to be 
calculated.  Values given as mean ± standard deviation, n=6 (independently 
treated technical replicates), * p<0.05, ** p<0.005.  Statistical significance is 
relative to vehicle control at appropriate time point unless stated otherwise, by 
Mann-Whitney U and Kruskal-Wallis tests. 
 
 
Figure 5.4.5. ELF97 Dual differentiation assay  
Example images of hADSCs culture in basal or dual differentiation (50:50 mix of 
osteogenic and adipogenic media) for 21 days, with the addition of AR28 at 
concentrations stated or DMSO control.  The samples were assayed using ELF97 
substrate, and imaged by fluorescence microscopy. 
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AR28 at 6320 nM lead to large amounts of cell death within 7 days of treatment, 
resulting in abnormal ELF97 staining, which caused increases in all output 
measurements that were not the result of differentiation.  However, increases in the 
number of ELF-97 positive foci, and total area of staining were detected in response 
to the dual lineage conditions relative to the basal media control, with inhibition of 
this increase in response to AR28 at concentrations of 200 nM and above (Figure 
5.4.6 A+B).  Similarly, the increase in the average staining intensity was enhanced in 
differentiation conditions compared to the basal media at day 7, and the intensity was 
reduced by AR28 at concentrations of 200 nM or above at both time points (Figure 
5.4.6 C).  In contrast, the lower concentrations of AR28, between 2 and 20 nM, 
generated slight increases in both the number and total area of ELF97-positive foci 
(Figure 5.4.6 A+B).  However, due to the relatively high variation between the 
images from the replicate wells they failed to be statistically significant.  The 
intensity of the staining in response to these lower concentrations remained 
unchanged (Figure 5.4.6 C). 
5.4.2 BMP2 and canonical Wnt interactions 
5.4.2.1 BMP2 and AR28 act synergistically to stimulate osteogenesis 
As an alternative to osteogenic cocktails, BMPs can be used to induce osteogenesis, 
and have been shown to be dependent on canonical Wnt signalling (Chen et al, 
2007b; Cheng et al, 2003; Tang et al, 2009).  Therefore to see how AR28-mediated 
increased canonical Wnt signalling impacted on BMP2 induced osteogenesis, MSCs 
were treated with 100 ng/ml BMP2, with the addition of AR28 or DMSO vehicle 
control, and cultured for 7 days before ALP enzyme histochemistry staining (Figure 
5.4.7).  BMP2 alone caused very little effect on ALP staining of the MSCs, and 
similarly, AR28 alone did not alter ALP staining.  However, together BMP2 and 
AR28 induced a large increase in ALP staining of the MSC cultures, suggesting a 
synergistic effect between BMP and canonical Wnt signalling on the induction of 
osteogenesis.  The increase in staining manifested itself as an increase in the number 
of cells expressing ALP, but also as increased staining intensity for each cell 
compared to positive cells in control cultures.  The combination of BMP2 and AR28  
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Figure 5.4.7. ALP Enzyme histochemistry showing BMP2 and AR28 act 
synergistically to enhance osteogenisis 
MSCs (A) K9, B) FH429) were cultured for 7 days in basal conditions ± 
100 ng/ml BMP2, with AR28 at concentrations given, or DMSO control.  
Samples were stained for ALP imaged by brightfield microscopy.  Representative 
images shown.  BMP2 or AR28 alone caused very little effect on ALP staining, 
however in combination generated large clear increases in ALP staining. 
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Figure 5.4.8. pNPP assay showing BMP2 and AR28 act synergistically to 
enhance osteogenisis 
MSCs (A) K9, B) FH452 C) FH390) were cultured for up to 7 days in basal 
conditions ± 100 ng/ml BMP2, with AR28 at concentrations given, or DMSO 
control.  ALP activity normalised to cell number (given as nmoles pNP/min/µg 
DNA) was calculated at 3 and 7 days. Values given as mean ± stdev., n=6 
(independently treated technical replicates), * p<0.05, ** p<0.005.  Statistical 
significance is relative to BMP2, DMSO control at appropriate time point unless 
otherwise stated, by Mann-Whitney U and Kruskal-Wallis tests. 
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can therefore increase the number of cells that progress towards an osteogenic 
lineage, but also increase the rate of progression. 
The degree of ALP activity was also quantified using the pNPP ALP activity assay, 
normalising to DNA, which showed a very similar trend to the ALP staining (Figure 
5.4.8).  However, using this more sensitive method, small increases in ALP activity 
could be detected with BMP2 alone after 7 days treatment.  The increase in ALP 
activity varied greatly between the 3 donors tested, with basal levels of ALP activity 
being equally variable; however the trend was the same irrespective of the level of 
ALP activity.  As the ALP activity is normalised to DNA, a relative change in cell 
number could also be calculated.  Unlike during the classical osteogenic 
differentiation, and the more mild form discussed in chapter 4, the increase in ALP 
activity caused by the combination of BMP2 and AR28 is not accompanied by large 
increases in cell number, suggesting an alternative mechanism.  
5.4.2.2 AR28 inhibits BMP2 induced Sox9 activity 
BMPs are also known to stimulate chondrogenesis through the up-regulation and 
activation of Sox9 (Majumdar et al, 2001).  Therefore the ability of BMP2 to 
stimulate Sox9, and the effect of AR28 was investigated.  This was first assayed by 
the use of a luminescent Sox9 activity reporter generated from 4 tandem repeats of 
the Sox9 responsive sequence from the collagen II promoter (Muramatsu et al, 
2007).  The reporter was transfected into C3H10T1/2 cells, alongside pCMV-renilla, 
as a transfection control, treated with a combination of 300 ng/ml BMP2 and varying 
AR28 concentrations for 48 hours.  BMP2 generated large increases in Sox9 activity, 
of between ~20 and ~40 fold over basal levels depending on the passage of 
C3H10T1/2 cells used.  The addition of AR28 dramatically reduced this increase in 
Sox9 activity by approximately 50% at 0.05 µM and down to basal levels by 0.5 µM 
(Figure 5.4.9 A).  In a similar assay, Sox9 activity was stimulated by the 
over-expression of Sox9 in C3H10T1/2 cells (Figure 5.4.9 B).  However, this 
increase was not affected by AR28, suggesting that AR28 did not cause inhibition of 
Sox9 transactivity at the level of protein stability or activity, but either during BMP2 
signal transduction or DNA transcription/translation.   
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Figure 5.4.9. AR28 inhibits Sox9 activity induced by BMP2, but not Sox9 
over-expression. 
A) C3H10T1/2 cells were co-transfected with the 4Col2E firefly reporter plasmid 
and pCMV-Renilla before being treated with a combination of BMP2 and AR28 
as stated.  Firefly and Renilla luciferase were assayed after 48 hours of treatment. 
B) C3H10T1/2 cells were co-transfected with the 4Col2E firefly reporter plasmid, 
pCMV-Renilla and pRK5-Sox9 before being treated with AR28 or DMSO control 
as stated. Firefly luciferase was normalised to Renilla luciferase.  The relative 
increases, compared to respective vehicle controls, were calculated.  The graph 
presents mean ± standard deviation of six independently transfected and treated 
technical replicates.  n=6, * p<0.05, **.  Statistical significance is relative to 
vehicle control at relevant time point, by Mann-Whitney U and Kruskal-Wallis 
tests. C) Total cell extracts were obtained from C3H10T1/2 cells transfected with  
pRK5-Sox9 and cultured with AR28 at the concentration given, vehicle control 
(DMSO) or a no treatment control for 48 hours, and analysed by western blot.  
Membranes were probed against Sox9 and GAPDH for the loading control. 
 
181 
 
 
Figure 5.4.10. Sox9 over-expression does not inhibit β-catenin accumulation 
in response to AR28 
Total cell extracts were obtained from HEK293 cells transfected with pRK5-Sox9 
and empty pRK5 vector (total 300 ng/well) at the concentrations given (ng 
plamid/well) and cultured with 2.5 µM AR28, for 48 hours, and analysed by 
western blot.  Membranes were probed against A) Sox9, B) β-catenin, and 
GAPDH for the loading control. 
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This was supported by protein analysis of Sox9 over-expression studies in 
C3H10T1/2 cells.  Western blot analysis of Sox9 protein levels demonstrated 
transfection of the over-expression vector resulted in large increases in Sox9 protein 
levels after 48 hours.  Sox9 protein levels fluctuated slightly between treatments but 
no clear dose-dependent effect of AR28 on protein levels was detected at 
concentrations of 1-5 µM.  10 µM AR28 did reduce Sox9 levels slightly (Figure 
5.4.9 C), however this is a very high concentration, and could result in off target 
effects and toxicity.  Conversely, Sox9 has been shown to alter the degradation of 
proteins (Cheng & Genever, 2010), therefore the effect of Sox9 over-expression was 
assayed for its effect on AR28 induced β-catenin stability.  AR28 caused clear 
increases in the levels of β-catenin in HEK293 cell, but was not affected by the over-
expression of Sox9 (Figure 5.4.10).   
5.4.2.3 AR28 causes a switch from chondrogenesis to osteogenesis in the response 
to BMP2 
As this work in the mouse multipotent mesenchymal cell line, C3H10T1/2 suggested 
that BMP2 could stimulate chondrogenic differentiation, and AR28 could inhibit this 
process at or prior to Sox9 translation, study of gene expression in human MSCs was 
performed in response to BMP2/AR28 combinations.  As the above results had 
implicated the involvement of BMP2 and AR28 in both osteogenesis and 
chondrogenesis, qPCR primers for genes in both differentiation pathways were 
optimised.  The primers for the osteogenic genes Runx2 and ALP along with the 
housekeeping gene RPS27A were optimised using cDNA generated by combining 
several samples from MSCs cultured in osteogenic conditions, while primers for the 
chondrogenic genes Sox9, Aggrecan 1 and Collagen IIa1(Col2a1) were optimised 
using cDNA generated from homogenised human cartilage.  qPCR was performed 
using these primers against a 10-fold serial dilution of the cDNA, amplification plots 
and dissociation curves were generated and the threshold set to allow for CT 
calculation (Figure 5.4.11 A+B).  Using the CT values standard curves were 
generated for each gene (Figure 5.4.11 C+D).  All primers pairs amplified 
efficiently, demonstrated by standard curves with gradients of approximately -3.   
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Figure 5.4.11. Primer optimisation 
Primer optimisation was performed using either combined cDNA from osteogenic 
differentiation of MSCs for the osteogenic genes, or cDNA from homogenised 
cartilage for chondrogenic genes.  A 10 fold serial dilution of the sample was 
generated.  These cDNA concentrations were analysed with the primer pairs in 
Table 5.3.5 and run on an ABI Prism 7000.  A) Example amplification plot and 
B) dissociation curves of RPS27A primer pairs.  C) Standard curves were 
generated from the CT values for each primer pair.  D) The gradient of the 
regression line for each primer pair.   
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To analyse the effect of BMP2 and AR28 on the expression levels of these genes, 
three MSC donors were cultured in basal media with the addition of 100 ng/ml 
BMP2 and 0.5 µM AR28 or DMSO for 24 hours or 5 days.  Control samples in basal 
media alone were also produced.  RNA was extracted and cDNA generated for 
analysis by qPCR.  Fold changes in gene expression were produced using the 2
-ΔΔCt
 
method, normalising to the housekeeping gene RPS27A, and relative to the 24 hour 
basal media sample (Figure 5.4.12, Figure 5.4.13 and Figure 5.4.14).  Results for 
Sox9 expression matched the reporter assays in C3H10T1/2 cells, with increased 
expression in response to BMP2 treatment.  The fold-change increase varied between 
the three donors tested, from approximately 1.5-fold to 3-fold, yet in all donors the 
increase was repressed by the addition of AR28, back to basal levels.  The effect of 
BMP2 and AR28 on Runx2 expression was less clear.  BMP2 generated small 
increases in gene expression, similar to that for Sox9, however AR28 failed to 
generate a regular trend between the donors.  Irrespective, the effect on the later 
osteogenic and chondrogenic gene markers was much more striking.  As predicted 
from ALP activity assays, BMP2 caused small increases in ALP expression levels in 
two of three donors.  The third donor, K37, showed a reduction in ALP levels upon 
BMP2 treatment, but in the same manner as the two other donors, ALP transcript 
levels increased further upon AR28 addition.  The fold-changes in ALP expression 
varied greatly between donors, which was also the case for the chondrogenic 
markers Aggrecan and Coll2a1.  BMP2 increased both Aggrecan and Coll2a1 after 5 
days of treatment in all donors except Coll2a1 in donor FH390, which did not show 
any changes in expression levels.  As with the key transcription factor Sox9, AR28 
prevented this increase in chondrogenic markers reducing the expression back to 
basal levels.  In summary BMP2 caused an increase in the chondrogenic markers, 
Sox9, Aggrecan and Col2a1 after 5 days treatment.  This increase in chondrogenic 
gene expression was inhibited by AR28 addition, with a switch to increases in the 
osteogenic marker, ALP. 
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Figure 5.4.12. qPCR analysis of chondrogenic and osteogenic markers in 
response to BMP2 and AR28. (K16) 
cDNA samples were generated from MSCs (K16) treated for 24 hours and 5 days 
with 100 ng/ml BMP2 and 0.5 µM AR28 or DMSO control.  Basal media plus 
DMSO samples were also generated as an untreated control.  cDNA samples were 
analysed by qPCR using primer pairs against Sox9, Aggrecan, Col2a1, Runx2 and 
ALP, and plotted as relative increases in gene expression relative to day 3 basal 
media controls.  C
T
 values ± standard deviation of the technical replicates are 
presented in the corresponding tables. 
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Figure 5.4.13. qPCR analysis of chondrogenic and osteogenic markers in 
response to BMP2 and AR28 (FH390) 
cDNA samples were generated from MSCs (FH390) treated for 24 hours and 5  
days with 100 ng/ml BMP2 and 0.5 µM AR28 or DMSO control.  Basal media 
plus DMSO samples were also generated as an untreated control.  cDNA samples 
were analysed by qPCR using primer pairs against Sox9, Aggrecan, Col2a1, 
Runx2 and ALP, and plotted as relative increases in gene expression relative to 
day 3 basal media controls.  C
T
 values ± standard deviation of the technical 
replicates are presented in the corresponding tables. 
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Figure 5.4.14. qPCR analysis of chondrogenic and osteogenic markers in 
response to BMP2 and AR28 (K37) 
cDNA samples were generated from MSCs (K37) treated for 24 hours and 5 days 
with 100 ng/ml BMP2 and 0.5 µM AR28 or DMSO control.  Basal media plus 
DMSO samples were also generated as an untreated control.  cDNA samples were 
analysed by qPCR using primer pairs against Sox9, Aggrecan, Col2a1, Runx2 and 
ALP, and plotted as relative increases in gene expression relative to day 3 basal 
media controls.  C
T
 values ± standard deviation of the technical replicates are 
presented in the corresponding tables. 
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5.5 Discussion 
Many studies have demonstrated the involvement of canonical Wnt signalling in 
bone homeostasis and osteoblast differentiation, however Liu et al (2009) went 
further to propose a differential inhibition of adipogenesis and osteogenesis by 
Wnt3a signalling.  When grown in a binary differentiation medium, low level Wnt 
signalling lead to the inhibition of adipogenesis, without reducing osteogenesis.  This 
reduction in adipogenesis induced an increase in precursor cells available for 
osteogenic differentiation, and therefore increased osteogenic differentiation.   
To investigate whether AR28 could also generate this shift towards osteogenesis in 
dual differentiation conditions, MSCs were treated with a 50:50 mix of adipogenic 
and osteogenic medium and subjected to AR28 treatment.  Multiple analysis 
techniques were used to study adipogenesis and osteogenesis, culminating in high 
content imaging based assays with a wide range of AR28 concentrations to ensure all 
degrees of canonical Wnt activation were studied.  However, these studies did not 
replicate the differential effects on adipogenesis and osteogenesis described by Liu et 
al (2009), where canonical Wnt activation by Wnt3a lead to an increase in 
osteogenesis as the expense of adipogenesis when subjected to dual lineage 
conditions.  Under the conditions described here, using either the osteogenic 
(including dex), adipogenic or dual differentiation conditions, AR28 treatment 
inhibited both adipogenesis and osteogenesis at similar concentrations, between 0.05 
and 0.5 µM, therefore not allowing for the increase in osteogenesis at the expense of 
adipogenesis.  Small, but non-significant increases in osteogenesis were observed 
using the high content ELF97 assay at low AR28 concentrations, 2 – 20 nM.  
However, these concentrations did not correspond with decreases in adipogenesis, as 
would be expected for a change in preference towards the osteogenic lineage.  
Adipogenesis was also slightly increased at these lower AR28 concentrations at day 
7.  Therefore these small differences are not due to differential responses to 
canonical Wnt signalling, but are likely due to an unknown effect on the MSC 
precursor population, increasing the potential for both lineages. 
The discrepancy between these findings and those published by Liu et al. (2009) 
may be due to multiple reasons.  Firstly, the medium used to induce the dual 
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differentiation differs, as the previously published work uses Lonza differentiation 
supplements, and optimised mesenchymal growth supplements.  This may result in 
different effects of canonical Wnt signalling on the differentiation process creating 
the differences in differentiation inhibition.  Secondly, AR28 is non-selective in its 
stimulation of the canonical Wnt signalling pathway due to its action downstream of 
receptor binding, while Wnt3a as used by Liu et al (2009) is dependent on the 
receptor expression on the target cell.  It is possible that differentiating adipocytes 
and osteoblasts have different capacities to respond to Wnt3a, causing varying 
degrees of differentiation inhibition.  Therefore by bypassing the ligand/receptor 
binding process, AR28 would override any target cell-specific effects, generating the 
same level of β-catenin stabilisation irrespective of receptor expression.  The latter 
could easily be tested by the analysis of the effect of recombinant Wnt3a or Wnt3a 
conditioned media alongside AR28 to detect any differences in differentiation. 
The results described in this chapter highlight the interactions between BMP2 and 
canonical Wnt signalling in the differentiation of MSCs towards both osteogenesis 
and chondrogenesis.  In relation to osteogenesis, BMP2 was capable of generating 
small increases in the early osteogenic marker ALP, implying increased onset of 
osteogenesis.  This is a process well documented in the literature both in vivo (Cheng 
et al, 2001) and in vitro (Cheng et al, 2003), and has instigated a range of clinical 
application studies looking into the use of BMPs to aid in fracture repair 
(Lissenberg-Thunnissen et al, 2011; Pecina et al, 2001; Southwood et al, 2004).  
Indeed a product called InFuse has been approved for therapeutic use. However, the 
response of mouse and human MSCs to BMPs varies, with much lower levels of 
osteogenesis in vitro by human MSCs, and higher concentration requirement for in 
vivo fracture repair (Diefenderfer et al, 2003).  Similarly the results presented here 
showed relatively small increases in ALP by BMP2 alone, with the exception of 
donor FH390.  However, the addition of AR28 to these cultures markedly increased 
the levels of ALP activity, suggesting the need for activated canonical Wnt 
signalling in the onset of BMP2-induced osteogenesis.  This requirement has been 
noted before, both in in vivo models (Chen et al, 2007b) and C3H10T1/2 in vitro 
studies (Tang et al, 2009).  Tang et al. (2009) demonstrated that BMP9 and Wnt3a 
could enhance the others ability to induce ALP activity of C3H10T1/2 cells, and that 
BMP9-induced osteogenesis was dependent on functional canonical Wnt signalling 
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by β-catenin knockdown experiments.  Therefore despite the inability of canonical 
Wnt alone to induce osteogenesis of human MSCs, the requirement for functional 
canonical Wnt signalling in BMP2-induced osteogenesis, as in mice, appears to 
remain.  Additionally Deifenderfer et al. (2003) noted a range of degrees of 
osteogenesis in response to BMPs by human MSCs, which was also identified in the 
work presented in this chapter.  I propose this could be due to varying levels of 
endogenous canonical Wnt signalling between the donors.  To test this hypothesis, 
western blot analysis of active β-catenin in the different donors could be analysed 
and compared to the responsiveness of the donors to BMP2 signalling.  If the 
hypothesis is correct, one would expect the donors with the highest endogenous 
canonical Wnt signalling to respond more positively to BMP2.   
The synergistic effect of BMP2 and AR28 on stimulating osteogenesis also suggests 
a therapeutic role for AR28.  As stated above BMPs are being used to heal bone 
fractures in both animal models and humans, however the concentrations required in 
humans are relatively high.  Various side effects associated with high BMP 
concentrations are being suggested and studied, and the combination of expensive 
manufacturing costs of BMPs, and the supra-physiological concentrations make 
treatment relatively cost-ineffective.  Therefore, the addition of a canonical Wnt 
activator, such as AR28, to the site in combination with BMP signalling could 
increase the osteogenic differentiation of the endogenous MSCs at lower BMP 
concentrations, reducing both potential side effects and cost. 
BMPs are also known to stimulate chondrogenesis of MSCs, to which the results 
presented in this chapter conform.  BMP2 was capable of stimulating Sox9 reporter 
expression in C3H10T1/2 cells and up regulating the chondrogenic specific genes, 
Sox9, Aggrecan and Col2a1, in human MSCs.  Furthermore, this increase in both 
reporter activity and gene expression was inhibited by the addition of AR28 to the 
culture, simultaneously inducing an increase in the osteogenic specific gene ALP.  
Canonical Wnt signalling has been shown to be important in the commitment of 
progenitor cells to form either chondrocytes or osteoblasts during development by a 
selection of conditional β-catenin knock outs and Wnt14 over-expression studies in 
mouse models (Day et al, 2005; Hill et al, 2005). These studies demonstrated that 
increased canonical Wnt signalling within the progenitor cells promoted 
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osteogenesis and chondrocyte hypertrophy and blocked chondrocyte differentiation, 
while canonical Wnt inhibition resulted in increased cartilage formation at the 
expense of osteogenesis.  The results described in this chapter also suggest that the 
interplay between these two key signalling pathways is important in this bi-lineage 
commitment decision, in which canonical Wnt signalling can act as a switch to alter 
the differentiation fate from a chondrocyte to an osteoblast, a process that is 
necessary for endochondral bone formation.   
These findings also illustrate the large differences that can be attained between 
donors, and their preference for a particular pathway.  FH390 showed a strong 
preference for osteogenesis with high basal levels of ALP (ALP activity assay and 
CT values) but generated low increases in chondrogenic genes in response to BMP2.  
While K37 showed relatively poor osteogenic differentiation when assayed for ALP 
transcription in response to the combination of BMP2 and AR28, but expressed very 
high levels of Col2a1 (50-fold increase) and Aggrecan (4-fold increase) in response 
to BMP2 alone.  Donor K16 appeared to fall in between these two extremes with 
similar capacity for both chondrogenesis and osteogenesis.  These results 
demonstrate that MSC cultures from different donors can vary dramatically in their 
preference to differentiate towards a particular lineage, yet they respond in the same 
manner in response to BMPs and Wnt, all be it by different degrees.  
One mechanism for the up-regulation of Sox9 by BMP2 has been proposed by Jin et 
al. (2006), where BMP2 leads to the down-regulation of canonical Wnt signalling 
via p38 mitogen-activated protein kinase activation, which reduced the canonical 
Wnt-induced proteosomal degradation of  Sox9.  However, I showed that AR28 did 
not affect either the activity or the stability of over-expressed Sox9 in C3H10T1/2 
cells.  This lack of response may be due to the unnaturally high levels of CMV-
driven Sox9 expression, rendering the Wnt induced degradation obsolete.  BMP2 did 
however increase the mRNA levels of Sox9 in human MSCs which was prevented 
by AR28 treatment.  This provides an alternative explanation for BMP2-induced 
chondrogenesis where BMP2 can cause increased transcription of the Sox9 gene, 
which is regulated by canonical Wnt signalling through the reduction in gene 
expression. 
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A transcription factor which has been suggested as a key player in the switch 
between chondrogenesis and osteogenesis of osteochondo progenitor cells is osterix 
(Tominaga et al, 2009).  MSCs, ST-2 and C3H10T1/2 cells were shown to respond 
differently to BMP6, with C3H10T1/2 cells preferentially differentiating towards 
chondrocytes, while MSCs and ST-2 cells preferentially formed osteoblasts.  This 
difference was shown to be due to varying expression levels of osterix, where higher 
expression levels caused osteogenesis.  Furthermore, over-expression of osterix in 
C3H10T1/2 cells caused a reduction in chondrogenesis and an increase in 
osteogenesis, similar to the switch described in this work when MSCs were treated 
with a combination of BMP2 and AR28.  Due to these similarities, future work may 
look into the levels of osterix expression and activity in the MSC cultures treated 
with BMP2 and AR28, in order to identify any changes in Osterix in response to 
AR28.  The requirement of osterix in the switch from chondrogenesis to 
osteogenesis could also be studied by RNAi knockdown of osterix expression during 
the combination treatments. 
Further information may also be gained by the studying the expression levels of 
additional genes during the BMP and AR28 combination treatments, either through 
qPCR or on a more global level by mRNA microarrays.  This would allow for the 
identification of other differentiation genes to be studied, potentially identifying the 
point at which the switch toward osteogenesis occurs, and any point at which further 
external signals are required to continue the progression of the differentiation 
process.  The use of a microarray could also lead to the identification of novel or 
unexpected genes involved in the chondro- osteogenic switch. 
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Chapter 6: Discussion 
The work presented in this thesis provides a comprehensive assessment of the effect 
of canonical Wnt on the in vitro differentiation of human MSCs using a potent and 
selective GSK3β inhibitor, AR28, with a particular focus on osteogenic 
differentiation.  Briefly, potency and selectivity of AR28 to activate the canonical 
Wnt signalling pathway was demonstrated (Chapter 3), generating increases in 
stabilised β-catenin and TCF/LEF1 transcription factor activity in vitro, and the 
duplication of the Xenopus embryonic axis upon injection into the ventral marginal 
zone.  AR28 was subsequently used to identify the effect of activated canonical Wnt 
signalling on human MSC differentiation (Chapter 4).  These investigations 
identified potential reasons for the discrepancies in the literature regarding the effect 
of canonical Wnt signalling on osteogenic differentiation, whilst identifying novel 
and valuable insights into the mechanisms behind these effects.  Finally the effect of 
increased canonical Wnt signalling during bi-potential conditions was investigated 
(Chapter 5), which identified canonical Wnt signalling as an important regulator of 
the osteo/chondrogenic commitment decision in response to BMP signalling, acting 
through the down regulation of Sox9 expression and activity, and upregulation of 
ALP. 
6.1 Role of canonical Wnt signalling in MSC differentiation 
A large number of studies have looked into the effect of over-expression of 
canonical Wnt signalling on the differentiation of MSCs towards adipogenic, 
osteogenic and chondrogenic lineages.  However, many contradicting effects are 
identified by different groups, most strikingly the strong osteo-induction of canonical 
Wnt signalling on mouse mesenchymal/osteogenic precursor cells, yet apparent 
inhibition of osteogenic differentiation of human MSCs. More recent work proposes 
the importance of the stage of differentiation to which canonical Wnt activation is 
applied (Eijken et al, 2008; Quarto et al, 2010).  The work presented in this thesis 
used a range of osteogenic stimuli and osteogenic outputs to comprehensively study 
the effect of activated canonical Wnt signalling, by GSK3β inhibition, on the 
osteogenic differentiation of MSCs, whilst confirming the inhibitory effect of 
canonical Wnt signalling on adipogenesis.  In combination with published work, 
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these findings have allowed for the generation of a working hypothesis for the role of 
canonical Wnt signalling in the differentiation of MSCs (Figure 6.1.1). 
Results presented in section 4.4.3 and those published by other groups identifies the 
inhibition of dexamethasone induced osteogenic differentiation of human MSCs by 
canonical Wnt signalling, yet work by Krause et al. (2010) and that presented in 
section 4.4.4 showed increases in the early marker, ALP in response to canonical 
Wnt signalling in combination with a mild osteogenic stimulus, excluding 
dexamethasone.  It is therefore proposed that canonical Wnt signalling can act to 
stimulate the early stage of osteogenic differentiation in the absence of 
dexamethasone, but is detrimental to the dexamethasone-induced maturation of 
osteoblasts (Figure 6.1.1).  In addition to these findings supporting that of others, the 
results presented in section 4.4.5 also suggest a mechanism behind this increase in 
osteogenic precursors.  Increases in cell number could be detected in response to 
canonical Wnt activation, most noticeably when in combination with the mild 
osteogenic stimuli.  It is therefore proposed that canonical Wnt signalling acts to 
increase the proliferation of the osteogenic precursor cells, increasing the pool of 
osteogenic precursors, allowing for increased osteoblasts upon maturation (Figure 
6.1.1).  The pre-treatment experiments presented in section 4.4.6 also support this 
hypothesis, in which small increases in cell number can be detected after one week 
treatment with AR28 in basal conditions.  These cells showed an increased potential 
for osteogenesis, possibly through the increased number of osteo-progenitor cells.  
As adipogenesis was not enhanced, this stimulatory effect cannot simply be due to 
increased multipotent MSC proliferation, as one would expect all lineages to be 
enhanced in this case.  This work also complies with the proposal for 
transdifferentiation from adipocytes to osteoblasts by the inhibition of PPARγ. 
Canonical Wnt signalling is a known inhibitor of PPARγ (Okamura et al, 2009), 
causing the well documented decrease in adipogenesis.  Further work, discussed in 
section 4.5, also implicates the involvement of PPARγ in regulating osteogenesis, 
therefore it is highly possible that canonical Wnt signalling could act upon 
adipogenic precursors, preventing PPARγ expression, causing a switch in gene 
expression to that of an osteoblast precursor cell (Figure 6.1.1).  This would result in 
the increase in osteogenesis detected after AR28 pre-treatment, and the reduction in 
adipogenesis.  Unlike the work by Liu et al. (2009), the study described in section 
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Figure 6.1.1. Schematic showing involvement of canonical Wnt in 
osteo/adipogenesis of MSCs 
Canonical Wnt signalling inhibits adipogenic differentiation of MSCs, and can 
push pre-adipocytes towards osteoblasts by the inhibition of PPARγ.  Canonical 
Wnt signalling enhances early osteogenic differentiation and increases osteoblast 
precursor proliferation, but inhibits dexamethasone-induced maturation. 
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5.4.1 did not show a differential inhibition of adipogenesis and osteogenesis in 
response to canonical Wnt signalling in the presence of a bi-potential induction 
media.  However, upon pre-treatment with AR28, MSCs differentiate more readily 
towards osteoblasts, and less towards adipocytes, as mentioned above.  Therefore if 
these cells were subsequently subjected to the bi-potential induction media, one 
would expect a selective preference towards osteogenic differentiation, suppressing 
further the inhibition of adipogenesis seen under single lineage conditions. 
In addition to the work discussed above regarding the classical differentiation of 
MSCs using β-glycerophosphate, L-ascorbic acid and dexamethasone, findings 
presented in section 5.4.2 describe the effect of induced canonical Wnt signalling on 
BMP2-induced osteogenesis and chondrogenesis.  BMPs can induce both osteogenic 
and chondrogenic differentiation (Cheng et al, 2003; Sampath et al, 1992), and 
canonical Wnt signalling can increase the progression of osteogenesis, but decrease 
chondrogenesis (Day et al, 2005; Hill et al, 2005; Tang et al, 2009).  However, to my 
knowledge the work presented here is the first to demonstrate the simultaneous 
increase in osteogenic markers and decrease in chondrogenic markers in response to 
canonical Wnt activation in human MSCs.  Furthermore, the findings offer novel 
reasoning for this switch from chondrogenesis to osteogenesis (Figure 6.1.2).  Sox9 
activity and chondrogenic-specific gene mRNA levels increased in response to 
BMP2 treatment but were reduced upon canonical Wnt activation by AR28.  
Furthermore, AR28 had no effect on over-expressed Sox9 protein levels or activity, 
suggesting a role for canonical Wnt signalling during transcriptional control of the 
Sox9 gene.  These findings suggest a model for BMP2-induced differentiation of 
MSCs, where BMP2 exposure leads to the generation of an osteo-chondro progenitor 
cell, which in the absence to canonical Wnt signalling progresses towards a 
chondrogenic lineage, supported by the low level of osteogenesis in the absence of 
AR28.  Following canonical Wnt activation, the level of Sox9 is reduced through 
decreased transcription, preventing the upregulation of the chondrogenic genes, and 
a switch to the osteogenic markers through Runx2 expression.  
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Figure 6.1.2. Schematic showing BMP2 and Canonical Wnt interactions 
during osteo/chondrogenic differentiation 
BMP2 induces MSCs to differentiate towards an osteo-chondro progenitor, which 
in the absence of canonical Wnt signalling progress towards the chondrocyte 
lineage due to increased Sox9 expression.  In the presence of canonical Wnt, 
Sox9 expression is reduced, preventing chondrogenesis and allowing osteogenesis 
via Runx2 expression. 
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 The results discussed above regarding canonical Wnt signalling and the switch to 
osteogenesis in combination with BMPs, bears resemblance to that of Hh signalling 
discussed in 1.4.3.3, in which Shh leads to the increased expression and activity of 
Sox9 through the upregulation of Nkx3.2.  It is therefore likely that all three 
signalling pathways, BMP, Wnt and Hh, are acting in combination in response to 
environmental and hormonal cues to regulate the chondrogenic and osteogenic 
differentiation of MSCs. 
6.1.1.1 Therapeutic potential of canonical Wnt signalling and MSC differentiation 
The use of canonical Wnt activation in the treatment of bone disorders is a 
reoccurring theme, and the results presented in this thesis support its potential.  
Canonical Wnt upregulation is known to generate increased bone mass and density 
in mice and humans.  The findings described here suggest that this is likely through 
the increased proliferation of osteogenic precursor cells, and when in combination 
with intrinsic BMP signalling, increased differentiation.  Activation of the canonical 
Wnt pathway could therefore be used in the treatment of genetic or age-related bone 
disorders where increased bone formation is required.   
In addition to this straightforward approach, canonical Wnt activation could be used 
in combination with other treatments to improve their efficiency.  For example 
during glucocorticoid (GC) treatment which can often lead to chronic osteoporosis.  
Canonical Wnt activation has the potential to tackle many of the effects of prolonged 
GC treatment as discussed in section 4.5.  Conversely, Wnt activation may be used 
to enhance the effect of BMP treatment during fracture repair, allowing a greater 
osteogenic response to lower BMP concentrations as discussed in section 5.5.  
Alternatively, the manipulation of the canonical Wnt pathway by inhibition and 
activation may allow for the controlled sequential formation of chondrogenic 
followed by osteogenic cells, mimicking the endochondral ossification process, 
potentially generating more natural bone. 
However, as with all therapeutic applications, safety must be considered.  Firstly, off 
target effects both through the activation of the canonical Wnt pathway in other 
tissues or by other roles of GSK3β, if using an inhibitor such as AR28, could 
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generate unknown side effects.  These are most relevant for treatments involving 
systemic administration, such as those for osteoporosis, but much less important 
when selectively treating an area such as during fracture repair.  A second major 
consideration is that of the oncogenic potential of canonical Wnt signalling (Polakis, 
2012).  Wnt signalling is often up regulated in tumours, suggesting a link between 
abnormal Wnt signalling and the onset of cancer, however there remains an absence 
of data showing the activation of canonical Wnt in normal tissues causes the 
formation of tumours.   
Given these potential drawbacks in canonical Wnt activation within a patient, it is 
likely that its manipulation may first be used in the generation of biological cell 
scaffolds prior to implantation, or in cases where the potential benefit : risk ratio 
would be more acceptable such as treatment of osteolytic leasons in multiple 
myeloma patients (Heath et al, 2009).  The identification of the mechanisms 
underlying in vitro osteogenic differentiation, such as those identified in this thesis, 
will allow for greater control in the design and formation scaffolds including those 
containing multiple cell types, through the controlled addition of various inductive 
cues such as BMPs and canonical Wnt signalling. 
6.2 Differentiation stimulus and species-specific effects 
The results presented in this thesis may also provide some insights into the 
discrepancies in the field regarding the effect of canonical Wnt signalling on 
osteogenic differentiation in vitro.  There have been a large number of studies in 
mouse cell lines showing that canonical Wnt signalling can increase the expression 
of osteogenic markers, while work in human MSCs has generated conflicting data, 
with reduced osteogenesis in response to canonical Wnt signalling.  These 
differences could easily be thought to be due to differences in the cell types used and 
differences between mouse and human cells, however I propose an alternative 
explanation.  Osteogenesis of mouse cells rarely uses dexamethasone to induce 
differentiation, and demonstrate increased expression of bone markers upon 
canonical Wnt stimulation (Table 6.2.1), while the majority of human MSC 
osteogenic differentiation requires the use of dexamethasone to stimulate 
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differentiation and mineralisation, which is inhibited by canonical Wnt 
signalling (Table 6.2.1).  Yet, if human MSCs are differentiated without 
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Table 6.2.1. Publications relating the effect of Canonical Wnt stimulation on osteogenesis.  
Table showing the cell type, differentiation conditions and canonical Wnt stimulus, related to the effect on the osteogenic differentiation. 
β-glycerophosphate (β-GP), L-Ascorbic Acid (L-Asc), Dexamethasone (Dex). 
 
Author Cell type Differentiation media Canonical Wnt stimulus Effect 
Kulkarni et al. (2006) C3H10T1/2 None LY603281 Increased bone markers mRNA 
 Jackson et al. (2005) C3H10T1/2 None Wnt3a Increased bone markers mRNA 
Bennett et al. (2005) ST2 β-GP Chir-99021 Wnt10b Increased bone markers and vK 
Li et al. (2005) mouse BM osteoblasts β-GP, L-Asc, 10pM Dex Wnt3a conditioned media Increased mineralisation 
Cawthorn et al. (2012) ST2 β-GP, L-Asc Wnt10a/b over-expression Increased ALP and ARS 
Kang et al. (2007) ST2 β-GP, L-Asc Wnt10b over-expression Increased vK and calcium deposition 
Heo et al. (2010) PDL fibroblasts (human) β-GP, L-Asc LiCl Increased ALP and mineralisation 
Gregory et al. (2005) hMSCs β-GP, L-Asc, 100pM Dex LiCl Increased ARS 
Liu et al. (2009) hMSCs Lonza Wnt3a Reduced ALP and ARS 
Baksh et al. (2007a) hMSCs β-GP, L-Asc, 10nM Dex Wnt3a Reduced ALP 
Boland et al. (2004) hMSCs β-GP, L-Asc, 10nM Dex Wnt3a Reduced differentiation 
De Boer et al. (2004) hMSCs β-GP, L-Asc, 10nM Dex LiCl, Wnt3a Reduced ALP and mineralisation 
Tang et al. (2009) C3H10T1/2 BMP9 Wnt3a, stabilised β-catenin  Increased ALP activity 
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dexamethasone we and others (Krause et al, 2010) have shown small increases in 
early stage differentiation can be detected in response to canonical Wnt signalling.  
Therefore, I propose that it is the requirement for dexamethasone to induce strong 
osteogenesis, leading to its use in human, but not mouse osteogenic studies that has 
created these discrepancies between findings.  The lack of requirement for 
dexamethasone in the mouse cell lines has allowed for the study of canonical Wnt 
signalling in a dexamethasone independent role, similar to that described in this 
thesis.  The use of BMPs as stimulators of osteogenesis may have added further 
confusion, as both mouse (Tang et al, 2009) and human cells (Chapter 5) respond 
with increased osteogenesis upon canonical Wnt stimulation in the presence of 
BMPs.  Therefore the choice of osteogenic stimulus is extremely important when 
studying the role of other factors in the differentiation process, and must be carefully 
considered to accurately replicate the in vivo scenario one is trying to replicate. 
6.3 Future directions 
The work presented in this thesis generates two main areas of further research to 
consider.  Firstly, the role of canonical Wnt-induced proliferation is shown to be 
necessary for the osteogenic differentiation of MSCs, and it is proposed to act to 
increase osteogenic precursor numbers.  With this in mind, future work would aim to 
gain a better understanding of the proliferation of the different populations within the 
MSC culture.  To study the effect of proliferation on the very early precursors, cells 
would need to be identified by their transcription factor expression and activity.  The 
adipogenic transcription factors C/EBPβ and PPARγ, and the osteogenic 
transcription factors Runx2 and Osterix are considered the key regulators of the 
differentiation commitment decisions and are therefore very early markers of the two 
lineages (Frith & Genever, 2008).  The nature of transcription factors dictates that 
they are expressed in relatively low levels, making immunocytochemistry 
challenging; however there are antibodies available for the analysis of these 
transcription factors (Luciani et al, 2010; Nakahara et al, 2010; Plutzky, 1999).  If 
successful, these immunocytochemical techniques would allow for the identification 
of pre-adipocytes or pre-osteoblasts within the population, which could then be 
analysed for proliferation by BrdU incorporation or similar imaging based assays.  
An alternative approach that would allow for the study of cell populations over time 
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would involve the use of cell lines expressing fluorescent transcription factor 
reporters.  Reporter constructs have been published for several of these key 
transcription factors (Ducy et al, 1997; Fukui et al, 2000; Gijsbers et al, 2011; Sinha 
et al, 2010; Strecker et al, 2012), and could be adapted for fluorescent reporter 
expression.  The osteogenic or adipogenic precursors could then be imaged over time 
in various conditions to see how they respond, both in proliferation and migration, or 
incorporated into a CFSE assay.  However, again there are difficulties associated 
with this approach, most notably the difficulties in generating stable reporter lines of 
MSCs.  MSCs are a primary cell line, and as such do not proliferate indefinitely in 
culture, therefore either a multipotent cell line such as C3H10T1/2, ST2 or 
immortalised MSCs must be used, however these may not behave in the same 
manner. 
The study of osteogenic precursor proliferation in vivo may also offer valuable 
insights into the manner in which canonical Wnt can increase bone mineral density 
in mouse models.  Strecker et al. (2012) published the generation of an osterix-
cherry reporter mouse, which contained osterix-positive cells within the bone 
marrow that did not express BSP, and proposed they marked early osteoprogenitor 
cells.  The combination of this reporter mouse and AR28 administration would allow 
for the analysis of changes in osteogenic progenitor cell numbers and location.  
There is then also the potential to incorporate BrdU analysis into this system 
(Thiagarajah et al, 2007) to study the proliferation of the Osx positive cells, 
providing additional information with regard to the importance of osteogenic 
precursor proliferation in the AR28 induced increase in bone mineral density. 
The second area of work which could be followed up involves the role of canonical 
Wnt in the commitment decision of BMP2-induced osteochondral progenitor cells.  
The results presented show a clear switch to osteogenesis in response to canonical 
Wnt signalling, but the mechanisms underlying this switch are unknown.  One 
potential mechanism involves the transcription factor Osx (See 5.5), and would 
provide an interesting starting point to continue this investigation. 
204 
 
6.4 Conclusion 
The work presented in this thesis has provided confirmation of the ability of AR28 to 
stimulate the canonical Wnt pathway both in vitro and in vivo, and shown AR28 to 
have little effect on other signalling pathways under the conditions studied.  This 
supports the notion that AR28-induced increases in bone mass are dependent on the 
up-regulation of the canonical Wnt signalling pathway.  This work has also lead to 
an increased understanding of the role of canonical Wnt signalling during MSC 
differentiation, and provided reasoning for many of the discrepancies in the 
literature, whilst at the same time identified novel avenues of research to be studied.  
Furthermore it has confirmed the potential for AR28 as a pharmacological stimulator 
of the canonical Wnt pathway and supports its use in the therapeutic manipulation of 
the pathway. 
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List of Abbreviations 
Add1  Adipocyte differentiation and determination factor-1 
ALP  Alkaline phosphatise 
AMH  Anti-Müllerian Hormone 
APC  Adenomatous polyposis coli 
ARS  Alizarin Red S 
BCNE Blastula Chordin and Noggin expression 
BIO  6-bromoindirubin-3′-oxime 
BMP  Bone morphogenetic protein 
BSP  Bone sialoprotein 
C/EBP  Ccaat-enhancer-binding protein 
CFU  Colony forming unit 
CHOPs  C/EBP homologoues proteins 
CK1  Casein kinase 1 
Col10A1  Type X collagen alpha 1 
Col11A2  Type XI collagen alpha 2 
Col1A1  Type I collagen alpha 1 
Col2A1  Type II collagen alpha 1 
Dhh  Desert Hedgehog 
DKK  Dickkopf 
Dvl  Dishevelled 
EDTA Ethylenediaminetetraacetic acid 
ES cell  Embryonic stem cell 
FABP Fatty acid binding protein 
FAS  Fatty acid synthase 
FGF  Fibroblast growth factor 
Fzd  Frizzled 
GDF Growth and Differentiation Factor 
GLUT4  Glucose transporter 4 
GSK  Glycogen synthase kinase 
Hh  Hedgehog 
HMG  High mobility group 
HSC  Hematopoietic stem cells 
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IBMX Isobutylmthylxanthine 
Ihh  Indian Hedgehog 
iPS  Induced pleuripotent stem 
LEF/TCF  T Cell Transcription factor/Lymphoid enhancer-binding factor 
LIF  Leukaemia inhibitory factor 
LPL  Lipoprotein lipase 
LRP  Low density lipoprotein receptor protein 
MEF  Mouse embryonic fibroblast 
MKP-1  Mitogen-activated protein kinase phosphatase-1 
MSC  Mesenchymal stem cell 
NF Nieuwkoop and Faber stage 
NFAT Nuclear factor of activated T cells 
OC  Osteocalcin 
ON  Osteonectin 
OP Osteopontin 
Osx  Osterix 
PKA  Protein kinase A 
PPAR Peroxisome proliferator-activated receptor 
Ptc  Patched 
PTHrP  Parathyroid hormone-related protein 
RI Type I receptor 
RII Type II receptor 
SBE  SMAD binding element 
SCID  Severe combined immunodeficient 
sFRPs Frizzled-related proteins 
Shh  Sonic Hedgehog 
Smo Smoothened 
SREBP1  Sterol regulatory binding element protein-1  
TGF  Transforming growth factor 
vK  von Kossa 
WIFs  Wnt inhibitory proteins 
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